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Abstract 
CD8+ T cells have been implicated in protective immune responses in pre-erythrocytic 
malaria and pathogenic responses in blood stage malaria, making them an important 
factor in determining the outcome of infection. Natural exposure to pre-erythrocytic 
malaria infection does not elicit sterile protection in humans, whereas multiple 
immunisations with large numbers of radiation attenuated sporozoites can. This 
protection is largely due to parasite-specific CD8+ T cells; however, antibody 
responses have also been shown to be functional in pre-erythrocytic infection. 
Unfortunately, there is a paucity in known antigens other than the immunodominant 
protein circumsporozoite protein (CSP) that are recognised by antibodies in the pre-
erythrocytic stages. With regard to blood stage infection, there are a variety of 
outcomes ranging from non-clinical patent infection to cerebral malaria due to 
immune-mediated pathology. Indeed, there are several different mouse models of 
malaria that each produce different outcomes, suggesting there may be subtle 
differences in immune regulation, which has previously been investigated by our 
group but is not fully understood. 
 
The research presented here attempts to address three hypotheses. First, I 
hypothesised that the requirement for high doses of antigen at multiple intervals for 
sterilising protection is at least in part due to inhibition of CD8+ T cell activation via 
regulatory pathways that are stimulated during exposure to attenuated sporozoites. 
Secondly, I hypothesised that T cell regulation during blood stage infection through 
the interleukin 10 receptor (IL-10R) confers resistance in a BALB/c model of Pb ANKA 
infection, which is normally refractory to experimental cerebral malaria (ECM). Finally, 
I hypothesise that protective immunisation of C57BL/6 and BALB/c with attenuated 
Pb ANKA sporozoites leads to the production of non-CSP antibodies that may be 
viable candidates for further vaccine research. 
 
In order to test my first hypothesis I investigated co-inhibitory molecules cytotoxic T 
lymphocyte antigen 4 (CTLA-4), programmed death ligand 1 (PD-L1) and PD-L2 and 
regulatory cytokines IL-27 and IL-10. Using mouse models, I gave a single non-
protective immunisation of γ-radiation attenuated Pb ANKA sporozoites and 
investigated the CD8+ T cell immune response in the absence of each regulatory 
pathway. Antibody-mediated blockade of CTLA-4 concurrently with a normally non-
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protective radiation attenuated Pb ANKA sporozoite immunisation in C57BL/6 mice 
led to a significant increase in sporozoite antigen-specific interferon gamma (IFNγ) 
producing CD8+ T cells upon re-stimulation. Additionally, this resulted in sterile 
protection when challenged 14 days after blockade and immunisation; however, 
protection was greatly reduced when challenged after 45 days. Using mice deficient 
in IL-27R or using antibody blockade of PD-L1, PD-L2 and IL-10 with a non-protective 
single immunisation of radiation attenuated Pb ANKA sporozoites did not lead to 
significantly increased CD8+ T cell activation upon re-stimulation. Neither did it result 
in increased protection from parasite load in the liver. These experiments are a proof 
of principle that certain regulatory pathways can significantly reduce protective CD8+ 
T cell responses to sporozoite immunisation. 
 
For my second hypothesis, I investigated CD4+ and CD8+ T cell responses to Pb 
ANKA blood stage infection in ECM resistant BALB/c mice treated with antibodies to 
block the IL-10R. I show that blockade of the IL-10R leads to increased CD4+ and 
CD8+ T cell production of IFNγ with blood stage Pb ANKA infection. Other work in this 
chapter shows that IL-10R blockade leads to increased ECM as a result of increased 
brain pathology. Additionally, I show that IL-10R blockade with Pb ANKA blood stage 
infection leads to an increase in expression of CTLA-4, but not PD-1 on CD4+ CD8+ 
T cells. This suggests that there may be a relationship between IL-10- and CTLA-4-
mediated regulation in Pb ANKA blood stage infection of BALB/c mice. 
 
To address my third hypothesis, I used a novel immunisation schedule using Pb 
ANKA sporozoites that express Pf CSP rather than Pb ANKA CSP. One immunisation 
with transgenic parasites followed by a booster immunisation with Pb ANKA was 
performed using C57BL/6 and BALB/c mice to boost non-CSP responses. This led to 
antibodies that recognised previously validated pre-erythrocytic antigens and 
functionally inhibited sporozoite invasion of hepatocytes in vitro. Using high-density 
microarray technology I investigated all proteins expressed during the pre-
erythrocytic stages of Pb ANKA using serum from these immunised mice. Results 
show antibody responses to previously unidentified pre-erythrocytic antigens and 
therefore potential antigens for future vaccine research. 
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1.1 Malaria and its global impact 
 
Worldwide, 3.4 billion people are at risk of malaria infection, with 212 million new 
clinical cases (estimate range from 148-304 million) and 429,000 fatalities (estimate 
range from 235,000-639,000) in 20151. This creates a huge global burden on health 
systems as rapid, effective diagnosis and treatment are required to address mild 
disease and to prevent potential cerebral complications, coma and death that can 
occur in severe disease. Due to the widespread nature of malaria, diagnosis and 
treatment are often required in remote and underdeveloped areas, further 
complicating the responsibility of government and regional health programmes. 
Malaria not only influences worldwide spending on public health, but also influences 
national and international economies as constant exposure to malaria leads to a 
reduction in the available national workforce. Between 1965 and 1990 the average 
growth of income per capita in countries with endemic malaria was 0.4% compared 
to an average of 2.3% in non-endemic countries2. Although establishing direct 
correlation between malaria and poverty is difficult, individual studies have found that 
malaria is related to reduced education3, worker productivity4, household savings5 
and international trade4. Both directly and indirectly, malaria impacts all levels of 
society from an individual to global scale. National and international efforts to tackle 
the burden of malaria have reduced the rate of new annual cases by 37% and death 
rates by 60%; however, a global reduction does not reflect fluctuations in malaria at 
a national level. Eradication of malaria has been seen in a number of countries but it 
is still possible to see resurgence in disease. Venezuela was the first country to 
eradicate malaria from its most populated areas in 1961; however since the late 
1990’s there has been a continued increase in malaria cases, showing poor control 
of the spread of malaria and other infectious diseases6. As eradication can be 
temporary, novel avenues of research should be explored to help maintain eradication 
and help achieve elimination. 
 
Protozoan parasites of the Plasmodium genus are the aetiological agents of malaria, 
with Plasmodium falciparum (Pf), Plasmodium vivax (Pv), Plasmodium knowlesi (Pk), 
Plasmodium malariae (Pm) and Plasmodium ovale (Po) species capable of infecting 
humans and causing disease. The Plasmodium genus is a member of the Hematozoa 
clade within the Apicomplexa phylum and is closely related to other apicomplexans 
including Toxoplasma in the coccidia clade, Cryptosporidium in the cryptosporidia 
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clade and Eugregarinorida in the gregarines clade. Pf is the most widely studied of 
the Plasmodium species and causes the most fatalities globally with the majority 
being infants and children under 5 years of age7. Death as a result of malaria infection 
can be due to several complications. These include severe anaemia and jaundice 
due to the loss of erythrocytes, organ failure (particularly renal failure) due to deposits 
of immune complexes, acidosis, respiratory distress including acute respiratory 
distress syndrome (ARDS) and cerebral malaria due to sequestration of infected 
erythrocytes in the microvasculature of the brain. Pv infection can also result in severe 
malaria; however it is not studied to the extent of Pf, despite it causing an estimated 
50% of clinical cases outside of Africa8. Interestingly, it is able to cause relapse 
infections up to several months after clinical symptoms are treated. This is a result of 
the dormant hypnozoite life stage, unique to Pv and Po of the human infective 
species. Unfortunately the mechanisms by which the hypnozoite is formed and 
activated remain poorly understood. Pk is a predominantly primate pathogen that can 
infect humans via macaque monkeys9 but to date no natural human to human 
transmission has yet been documented. Pm and Po infect humans but do not cause 
severe malaria and account for a comparatively small number of cases annually. 
 
1.2 Malaria control 
 
Unfortunately, the complexity and genetic plasticity of the malaria parasite has led to 
increasing drug resistance10. Chloroquine resistance was first reported at the border 
of Thailand and Cambodia in 1957 and proguanil resistance was observed as early 
as 1 year after its introduction11. Artemisinin has been more successful; however 
resistance was seen in 2009, again at the Thailand-Cambodia border12. In order to 
reduce the development of resistant parasites, artemisinins are usually given as part 
of Artemisinin Combination Therapy (ACT). This is beneficial for two reasons, firstly 
there is a much lower chance of a parasite spontaneously developing resistance to 
two antimalarial drugs at the same time and secondly, partnering artemisinins, which 
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In order to control the mosquito vector itself, large-scale spraying of DDT was 
introduced after WWII. Although further research confirmed DDT caused a 
detrimental effect on the environment13, the use of novel and safer insecticides has 
resulted in much greater control of malaria transmission. The uses of insecticides 
include insecticide treated bed nets (ITN’s) and indoor residual spraying, both of 
which significantly contribute to reductions in morbidity and mortality7,14. Although 
strategies exist that can significantly influence malaria prevalence and treatment, 
increasing resistance and changes in global politics and economies can in some 
cases quickly reverse the positive contributions these methods make to malaria 
eradication. As such, more research is required to discover novel drugs, novel 
insecticides and in particular to develop novel vaccines that could significantly 
contribute to international eradication and elimination programmes. 
 
1.3 The Plasmodium life cycle 
 
Members of the Plasmodium genus are protozoan parasites that have developed a 
complex life cycle, which requires vertebrate hosts and invertebrate vectors (Figure 
1.1). Differentiation of the parasite allows for successive specificity to different tissues 
or cell types in order to successfully progress through the life cycle. Parasites are 
transferred from an infected female Anopheles mosquito to a vertebrate host during 
a blood meal, which is necessary for egg production in females. Motile invasive 
Plasmodium sporozoites exist within the distal areas of the lateral lobes of the salivary 
glands, primarily in extracellular secretory cavities15. Here they form aggregates; 
however individual parasites gradually relocate to the salivary ducts where they are 
susceptible to being ejected by the mosquito vector15. The female mosquito injects 
saliva during a blood feed to prevent clotting and with it an infected mosquito transmits 
sporozoites. Small numbers of roughly 10-10015–18 are released into the dermis of the 
vertebrate host where they immediately encounter substrate for surface proteins 
involved in motility. Sporozoites use gliding motility and cell traversal to move through 
the dermis and enter the peripheral blood system19 or lymphatic system20. Motility is 
largely via thrombospondin-related adhesion protein (TRAP), which recognises 
sulphated glycoconjugates in addition to other, as yet undescribed host proteins. 
TRAP is an abundant protein on the surface of the sporozoite; however it is mainly 
present within the micronemes21 where it is secreted for motility and invasion. TRAP 
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binds to substrate present on the surface of host cells and travels towards the 
posterior end of the parasite via an actin-myosin system located at the inner 
membrane complex (IMC) where they are cleaved and released22. Salivary gland 
sporozoites have a tropism for the vertebrate liver and with 30% of the total blood 
volume passing through the liver every minute23, sporozoites can rapidly sequester in 
the liver once they have entered the peripheral blood system24. Specificity to the liver 
is due to the circumsporozoite protein (CSP), the major surface protein of sporozoites 
and may be secreted from the apical end25. Heparan-sulphate proteoglycans are 
expressed at high levels on hepatocytes26, projecting through the fenestrae of the 
liver sinusoids where they are recognised by CSP27. This has been confirmed through 
incubation of liver sections with recombinant CSP, showing preferential localisation 
at the hepatocyte surface27. An effective cell traversal mechanism allows the 
sporozoite to cross the liver sinusoid endothelial cells and space of Disse to 
eventually invade the liver parenchyma. 
 
The pre-erythrocytic or liver stage involves the intra-hepatic development of 
sporozoites into merozoites that can bind to and invade red blood cells (RBCs). 
Sporozoites first traverse several hepatocytes before entering a final cell by forming 
an invagination of the host cell membrane and creating a parasitophorous vacuole 
(PV) that is subsequently altered to express Plasmodium-specific proteins. Through 
schizogony, thousands of merozoites that are specific to the next life stage are 
produced. Schizogony involves the asynchronous division of the nucleus multiple 
times to create a syncytium, followed by budding off of daughter cells28. In some 
Plasmodium species, including Pv, Po and the non-human primate parasite P. 
cynomolgi, another form called the hypnozoite is produced which can remain dormant 
in the liver for months before re-activation through as yet unknown mechanisms. 
Once schizogony is complete, groups of merozoites bud off the hepatocyte in 
merosomes and traverse to the blood circulation where they are released and can 
rapidly infect RBCs.  
 
The erythrocytic or blood stage can result in the clinical symptoms of malaria. 
Merozoites bind to RBC membranes with stochastic orientation via recognition of 
erythrocyte surface proteins and re-orientate themselves to allow the apical end to 
form a tight junction for PV formation29. More merozoites or sexual stage gametocytes 
are generated within the PV again by schizogony. Once complete, the schizont and 
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RBC membranes rupture and merozoites are released, leading to febrile illness in the 
host. Reinfection and RBC rupture is repeated, giving recurrent episodes of fever 
ranging from 24 hours for Pf, Pv and Po (tertian fever) to 72 hours for Pm (quartan 
fever). Male microgametocytes and female macrogametocytes have been reported 
to survive in the blood circulation for between 3.4 days30 and 6.5 days31 and must be 
ingested by female Anopheles mosquitoes during a blood meal for successful 
transmission and continuation of the life cycle. In the mosquito gut the gametocytes 
develop into gametes as a result of a reduction in temperature, changes in pH and 
the presence of xanthurenic acid32–34. Gametes fuse to form zygotes and become 
motile ookinetes, which traverse the gut epithelium and sequester in the gut basal 
lamina. There they develop into oocysts and begin a phase of sporogony, which 
generates thousands of sporozoites. As ookinetes are diploid and sporozoites are 
haploid, sporogony occurs by the meiotic division of the ookinete nucleus to form a 
polyploid nucleus with 4 haploid nuclei. As an oocyst these nuclei divide as in 
schizogony by asynchronous mitosis to generate sporozoites. With oocyst rupture, 
sporozoites are released into the mosquito hemolymph and preferentially locate to 
the salivary glands, possibly through CSP recognition of proteins expressed by 
salivary gland cells35. Once in the salivary cavities they can be transmitted to a new 
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Figure. 1.1: The Plasmodium life cycle36.  
Sporozoites enter the vertebrate host via inoculation by an infected female Anopheles 
mosquito blood meal and localise to the liver where they infect hepatocytes and develop into 
thousands of merozoites (1). Merozoites enter the blood circulation and infect RBC’s as part 
of the blood stage, where they cyclically proliferate, rupture the host cell and re-infect new 
RBC’s (2). Some merozoites develop into sexual stage gametocytes, which remain in the 
blood and can be taken up by a female Anopheles mosquito during a blood meal. In the 
mosquito gametocytes develop into gametes and fuse to form an ookinete (3). In the gut basal 
lamina, sporogony occurs in the oocyst before the oocyst ruptures and releases sporozoites, 
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1.4 Whole sporozoite vaccination strategies for 
malaria pre-erythrocytic stages 
 
Drug treatment and vector control strategies significantly contribute to decreased 
malaria incidence and have been sufficient to eradicate malaria in some areas of the 
world37; however eradication is increasingly difficult, particularly due to parasite 
resistance to drugs38 and vector resistance to insecticides39. In order to supplement 
these strategies and add to the interventions available against malaria globally, an 
effective vaccine would significantly contribute to eradication and elimination 
programmes by eliciting extended sterile immunity in vaccinated individuals, reducing 
both disease and transmission. 
 
Vaccination with radiation attenuated sporozoites (RAS) can elicit protection against 
subsequent challenge with infectious sporozoites. This was first identified in mice 
using x-radiation attenuated P. berghei (Pb) sporozoites as a vaccination in an A/J 
mouse model40. Using this strategy, patent infection was reduced from 90% in 
controls to 37% in mice vaccinated with a sufficient number of radiation attenuated 
sporozoites. Later studies using γ-radiation attenuated sporozoites were able to show 
complete protection using Pb as well as P. yoelii (Py) species41. Used in mice, Pb and 
Py provide good models of malaria infection as they can induce severe disease 
including experimental cerebral malaria (ECM) in susceptible mice such as C57BL/6 
or non-lethal infection can be observed using certain parasite strains such as Py 
17XNL. Further to mouse models, the same radiation attenuation strategy with P. 
cynomolgi sporozoites can also induce protection in rhesus monkeys42. The success 
of these investigations has been translated to humans using vaccines designed using 
γ-radiation attenuated Pf sporozoites43,44 and has set a gold standard of immunisation 
in malaria vaccine research. Unfortunately, using RAS as a global vaccine would 
require overcoming several obstacles. Sporozoites must be isolated from mosquito 
salivary glands as there are no scalable methods for culturing infectious sporozoites 
in vitro. Mosquitoes must be grown in sterile conditions and the resulting sporozoites 
must be a pure suspension, which is expensive but has been achieved to a sufficient 
level for human vaccine trials45. Importantly, controlled irradiation is critical as 
insufficient attenuation can lead to patent malaria and excessive irradiation can 
prevent any sterilising immunity46. Even though this method of attenuation is very 
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effective, the risk of sub-optimal irradiation increases with increasing batch sizes, 
making scaling-up of this method more problematic than other strategies such as a 
sub-unit vaccine design. 
 
From the positive results shown in early experiments of sporozoites attenuation by 
irradiation and its potential for eliciting protection, some research has progressed to 
investigating other methods of parasite attenuation. Sequencing of the Plasmodium 
genomes including Pf 47–49 and the murine species Pb 50 has led to greater 
understanding of these parasites and has enabled the generation of genetically 
attenuated parasites (GAPs), whose attenuation is controlled by genetic 
manipulation. The large number of genes available (over 5000) and their plasticity 
throughout the life cycle creates difficulties with identifying appropriate candidates. 
Good candidate genes for GAP must not be essential for parasite survival during the 
erythrocytic and mosquito stages (important for parasite generation), but must be 
required for complete, functional liver stage development. By following the 
progression of parasite development after a single gene deletion, GAPs facilitate an 
increased understanding of the biology of the parasite. Using GAP techniques, 
Plasmodium parasites can be generated that arrest in early liver stages51,52 or arrest 
late in the liver stage53. Arresting parasites at different times during development 
leads to different advantages such as reduced risk of breakthrough infection if arrest 
is early compared to apparent increased antigen exposure if parasites arrest late in 
development. Further to this, multiple genes can be investigated simultaneously in 
one parasite to optimise vaccine candidates54. GAPs provide a promising avenue for 
future research as they allow for reliable, reproducible, specific attenuation of 
parasites; however they have several similar limitations to the gold standard as 
production of parasites still requires development in the vector. There is also a risk of 
future stochastic genetic changes that could reverse the attenuation, resulting in the 
generation of a virulent strain that could induce disease. 
 
Another vaccine strategy uses sporozoite injection with concurrent anti-malarial drug 
treatment. This method allows for full liver stage development of the parasite before 
blood stage arrest as a result of chemotherapy. The advantage of this strategy is that 
the immune system is exposed to all antigens that are expressed in the liver stage, 
whereas irradiation or genetic manipulation attenuates the parasite before full liver 
stage development is completed. Immunisation with blood stage parasites under a 
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drug regimen can also induce protection from both blood and liver stage parasites, 
indicating cross-over protection55. 
 
Although most of today’s vaccines rely on attenuation or inactivation of the pathogen 
itself, subunit vaccines are regarded as an optimal strategy for vaccine design. They 
are consistent, stable, scalable and non-infectious; however the subunit vaccination 
should generate a level of immune protection that is capable of preventing patent 
disease. The RTS, S vaccine, currently the most advanced malaria vaccine, consists 
of B and T cell epitopes to CSP with hepatitis antigen. It has 27% efficacy in infants 
and 39% efficacy for children between 5-17 months45. It is promising that we can now 
develop a vaccine that has some efficacy against malaria; however further research 
will be required to produce next generation vaccines that will assist in eradicating 
disease in endemic regions. The success of RTS, S depends on the CSP B and T 
cell epitopes as CSP is an immunodominant antigen during the pre-erythrocytic 
stages of infection. Towards the design of novel malaria vaccines; however, the 
addition of novel pre-erythrocytic antigens to CSP epitopes could increase the 
efficacy of a malaria vaccine and provide a much better tool for fighting disease and 
transmission. 
 
1.5 The adaptive immune response to Plasmodium 
infection 
 
1.5.1 Adaptive immune responses to pre-erythrocytic 
stage malaria 
1.5.1.1 CD8+ T cell responses to pre-erythrocytic stage malaria 
Although the immune response to malaria infection is complex and not yet fully 
understood, several studies have shown that activation of CD8+ T cell responses is 
non-redundant in protection against pre-erythrocytic malaria in mouse models, rhesus 
monkeys and humans41,56–60. Indeed, adoptive transfer of Py antigen-specific CD8+ T 
cells from immunised BALB/c mice into naïve mice is sufficient to confer sterile 
protection against subsequent sporozoite challenge61. As the liver stage of malaria 
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infection is relatively short and the number of inoculated sporozoites during natural 
infection is low, these CD8+ T cells must successfully eliminate a small number of 
infected hepatocytes (1 in 1x109 in humans, 1 in 1x106 in mice62) before blood stage 
infection. This requires a large number of antigen-specific effector memory CD8+ T 
cells that are capable of mounting a rapid cytotoxic response after infection59,63. 
Unfortunately, natural infection with malaria does not lead to sterilising immunity and 
this level of protection is best induced by multiple immunisations with large numbers 
of attenuated sporozoites. Therefore, there is something inherent to natural 
sporozoite infection that restricts the magnitude of parasite-specific CD8+ T cells to 
such an extent that sterile protection cannot be achieved. Further to this, 
understanding the mechanisms of protection is complicated by the fact that different 
strains of Plasmodium and different strains of mice lead to models that require subtly 
different immune responses for protection. This suggests that there is an added 
element to pre-erythrocytic protection that is context dependent. In mice, CD8+ T cell-
mediated protection against Pb is almost entirely dependent on interferon gamma 
(IFNγ) and tumour necrosis factor alpha (TNFα) production. Interestingly though, Py 
protection is additionally dependent on perforin64. In order to better understand why 
there are these differences in CD8+ T cell responses and why protection is only 
achieved with very high doses of antigen at multiple intervals, an important avenue of 
investigation is CD8+ T cell regulation. Unfortunately, there is currently a paucity of 
information regarding this. 
 
An interesting limitation of previous research into protective pre-erythrocytic 
mechanisms is that it has largely focussed on CSP-specific responses due to the 
immunodominance of CSP65. Therefore, most of our current understanding of pre-
erythrocytic immunity is a result of investigating CSP-mediated immune responses. 
To study the immune mechanisms further, a greater understanding of CD8+ T cell 
epitopes is required to provide positive T cell activation readouts. Using 
bioinformatics, Hafalla et al. in 2013 identified 600 CD8+ T cell Pb epitopes restricted 
to C57BL/6 alleles66. Using ELISPOT and intracellular staining of CD8+ T cells they 
validated these peptides and discovered TRAP and S20 protein epitopes. TRAP and 
S20 are both expressed during the sporozoite stage of the life cycle. TRAP is crucial 
for sporozoite motility and is expressed on the surface of the parasite, possibly 
making it a good target for CD8+ T cell responses. S20 is as yet uncharacterised and 
its location in the sporozoite is unknown; however, it too appears to have 
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immunogenic properties. This is important as it allows for a broader understanding of 
CD8+ T cell immune responses to pre-erythrocytic malaria. 
 
An important consideration for pre-erythrocytic malaria infection is that the liver itself 
is a unique immunological organ, which promotes immune tolerance through a variety 
of mechanisms, creating an environment that is not conducive to CD8+ T cell 
activation67. Blood arrives to the liver through the hepatic portal vein, transporting with 
it a multitude of exogenous digestive products generated in the gut. Due to this high 
presence of non-self antigen in the liver, there is a compensatory dampening of 
immune activation. The liver experiences constitutive expression of IL-10, particularly 
via dendritic cells (DCs)68, which decreases major histocompatibility complex II (MHC 
II) and B7 molecule expression on liver sinusoid endothelial cells (LSEC)69. The liver 
also promotes an increase in expression of factors involved in inducing T cell 
tolerance. In a classic mouse model of liver damage, Wei et al. investigated the 
expression of cytotoxic T lymphocyte antigen 4 (CTLA-4) and transforming growth 
factor beta (TGF) on regulator T (Treg) cells after concavalin-A treatment and found 
expression to be significantly increased in the liver compared to the spleen70. 
Increased CTLA-4 expression has also been linked to liver resident CD8+ T cells after 
RAS immunisation71. In separate investigations, Treg cells have been shown to 
promote T cell tolerance through the expression of CTLA-472,73. There is also 
increased expression of programmed death ligand 1 (PD-L1) in the liver by antigen 
presenting cells (APCs)74. With low antigen expression the binding of T cell 
programmed death receptor 1 (PD-1) to APC PD-L1 results in expansion but a lack 
of effector function75; however at sufficiently high antigen concentrations function can 
be achieved76. As mentioned previously, a high dose of antigen in the form of RAS 
can elicit sterile protection; however this might not be necessary if the mechanisms 
that force the requirement of such a high dose are modulated. 
 
Another method for liver immune suppression is through the action of resident APCs. 
The role of LSECs in malaria, if any, is largely unknown; however they are capable of 
antigen presentation and specifically activate CD4+ T cells towards a regulatory 
phenotype and can prevent cytotoxic CD8+ T cell activation77. In addition, the 
environment of the liver also influences DCs by preventing full differentiation, leading 
to an immature phenotype and preferential priming of regulatory T cells67. Maturation 
can be induced however by type I IFN, which are produced in response to viral 
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infection and which may be inhibited by other infections. This understanding of the 
liver environment shows that T cells in the liver are under constant negative regulation 
and therefore any changes could promote CD8+ T cell activation and improved 
immune responses. 
 
1.5.1.2 CD4+ T cell responses to pre-erythrocytic malaria 
With regard to the pre-erythrocytic stage, CD4+ T cells are involved in protection 
through intrinsic and extrinsic mechanisms. Carvalho et al. showed that CD4+ T cells 
were important in CSP-specific CD8+ T cell responses by blocking CD4 in BALB/c 
mice immunised against a Py CSP epitope78. Blockade reduced the magnitude of 
CSP-specific CD8+ T cells and this control of the CD8+ T cell response was shown to 
be dependent on IL-4. A second extrinsic mechanism is through CD4+ T cell induced 
B cell activation and secretion of neutralising antibody79; however CD4+ T cells can 
intrinsically mediate protection through Th1 expression of IFNγ. Oliveira et al. in 2008 
showed that immunisation of β2 microglobulin-/- mice with Py or Pb can still induce 
protection against challenge regardless of mouse genetic background79. When CD4 
was blocked using anti-CD4 antibodies protection was significantly abrogated. 
Similarly, when IFNγ was blocked protection was also reduced, suggesting that (in 
addition to activating B cells) IFNγ produced by CD4+ T cells in the absence of CD8+ 
T cells may influence protection. 
 
1.5.1.3 Antibody responses to pre-erythrocytic malaria 
During pre-erythrocytic malaria, antibodies have a short window of time in which to 
successfully recognise sporozoites and prevent infection as they travel from the 
dermis to the liver. Despite this challenge, high titres of pre-erythrocytic stage-specific 
antibodies have been shown to correlate with protection80. Indeed, in mouse studies 
it has been shown that antibodies generated by liver stage Py immunisation are 
sufficient to prevent hepatocyte invasion in vitro (also seen in Pb immunisation81,82) 
and help reduce, but not eliminate parasitaemia after in vivo transfer to a naïve 
mouse83. Interestingly, the manner in which antibodies offer protection is also different 
between different stages of malaria infection. Sporozoite-specific antibodies have 
been shown to act independently from complement activation, agglutination and 
opsonisation84,85, suggesting that antibodies could act by coating and neutralising 
parasites and impede host cell ingress. Although there is a clear shift in the salient 
adaptive immune mechanisms required as infection progresses from liver stage to 
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blood stages, antibodies continue to be an important avenue of research for both. 
CSP has been identified as a major immunodominant protein within the pre-
erythrocytic stage. The RTS, S vaccine currently in phase III clinical trials uses the B 
cell epitope repeat region of CSP as well as CSP T cell epitopes; however, there has 
been little advancement in the identification of novel pre-erythrocytic malaria B cell 
epitopes. In order to increase our understanding of B cell protective mechanisms, 
more antigens and their respective epitopes must be identified and studied. 
 
1.5.2 Adaptive immune responses to blood stage malaria 
1.5.2.1 CD8+ T cell responses to blood stage malaria 
Contrary to their critical role in protective immunity during pre-erythrocytic 
Plasmodium infection, CD8+ T cells show minimal contribution to protection against 
blood stage infection. Rather, they contribute towards immune-mediated pathology, 
particularly experimental cerebral malaria (ECM) in mouse models of blood stage 
infection of susceptible mice. Athymic nu/nu BALB/c mice that are infected with blood 
stage Pb ANKA do not show symptoms of ECM, unlike nu/+ BALB/c mice86. In 
another investigation, Yañez et al. showed the contribution of CD4+ and CD8+ T cells 
to ECM using both knock-out and antibody-mediated depletion mouse models87. 
C57BL/6 mice that do not express MHC II88 and C57BL/6 mice that were depleted of 
CD4 by antibodies as well as β2 microglobulin-/- and C57BL/6 mice that were depleted 
of CD8 by antibodies were all protected from ECM when infected with blood stage Pb 
ANKA parasites. Additionally, gene-targeted deficiency of IFNγ in mice also led to 
abrogation of ECM, highlighting it as a soluble mediator of ECM. Further research 
investigating the relationship of CD4+ and CD8+ T cells in ECM has suggested that 
CD4+ T cells that produce IFNγ during blood stage infection leads to the accumulation 
of CD8+ T cells in the brain, leading to CD8+ T cell degranulation and breaching of the 
blood-brain barrier89–92. In this context, CD8+ T cells are the principle mediator of ECM 
disease in mice but it is dependent on IFNγ producing CD4+ T cells. As there is no 
human model for cerebral malaria investigation, it is important to note that the 
contribution of CD8+ T cells to human cerebral malaria is not currently fully 
understood.  
 
Although blood stage Pb infection of C57BL/6 mice leads to ECM, this is not the case 
in BALB/c mice. Indeed, the virulence of blood stage infection in mice can be different 
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depending on both the Plasmodium species and the mouse strain used93. As yet, the 
differing immune mechanisms involved in these models and how they influence CD8+ 
T cell activation and pathology is poorly understood. Previous work by our group 
investigated CTLA-4 and PD-1 signalling during blood stage Pb ANKA infection in a 
C57BL/6 and a BALB/c mouse model94. Results showed that CTLA-4 and PD-1/PD-
L1 signalling independently influence resistance to ECM during blood stage Pb ANKA 
infection in both models and blockade of either pathway resulted in increased T cell 
activation and susceptibility to ECM in BALB/c mice. Kossodo and colleagues also 
investigated regulation by showing that IL-10 and TGFβ possibly contribute to 
protection against cerebral malaria, suggesting that negative regulatory pathways 
could reduce pathogenic T cell activation95. Interestingly, the lab of John Harty has 
suggested that the progression to blood stage infection is the culprit for low numbers 
of parasite-specific effector memory CD8+ T cells and therefore poor parasite control 
in endemic settings96. Regardless, it is clear that regulation has a significant impact 
on the course of blood stage infection and that understanding it will aid future 
therapeutic discovery. 
 
1.5.2.2 CD4+ T cell responses to blood stage malaria 
As blood stage infection involves the recurrent infection of RBCs that do not express 
MHC, protection is largely dependent on antibodies and helper CD4+ T cell activation 
of B cells97,98. As already mentioned, CD4+ T cells appear to be involved in ECM via 
the production of IFNγ; however, there is also evidence for them having a protective 
role. Multiple CD4+ T cell subgroups have been implicated in blood stage malaria99–
102; however, Treg cells have been studied extensively with respect to blood stage 
regulation. Although they do appear to be involved in malaria protection, the specifics 
of their role in protection is not fully understood96,103. With Py infection of BALB/c mice, 
Treg cells increase expression of Socks2, IL-10 and CTLA-4 among other regulatory 
molecules104. PD-1 expression is also increased during human infection of Pf and if 
this is investigated further using a C57BL/6 mouse model of Py infection, blockade of 
PD-1 and LAG3 leads to improved immune responses against Py malaria105. 
Interestingly however, CTLA-4 blockade in C57BL/6 mouse models of blood stage 
Pb infection increases T cell activation and exacerbates disease94,106. Although 
regulatory pathways appear to be able to significantly influence CD4+ T cell activation 
during blood stage malaria, further investigation is required in order to fully 
understand this complex system. 
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1.5.2.3 Antibody responses to blood stage malaria 
In blood stage malaria infection, B cells are crucial for protection. Continuous infection 
and reinfection with malaria, which is common in holoendemic regions, increases 
protective antibody titres to levels where individuals can control parasitaemia without 
sterilising protection80. Indeed, transfer of serum from people with naturally acquired 
non-sterile immunity to naïve individuals is sufficient to reduce disease and 
parasitaemia107. Antibody-mediated control is particularly important during the blood 
stages of infection as merozoites cyclically infect non-nucleated RBCs, which do not 
express MHC and therefore cannot directly present antigen to T cells. It has been well 
established that antibodies against the blood stages of malaria alone are capable of 
controlling parasitaemia108 and further research has revealed this protection can be 
through multiple mechanisms. These include merozoite neutralisation with109 or 
without complement110, antibody-dependent cell inhibition111, phagocytosis of infected 
RBCs through antibody help112 or antibody-dependent respiratory burst by 
neutrophils113. Our current understanding of the level of contribution of each of these 
mechanisms is; however, incomplete. 
 
1.6 Using high-density peptide array design to 
identify novel antibody targets 
 
In the post-genome era it has become possible to investigate biological mechanisms 
to a much greater resolution than ever before. Through technical developments in 
DNA sequencing it is now cheaper and quicker than ever before to predict all proteins 
that are encoded within a genome, allowing for unprecedented knowledge pertaining 
to possible drug and vaccine targets in pathogenic organisms. A technique that has 
become more and more sophisticated as –omics research has developed is the use 
of microarrays. Using microarrays allows for high-density, high-throughput 
investigation of thousands of molecular targets using chips as small as a glass slide. 
As proteins are encoded by the genome and dysregulation of proteins is inexorably 
linked to many diseases, the fields of transcriptomics and proteomics have become 
increasingly important in biomedical research. 
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As microarrays have gained in popularity their use has become increasingly diverse. 
Applications include protein expression profiling, molecular interaction mapping, 
biomarker discovery, drug target discovery, disease diagnosis and epitope mapping. 
In the discipline of vaccinology, the ability to probe thousands of possible vaccine 
targets at one time is particularly useful. Earlier research in vaccine development 
largely included isolating the pathogenic agent, attenuating it to the extent that it does 
not cause clinical symptoms but still induces immunity and injecting it to elicit 
protection. In order to identify specific targets proteins would have to be generated 
and investigated separately. To study multiple potential antigens on a miniaturised, 
parallel platform such as a microarray, the first and most time-consuming element is 
the synthesis of the peptide/protein library. A robust, multi-step process is to 
synthesise peptides/proteins first and then robotically transfer them to the array slide. 
Since the development of Solid Phase Protein Synthesis (SPPS) however114, 
molecules can be built directly on the surface of beads coated in a specific linker. The 
advantage of this method is that it allows for the synthesis of peptides and proteins 
that cannot be produced through cellular mechanisms, for example sequences that 
bacteria cannot generate, sequences that incorporate unnatural amino acids or 
sequences that require a modified backbone. This strategy has since been expanded 
to allow for rapid, parallel synthesis of a large array of randomly sequenced peptides 
or proteins through the split-and-pool technique115,116. In terms of vaccine target 
discovery, these developments in array technology allow for the synthesis of an entire 
proteome that can fit onto array chips that can be relatively easily probed and 
investigated. Carmona et al. in their 2015 paper investigating Trypanosoma cruzi 
antigenic determinants used microarray technology to screen 457 proteins from the 
CL-Brener strain117. The peptide library consisted of peptides 15 amino acids in length 
with a 14 amino acid overlap of the previous peptides sequence, resulting in more 
than 175,000 individual peptides. Synthesis of the peptide library involved the direct 
in situ SPPS generation of sequences on the array slide itself with a high resolution 
permitted by the use of photolithography techniques118. In their paper they describe 
over 120 novel linear antigenic determinants through analysis of these peptides when 
probed sequentially with naïve control and Chagas disease positive human sera. This 
paper shows an unprecedented examination of the most antibody specificities 
identified in parallel for a single human infection.  
 
The use of microarray design has clear advantages compared to its predecessors; 
however it is not a perfect system for identifying all epitopes within a biological 
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system. Other techniques such as ELISA are quicker and much simpler; however, 
they normally investigate antigenic determinants through non-covalent peptide 
immobilisation which does not specifically determine the orientation of the molecule 
on the slide, introducing variability. Even covalent immobilization could affect the 
molecular structure; however this is less of a concern for shorter peptides. Possibly 
the main disadvantage of peptide microarrays is that only linear epitopes can be 
identified, leaving non-linear epitopes that comprise approximately 95% of the 
potential antigenic regions unknown. In the context of malaria, microarrays have been 
used extensively to evaluate the immune response to malaria infection and to 
evaluate the efficacy of vaccination119. Interestingly though, they have not been 
utilised to identify novel pre-erythrocytic stage antigens using a mouse model of 
malaria. Here I will describe the use of microarray technology to investigate liver and 
sporozoite stage proteomes with the objective of vaccine target discovery. 
 
1.7 Aims and research objectives 
The work presented here concerns three main hypotheses. First that CD8+ T cell 
inhibitory regulation during exposure to pre-erythrocytic malaria infection is capable 
of negatively influencing protective CD8+ T cell responses. Secondly, that IL-10R 
signalling during blood stage infection of an ECM refractory mouse model of malaria 
is involved in ECM resistance. Finally, I hypothesised that protective pre-erythrocytic 
immunisation generates non-CSP antigen-specific antibody responses that may offer 
protective immunity towards pre-erythrocytic infection. 
 
In order to investigate these hypotheses I used mouse models of malaria. From my 
hypotheses my first objective was to investigate CD8 T cell regulatory pathways and 
their contribution to CD8+ T cell inhibition during a non-protective attenuated 
sporozoite immunisation. The pathways I chose to investigate were CTLA-4, PD-1, 
IL-27R and IL-10R signalling. My second objective was to confirm whether IL-10R 
signalling is involved in blood stage resistance to ECM using BALB/c mice that are 
normally resistant. My final objective was to validate a novel immunisation schedule 
that preferentially boosted non-CSP antibody responses and use serum from 
immunised mice to investigate novel pre-erythrocytic antigens using high-density 
microarray technology. 
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Malaria infection is initiated by the inoculation of Plasmodium sporozoites into the 
vertebrate host by female Anopheles mosquito vectors. Sporozoites preferentially 
locate to the liver where they invade and develop in hepatocytes. This is the pre-
erythrocytic stage of their life cycle, which is clinically silent and therefore a 
particularly interesting stage for drug and vaccine research. Immunisation with RAS 
elicits sterile protection against sporozoite challenge. By comparing protection in Pb 
immunised T cell deficient mice (thymectomised, irradiated, B cell reconstituted and 
anti-thymocyte serum treated) and B cell deficient mice (treated from birth with goat 
anti-mouse μ chain serum), Chen and colleagues showed that this protection is 
dependent on T cell, but not antibody responses120. Sporozoite challenge of 
immunised T cell deficient mice resulted in no protection but immunised μ-suppressed 
mice were still protected from challenge. Further to this, it has been shown that CD8+ 
T cells in particular are critical mediators of protection during the pre-erythrocytic 
stage. In their experiments, Weiss et al. successfully immunised BALB/c mice against 
Py sporozoite challenge by multiple immunisations with radiation attenuated Py 
sporozoites; however, this protection could be completely removed with the antibody-
mediated depletion of CD8 but not CD4 prior to challenge121. The sporozoite surface 
exhibits a high density of CSP, which is immunodominant and offers a considerable 
contribution to pre-erythrocytic immunity. Rodrigues and colleagues generated Py-
specific spleen derived CD8+ T cell clones using a BALB/c model of immunisation 
with γ-radiation attenuated Py sporozoites61. They found that clones specific for the 
region between amino acids 277 and 288 of Py CSP became highly cytotoxic upon 
exposure to MHC compatible cells that had previously been cultured with Py CSP 
peptide. The potency of this response was further investigated by adoptively 
transferring these clones into naïve BALB/c mice before challenge with Py 
sporozoites. Incredibly, adoptive transfer of two clones was sufficient to elicit 
complete sterile protection against challenge and this protection was through 
inhibition of liver stage parasite development. Work done by the Harty lab further 
supports the importance of cytotoxic T cell responses in protection against liver stage 
malaria through immunisation of BALB/c mice against Pb CSP122. Immunisation 
specifically targeted the development of memory CD8+ T cells through the use of DCs 
that were coated in CSP peptide, followed by a boosting immunisation with attenuated 
L. monocytogenes (actA and inlB deficient123) expressing the same peptide. This led 
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to sterile protection against Pb sporozoite infection with 5 separate challenges 
between 7 and 19 months after immunisation. Subsequent work by the Hill group 
supports the importance of focusing malaria vaccine research on the generation of 
CD8+ T cell responses through their development of the Adenovirus prime and 
Modified Vaccinia Ankara (MVA) boost regimen124. Protective CD8+ T cell responses 
generated against Pb ANKA CSP peptide were sufficient to elicit protection against 
Pb sporozoite challenge. Interestingly, protection was also elicited through 
immunisation against a TRAP peptide. These experiments highlight that antigen 
experienced CD8+ T cells are capable of recognising sporozoite antigens and 
responding with functional immunity, even in the absence of any other parasite-
specific immune mechanisms.  
 
Currently the gold standard in malaria immunisation requires multiple vaccinations 
with large numbers of whole, attenuated parasites, eliciting sterile immunity against 
the pre-erythrocytic stages of Plasmodium species40,43,125,126 . This exposes the 
immune system to a level of antigen that is many times greater than what is normally 
experienced in an endemic setting, eliciting sterile protection that cannot be achieved 
naturally. Why a single immunisation of RAS does not promote a sufficient protective 
CD8+ T cell immune response is an important question as a greater understanding of 
this would allow for the design of more efficacious RAS vaccines. It would seem that 
regulation of CD8+ T cell responses could account for the requirement of such high 
doses of vaccine at multiple intervals; however, there is a paucity of research that has 
addressed this facet of the pre-erythrocytic immune response. 
 
Promotion of appropriate immunological responses prevents uncontrolled atypical 
lymphoproliferation and activation in response to foreign antigens127,128 as well as 
autoimmune disease due to self-reactive T cells129. Due to the possible pathological 
outcomes of T cell stimulation, successful activation requires a series of signals that 
must occur within appropriate temporal and spatial boundaries. The first signal 
required is T cell receptor (TCR) recognition of exogenous peptide bound to a MHC 
molecule on an APC. This non-covalent interaction initiates the recruitment of co-
receptors that are crucial for eliciting an appropriate response and provides the site 
at which consequent stimulatory signals must occur. The second activating signal 
consists of costimulatory receptors that associate with the TCR and bind their cognate 
molecules, facilitating lowering the threshold of T cell activation and forming the 
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immune synapse. CD28 is a particularly potent costimulatory receptor that associates 
with the TCR. Successful binding of CD28 to the B7 molecules CD80 and CD86 
promotes intracellular phosphorylation of CD28, leading to activation of lymphocyte-
specific protein tyrosine kinase (Lck), growth factor receptor-bound protein 2 (GRB2) 
and phosphatidylinositol-3-kinase (PI3K) signalling pathways in mice130–133 . There is 
also evidence that CD28 has a temporal influence on T cell activation as it reduces 
the amount of time required for activation after TCR recognition of peptide bound to 
MHC134,135.  
 
After initial TCR activation, expression of inhibitory receptors including CTLA-4 
(CD152) and PD-1 (CD279) are upregulated in order to control the strength and 
duration of T cell activation136,137. CTLA-4 is normally present as a dimer at low 
concentrations on the CD8+ T cell surface due to clathrin-mediated endocytosis138; 
however, TCR activation drives the production of protein and translocation of 
intracellular CTLA-4 to the cell membrane. CTLA-4 co-inhibition of the TCR is not fully 
understood; however several studies show its potent effects are the result of both cell 
intrinsic and extrinsic mechanisms. CTLA-4 shares its MYPPPY binding motif with 
CD28 and has a higher affinity for their cognate molecules CD80 and CD86139, 
allowing it to directly compete with CD28 at the immune synapse and prevent 
prolonged TCR excitation. After binding to B7 molecules, CTLA-4 produces a 
negative cell intrinsic signal through the dephosphorylation of proteins involved in 
TCR signalling, including CD3ζ, zeta chain associated protein kinase 70 (ZAP70), 
and Lck140. Furthermore, Treg cells are able to influence the activation of effector T 
cells via their CTLA-4 in a cell extrinsic manner. Treg cells can recognize MHC-
peptide complexes and bind their CTLA-4 receptor to B7 molecules on the APC 
surface. Due to the higher expression of CTLA-4 on Treg cells compared to effector 
T cells, this competition prevents CD28-mediated activation of non-regulatory T 
cells141. It has also been shown that by transendocytosis, T cells can completely 
remove B7 molecules from the APC and degrade them in intracellular lysosomes142.  
 
PD-1 signalling is distinct from CTLA-4 signalling; however, it is also capable of 
dephosphorylating molecules downstream of the TCR. It is largely associated with 
CD8+ T cell exhaustion, particularly in chronic infection143. PD-1 monomers on the T 
cell surface bind to PD-L1 (CD274), which is expressed on B and T cells, 
macrophages and dendritic cells; and PD-L2 (CD273), which is expressed 
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constitutively on macrophages and dendritic cells144. Binding leads to PD-1 
localisation to the TCR and de-phosphorylation of CD3ζ, ZAP70 and protein kinase 
C Θ (PKCΘ) via recruitment of SHP2145–147. Recruitment of SHP2 can also inhibit 
CD28 signalling as well as TCR signalling due to blocking PI3K activation 
downstream of CD28148. 
 
Due to the efficiency with which these inhibitory receptors can regulate T cell 
activation, they have been investigated extensively as targets for therapeutic 
interventions. Blockade of PD-1 signalling has been shown to have a positive effect 
on resolving infection in chronic, but not acute disease 143. CTLA-4 blockade however; 
can increase the action of antigen-specific T cells in both acute and chronic 
infection149–151. Further research has investigated the outcome of infection if inhibitory 
receptors are blocked concurrently with vaccination. In their investigations into 
improving vaccines against chronic viral infection, Sang-Jun Ha and others used a 
C57BL/6 mouse model in which mice were immunised with recombinant vaccinia 
virus that expresses a Lymphocytic choriomeningitis virus (LCMV) CD8+ T cell 
epitope152. On and following the day of immunisation, mice were given doses of PD-
L1 blocking antibody to prevent PD-1 signalling. Upon challenge with LCMV, it was 
observed that there was a synergistic effect of immunisation and blockade, increasing 
epitope-specific CD8+ T cell function which subsequently protected against infection, 
even in the absence of CD4+ T cells. With regard to CTLA-4 blockade with 
immunisation, the Allison group have used a Listeria monocytogenes mouse 
model153. OT-1 CD8+ T cells were adoptively transferred into C57BL/6 mice, followed 
by a vaccination dose of L. monocytogenes that expressed the ovalbumin CD8+ T cell 
epitope SIINFEKL. Blockade of CTLA-4 during vaccination resulted in an increase in 
the number of epitope-specific effector memory OT-1 CD8+ T cells and increased 
TNFα production upon re-stimulation with SIINFEKL peptide. These discoveries have 
led to continued animal and human research into cancer immunotherapy, showing 
clearance of tumours after vaccination concurrently with blockade of CTLA-4154–156, 
PD-1 and in combination157,158. 
 
During blood stage infection, T cell responses have multiple potential functions of 
both protection and pathology. As the clinical symptoms of malaria occur during blood 
stage infection, it is important to understand how these responses are regulated and 
this has led to some research into pathways including CTLA-4 and PD-1. Both CTLA-
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4 and PD-1 are upregulated during blood stage malaria infection in humans and non-
human animals106,159–162; however, their effects appear to be context dependent. In a 
study by Lepenies et al. infection of BALB/c mice with blood stage non-lethal Py 
(17NL) or lethal Py (17L) parasites resulted in increased CTLA-4 expression on CD4+ 
T cells but blockade of CTLA-4 during infection led to strikingly contrasting results163. 
CTLA-4 blockade with non-lethal Py infection led to reduced peak parasitaemia and 
early clearance of infection but CTLA-4 blockade with lethal infection resulted in 
increased liver pathology. It is also important to note that expression of CTLA-4 and 
PD-1 differs with models of Plasmodium infection. Blood stage infection of ECM 
resistant BALB/c mice with Pb ANKA results, paradoxically, in lower expression of 
CTLA-4 and PD-1 on CD4+ and CD8+ T cells compared to ECM susceptible C57BL/6 
mice; however, blockade of CTLA-4 or PD-1/PD-L1 but not PD-1/PD-L2 leads to 
BALB/c mice becoming susceptible to ECM94.  
 
Unfortunately, there is little understanding as to the importance of CTLA-4 or PD-1 
signalling in pre-erythrocytic malaria infection. In this study I investigate this question 
using a C57BL/6 mouse model of pre-erythrocytic γ-radiation attenuated Pb 
sporozoite immunisation and subsequent challenge. I gave a normally non-protective 
single immunisation with γ-radiation attenuated Pb sporozoites to C57BL/6 mice 
concurrently with or without blocking antibodies against CTLA-4, PD-L1 or PD-L2. 
Using flow cytometry and antibody-mediated blockade I show that immunisation with 
CTLA-4 blockade, but not PD-L1 or PD-L2 blockade significantly induces the 
production of IFNγ by CD8+ T cells upon peptide re-stimulation. Challenge of these 
mice in vivo resulted in a significant number of mice from the CTLA-4 group having 
sterile protection after infection, which was not observed in PD-L1 or control groups. 
Through the depletion of IFNγ, CD4 and CD8 I show that CTLA-4 blockade-mediated 
protection is through both CD4+ and CD8+ T cells and their production of IFNγ. Using 
flow cytometry and antibody-mediated blockade I show that immunisation with CTLA-
4 blockade, but not PD-L1 blockade significantly induces the production of IFNγ by 
CD8+ T cells upon sporozoite peptide re-stimulation. This is a proof of principle that 
immune modulation of CTLA-4 can augment CD8+ T cell-mediated protection in a 
normally non-protective single immunisation of γ-radiation attenuated Pb ANKA 
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2.2 Materials and Methods 
 
2.2.1 Mosquito and mouse conditions 
C57BL/6 mice between 5-8 weeks were bred in-house at London School of Hygiene 
and Tropical Medicine (LSHTM) or by Charles River Laboratories (UK). They were 
housed in filter-topped cages up to 6 per cage with absorbent bedding, nesting 
material and enrichment. Their diet consisted of autoclaved water and food pellets. 
Procedures were performed under license from the United Kingdom Home Office 
under the Animals (Scientific Procedures) Act 1986 and approved by the Animal Care 
and Ethical Review Committee. 
 
Pb ANKA infected Anopheles stephensi mosquitoes grown either at LSHTM or the 
Max Planck Institute for Infection Biology, Berlin were kept at 22°C with 80% humidity 
and fed on 10% glucose solution (10% D-Glucose [Sigma-Aldrich] in distilled water). 
In order to generate infectious Pb sporozoites, blood stage parasites were first 
collected from infected C57BL/6 mice via cardiac puncture into 1.5ml Eppendorf tubes 
(Sigma) with heparin (Sigma) and kept on ice. Blood was diluted 1:2 in freezing media 
made from 7.5% Glycerol (Sigma) in RPMI complete (RPMI 1640 [Gibco] with 10% 
FCS [Gibco], 2% L-Glutamine [Gibco] and 1% Penicillin and Streptomycin [Gibco]) 
and kept at -80°C. When required, blood stage parasites were thawed and 200μl was 
injected intravenously (i.v.) into a naïve C57BL/6 mouse. After three days, blood was 
collected from the infected mouse via cardiac puncture and 100,000 infected RBCs 
were passaged into two naïve C57BL/6 mice. 4 days after passage, mice were given 
a terminal dose (100-150μl) of anaesthesia consisting of 50% phosphate buffered 
saline (PBS) (Gibco), 33% ketamine (Ketamidor, 100mg/ml [National Veterinary 
Services Limited]) and 17% xylazine (Rompun, 2% w/v [National Veterinary Services 
Limited]) intraperitoneally (i.p.) and placed on a cage of mosquitoes (70 mosquitoes 
per mouse) for a 30 minute blood feed. Ketamidor and Rompun were purchased 
under prescription through LSHTM’s Named Veterinary Surgeon. 18-20 days after 
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2.2.2 Whole sporozoite immunisation and challenge 
Female Anopheles stephensi salivary glands were dissected from infected 
mosquitoes in RPMI complete and Pb ANKA sporozoites were isolated through 
salivary gland homogenisation and centrifugation. Glands were homogenised using 
autoclaved plastic pestles in Eppendorf tubes and centrifuged at 10,000 rpm for 3 
minutes. The pellet was re-suspended in 200μl of RPMI complete and Pb ANKA 
sporozoites were counted on a C-chip haemocytometer (Digital bio). For 
immunisations, Pb ANKA sporozoites were diluted to 50,000/ml in RPMI complete. 
To attenuate by irradiation for immunisation, the suspension was exposed to gamma 
radiation at 1.2x104 centigray (cGY) for 20.5 minutes. C57BL/6 mice were immunised 
by an i.v. injection of 10,000 attenuated Pb ANKA sporozoites per mouse. For 
challenge, Pb ANKA sporozoites were diluted to 5,000 per ml in RPMI and 1,000 
parasites were given i.v. per mouse. Parasitaemia (%) was measured by microscopy 
using thin blood smears from mouse tail blood that were fixed in methanol and stained 
for 15 minutes with Giemsa (VWR Chemical) diluted 1:5 in water.  
 
2.2.3 Antibody blockade 
Antibodies were diluted from stock solutions to 1mg/ml in PBS. 0.2ml of α-CTLA-4 
[UC10-4F10-11], α-PD-L1 [9G2] or α-PD-L2 [TY5] antibodies (BioXcell) were given 
i.p. per mouse concurrently with γ-radiation attenuated Pb ANKA sporozoite 
immunisation. For experiments in which they were used for neutralisation (α-IFNγ 
[XMG1.2]) or depletion (α-CD4 [GK1.5] and α-CD8 [53.6.72]) (BioXcell) antibodies 
were given 3 days and 1 day before Pb ANKA sporozoite challenge. Immunised 
controls were given 0.2ml of PBS i.p. per mouse and no antibodies. Previous work by 
our group has shown that rat IgG isotype controls do not provide any protection 
against malaria challenge 94. 
 
2.2.4 Flow cytometry 
Spleens were passed through a 70nm pore nylon cell strainer (BD) and centrifuged 
at 1,800 rpm for 4 minutes. To lyse RBC’s the pellet was re-suspended in 1ml of 1x 
lysis buffer (10x lysis buffer [BD] diluted 1:10 in autoclaved distilled water) and 
incubated for 10 minutes. Splenocytes were washed by diluting to 10ml in RPMI 
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complete followed by centrifugation at 1,800 rpm for 4 minutes, discarding the 
supernatant and diluted to 2 million cells per well. Livers were perfused with PBS 
during dissection and also passed through a 70nm nylon cell strainer. The 
homogenate was centrifuged at 1,800rpm for 4 minutes and the pellet was re-
suspended in Percoll gradient (4% 10x PBS [Gibco], 36% Percoll[GE Healthcare] and 
60% RPMI) and centrifuged at 2,000rpm for 10 minutes. Supernatant was discarded 
and RBC’s were lysed using lysis buffer for 5 minutes and washed in RPMI using the 
same protocol as for splenocytes before being re-suspended to 180μl per condition. 
 
Sporozoite peptides from TRAP (SALLNVDNL) and S20 (VNYSFLYLF) were 
synthesised by Mimotopes (Melbourne, Australia) using 9-fluorenylmethoxycarbonyl 
(Fmoc) chemistry and pseudoprolines to prevent unwanted coupling164. Lymphocytes 
were re-stimulated with 10μg of peptide and brefeldin A (BFA) (ebioscience). 
Lymphocytes were incubated for 6 hours at 37°C with 5% CO2. Cells were stained 
with α-CD3 (V500), α-CD4 (APC), α-CD8a (PerCP Cy5.5), α-CD11a (e450), α-IFNγ 
(PE Cy7), α-TNFα (FITC), α-CTLA-4 (PE) or α-PD-1 (PE Cy7) as required 
(ebioscience). 
 
2.2.5 Real Time PCR (RT-PCR) 
Liver sections were added to 3ml of TRIzol (Fisher Scientific) in a 15ml Falcon tube 
(Fisher Scientific) and homogenised using a Power Gen 125 tissue homogenizer 
(Fisher Scientific). Between samples the homogeniser was washed in distilled water 
and between groups it was washed in a 1% sodium dodecyl sulphate (SDS) (Sigma) 
solution. 200μl of sample was mixed with 300μl of TRIzol and stored at -80C until 
RNA extraction. For RNA extraction 200μl of chloroform was added to the 500μl 
sample and centrifuged at 13,000 rpm for 15 minutes at 4C. The upper layer was 
then transferred into 1.5ml RNAse free eppendorf tubes (ThermoFisher). 250μl of 
isopropanol, 60μl of 3M Sodium Acetate and 0.5μl glycoblue (5mg/ml) was added per 
sample and all samples were left at -20C overnight. Tubes were spun at 13,000 rpm 
for 15 minutes at 4C and the supernatant was removed. Pellets were washed with 
400μl of ice-cold ethanol and re-suspended before spinning at 13,000 rpm for 10 
minutes at 4C. 80μl of RNAse/DNAse-free water (Sigma) was added per sample and 
all tubes were heated to 65C until pellets had dissolved. To 5μl of RNA sample, 5μl 
of Oligo dT-Primers and 0.5μl random primers (Retroscript kit, Ambion) were added. 
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Tubes were centrifuged, put at 75C for 3 minutes and centrifuged again before being 
put on ice. To each sample a mix of 10x RT buffer, dNTP, 4x RNAse inhibitor and 
MMLV-RT enzyme (Retroscript kit, Ambion) was added before centrifugation. 
Samples were heated to 42C for 60 minutes followed by 90C for 10 minutes. cDNA 
was diluted and primers for the mouse endogenous control glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (forward 5'-CGTCCCGTAGACAAAATGGT-3', 
reverse 5'-TTGATGGCAACAATCTCCAC-3') (Eurofins) and Pb ANKA 18S (forward 
5’-TGAGGCCGGTGCTGAGTATGTCG-3’, reverse 5’- 
CCACAGTCTTCTGGGTGGCAGTG-3’) (Eurofins) were added with SYBR Green I 
Master Mix (ThermoFisher). Samples were run for 15 minutes at 95C as an initial 
denaturing stage. Amplification was 40 repetitions at 95C (denaturation) for 15 
seconds, 55C (annealing temp) for 15 seconds and 65C (data collection) for 45 
seconds. The final sequence collected melting curve data, beginning at 95C 
(denaturation) for 15 seconds then increasing from 60C by 1C per minute to a final 
temperature of 95C. A 7500 Fast & 7500 Real-Time PCR System (Applied 





In response to the pre-erythrocytic stage of malaria, T cell-mediated responses are 
crucial in resolving infection. Adoptive transfer of BALB/c parasite-specific effector 
memory CD8+ T cells (CD62L-CD127+) alone is sufficient to elicit sterile protection 
against Pb ANKA sporozoite challenge in naïve BALB/c mice124, showing that CD8+ 
T cells can independently clear infection. Although regulation of CD8+ T cells through 
pathways including CTLA-4 and PD-1 have been shown to be involved in blood stage 
malaria, little is known with regard to these pathways during liver stage malaria 
infection and how they may influence CD8+ T cell responses to sporozoite infection. 
To address this, I investigated whether CTLA-4 and PD-1 production is upregulated 
by T cells in response to a single immunisation with γ-radiation attenuated Pb ANKA 
sporozoite immunisation in C57BL/6 mice. Following from this I used a C57BL/6 
mouse model to determine whether modulation of these pathways can influence the 
magnitude of antigen-specific CD8+ T cell responses after a single, normally non-
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protective vaccination and whether this contributes towards immune protection from 
sporozoite challenge. 
 
I first investigated CTLA-4 and PD-1 expression on CD4+ and CD8+ T cells using a 
C57BL/6 mouse model of immunisation. 2 weeks after a γ-radiation attenuated Pb 
ANKA sporozoite immunisation, spleens and livers were taken and lymphocytes were 
stained for T cell markers CD3a, CD4 and CD8 as well as PD-1 and intracellular 
CTLA-4 (Figure 2.1). These two organs were chosen for study as the spleen is an 
important secondary lymphoid organ and a site for T cell activation to blood borne 
antigens and the liver is the site of pre-erythrocytic infection and therefore local T cell 
responses. Using flow cytometry I was able to distinguish any differences in 
expression of these regulatory molecules between immunised and naïve mice. The 
histograms showing median fluorescence intensity (MFI) for CTLA-4 showed small 
shifts towards higher levels of CTLA-4 on CD4+ and CD8+ T cells with immunisation 
(Figure 2.1). This trend was much more apparent when I compared the numbers of T 
cells expressing CTLA-4 with or without immunisation. Indeed, with immunisation 
there was significantly higher expression of CTLA-4 in the spleen and liver for CD8+ 
T cells and in the liver for CD4+ T cells. Similarly, for PD-1 expression there appeared 
to be a shift towards more CD4+ and CD8+ T cells expressing PD-1 after immunisation 
and this achieved significance in the spleen and liver for both CD4+ and CD8+ T cells. 
These experiments show that immunisation with γ-radiation attenuated Pb ANKA 
sporozoites followed by ex vivo sporozoite antigen re-stimulation leads to an increase 
in the production of PD-1 and CTLA-4 by CD4+ and CD8+ T cells in both liver and 
spleen T cells, suggesting a possible involvement of both pathways in regulating T 
cell responses to subsequent Pb sporozoite antigen exposure. 
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Figure 2.1. Attenuated Pb sporozoite immunisation increases the expression of CTLA-
4 and PD-1 on CD4+ and CD8+ T cells. 
C57BL/6 mice were either naïve or immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. After 2 weeks spleens and livers were taken and lymphocytes were stimulated 
with 10μg/ml of TRAP peptide (SALLNVDNL) for 6 hours with BFA. After stimulation, cells 
were stained for CD4, CD8 and PD-1 and intracellularly stained for CTLA-4. Statistics 
performed using Mann-Whitney t test, data from three experiments with n=4 mice per group. 
 
Showing that Pb sporozoite immunisation leads to an increase in T cell expression of 
PD-1 and CTLA-4 led to my next question, how strongly does increased expression 
of CTLA-4 and PD-1 influence functional T cell responses to sporozoite peptide 
antigen re-stimulation? C57BL/6 mice were given a single immunisation of γ-radiation 
attenuated Pb ANKA sporozoites i.v. concurrently with CTLA-4 or PD-L1 blockade. 
This was done by giving an additional injection of blocking antibodies (α-CTLA-4 and 
α-PD-L1 respectively) i.p. at the time of immunisation. The rationale for using blocking 
antibodies is that genetically knocking out CTLA-4 is fatal and knocking out PD-1 
results in spontaneous autoimmunity. By using blocking antibodies the function of 
these proteins can be inhibited for a determined amount of time in isolation in WT 
mice. Furthermore, using blocking antibodies in this way inhibits T cell activation 
during the initial immunisation, but when mice are subsequently challenged, these 
proteins are functional and T cell activation is restored. Therefore, the absence of 
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CTLA-4 or PD-1 signalling during sporozoite exposure alone can be investigated. 
Although not performed in this investigation, confirmation of blocking antibody 
specificity could be done by performing a western blot using recombinant protein that 
is to be blocked and targeting it with blocking antibody, finally using a secondary 
antibody to detect successful binding.  
 
In order to examine changes in the total number of antigen experienced T cells using 
flow cytometry, I gated CD3+CD4+ and CD3+CD8+ populations using CD11a (Figure 
2.2). CD11a is a marker for antigen experienced T cells, co-localising with CD18 to 
form lymphocyte function associated protein 1 (LFA1), which binds to intercellular 
adhesion molecule 1 (ICAM1), increasing adhesion and the frequency of antigen 
recognition. As positive readouts for CD8+ T cell activation, previously identified pre-
erythrocytic stage linear antigen sequences originating in thrombospondin-related 
adhesion protein (TRAP) (SALLNVDNL)66 and sporozoite-specific protein 20 (S20) 
(VNYSFLYLF)66 were used. 2 weeks after a single sporozoite immunisation with or 
without α-PD-L1 or α-CTLA-4, spleens and livers were taken and lymphocytes were 
re-stimulated with the TRAP or S20 peptides. After a 6 hour incubation with peptide, 
cells were fixed and stained for T cell markers CD3a, CD4, CD8 and CD11a and 
effector cytokine IFNγ for flow cytometric analysis. Secretion of IFNγ is critical for 
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Figure 2.2. CTLA-4 blockade with immunisation influences the number of parasite-
specific CD8+ T cells in the spleen and liver; however PD-L1 blockade does not. 
C57BL/6 mice were either naïve or immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. with or without 200μg of blocking antibody (α-CTLA-4 or α-PD-L1) i.p. After 2 
weeks spleens and livers were taken and lymphocytes were stimulated with 10μg/ml of TRAP 
(SALLNVDNL) or S20 (VNYSFLYLF) peptide for 6 hours with BFA. After stimulation, cells 
were stained for T cell markers CD3a, CD4, CD8a, CD11a and IFN. Total numbers of antigen 
experienced (CD11a+) CD8+ and CD4+ T cells are shown as well as total numbers of IFN-
producing CD8+ T cells after peptide re-stimulation (IFN+ CD11ahi). Statistics performed using 
Kruskal-Wallis test with Dunn’s multiple comparisons post-test. Pooled data from three 
experiments with n=5 mice per group per experiment. 
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In the spleen CTLA-4 blockade with a single γ-radiation attenuated Pb ANKA 
sporozoite immunisation consistently increased the total number of TRAP and S20 
peptide-specific, antigen experienced T cells (CD8+CD11ahi and CD4+CD11ahi T 
cells) compared to immunised and naïve controls. Most importantly, there is a clear 
difference in the spleen between the effect of CTLA-4 blockade with immunisation 
and the effect of PD-L1 blockade with immunisation on antigen experienced CD4+ 
and CD8+ T cell populations (p=0.0035 and p=0.0003 respectively). Compared to 
immunised control groups, PD-L1 blockade with immunisation did not significantly 
increase the total number of antigen experienced CD4+ or CD8+ T cells. In contrast, 
if mice received CTLA-4 blockade with immunisation there was a significant increase 
in antigen experienced CD4+ and CD8+ T cell numbers compared to immunised 
controls (p=0.0112 and p=0.0309 respectively). This observation was also true when 
functional production of IFNγ was measured. In the spleen, CTLA-4 blockade 
significantly increased the number of TRAP-specific IFNγ producing cells compared 
to PD-L1 blockade (p=0.018) and naïve and immunised controls (p=0.0001 and 
p=0.0415 respectively). After S20 re-stimulation, α-CTLA-4 treated mice also had 
significantly more peptide-specific, IFNγ producing CD8+ T cells compared to α-PD-
L1 treated or immunised or naïve controls (p=0.0167, p=0.0465 and p=0.0001 
respectively).  
 
In the liver, total numbers of antigen experienced CD8+ and CD4+ T cells appear to 
be similar whether immunisation was accompanied by CTLA-4 or PD-L1 blockade, 
although there is a trend towards higher numbers of antigen experienced CD4+ T cells 
if α-CTLA-4 was given at immunisation. Even though statistical significance was not 
observed, there was also a trend towards more IFNγ-producing CD8+ T cells after 
peptide re-stimulation if CTLA-4 was blocked at immunisation.  
 
Taken together, these results show that immunisation with blockade of CTLA-4 but 
not PD-L1 can result in an increase in the capacity to generate antigen experienced 
CD8+ and CD4+ T cells compared to mice that only received immunisation. With 
regard to functional responses, it would also appear that CTLA-4 blockade with y-
radiation attenuated Pb sporozoite immunisation increases the number of TRAP- and 
S20-specific, IFNγ-producing CD8+ T cells. As TNFα is also an important CD8+ T cell 
cytokine that is associated with protection in pre-erythrocytic malaria, TNFα 
production by CD8+ T cells after stimulation with TRAP and S20 peptides was also 
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investigated; however, although there was a small trend towards higher levels of 
TNFα with CTLA-4 blockade and immunisation compared to other groups, this was 
not significant (Figure 2.S1). For this reason future experiments focused on CD8+ T 
cell production of IFNγ. 
 
Although PD-L1 signalling is much more widely studied than PD-L2 signalling, I also 
investigated the effect of blocking PD-L2 with a single immunisation (Figure 2.3). PD-
L1 and PD-L2 do not have identical signalling pathways and act independently; 
however, the results show that PD-L2 blockade also has no effect on IFNγ production 
by antigen-experienced CD8+ T cells compared to CTLA-4 blockade with 
immunisation. Following these results I decided to focus on CTLA-4 signalling and 
PD-L1 signalling as PD-L1 blockade is much more extensively described in relation 
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Figure 2.3. CTLA-4 blockade with immunisation increases the number of parasite-
specific CD8+ T cells in the spleen and liver; however PD-L2 blockade does not. 
C57BL/6 mice were either naïve or immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. with or without 200μg of blocking antibody (α-CTLA-4 or α-PD-L2) i.p. After 2 
weeks spleens and livers were taken and lymphocytes were stimulated with 10μg/ml of TRAP 
(SALLNVDNL) or S20 (VNYSFLYLF) peptide for 6 hours with BFA. After stimulation, cells 
were stained for T cell markers CD3a, CD4, CD8a, CD11a and IFN. Total numbers of antigen 
experienced (CD11a+) CD8+ and CD4+ T cells are shown as well as total numbers of IFN-
producing CD8+ T cells after peptide re-stimulation (IFN+ CD11ahi). Statistics performed using 
Kruskal-Wallis test with Dunn’s multiple comparisons post-test. N=5 mice per group. 
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The main beneficial function of sporozoite-specific CD8+ T cells is their ability to 
recognise and kill exoerythrocytic form (EEF) infected cells. Therefore, my next 
question was whether CTLA-4 significantly reduces the capacity of CD8+ T cells to 
control parasitaemia in vivo in my C57BL/6 mouse model. As immunisations were 
performed with γ-radiation attenuated Pb ANKA sporozoites that experience arrested 
development in the liver, any sterile protection elicited by CTLA-4 blockade would be 
due to increased immune responses against pre-erythrocytic stage parasites. 
C57BL/6 mice that were immunised with or without blocking antibodies were 
challenged with 10,000 Pb sporozoites 14 days after immunisation by i.v. injection.  
 
Figure 2.4 shows the liver burden of Pb ANKA after challenge by measuring the 
presence of Pb ANKA 18S RNA in the liver relative to the mouse endogenous control 
GAPDH 40 hours after challenge. 18S expression was chosen as it is ubiquitously 
expressed throughout the Plasmodium life cycle and mouse GAPDH was chosen as 
it is a classic housekeeping gene that is expressed in abundance and constitutively 
in mouse tissue. With α-CTLA-4 treatment at immunisation, there is a striking 
reduction of parasite load in the liver after Pb sporozoite challenge compared to α-
PD-L1 treatment at immunisation and naïve and immunised controls (p=0002, 
p=<0.0001 and p=0.0084 respectively). It is also clear that PD-L1 blockade with 
immunisation does not elicit improved parasite control in the liver compared to 
controls. This provides strong evidence that CTLA-4, but not PD-L1 regulates T cell 
responses during γ-radiation attenuated Pb ANKA sporozoite immunisation and 
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Figure 2.4. Blockade of CTLA-4 but not PD-L1 significantly reduces the liver load of 
parasites. 
C57BL/6 mice were immunised with 10,000 γ-radiation attenuated Pb ANKA sporozoites i.v. 
with or without 200μg of blocking antibody (α-CTLA-4 or α-PD-L1) i.p. Naïve and immunised 
mice were challenged with 10,000 Pb sporozoites two weeks after immunisations were 
performed. Parasite liver load was measured by RT-PCR using primers for the Pb 18S gene 
and control mouse GAPDH gene. Results are shown as target expression relative to mouse 
GAPDH expression. Statistics performed using Kruskal-Wallis test with Dunn’s multiple 
comparisons post-test with n=8 mice per group. 
 
Sporozoite challenge of naïve C57BL/6 mice results in patent parasitaemia in 100% 
of mice between day 3 and day 5 post-infection. If no further treatment is given, 
between days 7 and 10 the parasitaemia and the subsequent pathological immune 
responses result in ECM165. Therefore, if there is no patent parasitaemia in mice by 
day 7, mice are considered to have sterile protection from blood stage infection. 
Antibody blockade of CTLA-4 with a single, normally non-protective, immunisation of 
γ-radiation attenuated Pb ANKA sporozoites in C57BL/6 mice elicited 60-100% sterile 
protection up to 1 week after challenge; however, only 1 mouse in all experiments 
had sterile protection with PD-L1 blockade (Figure 2.5). This shows that signalling 
through the CTLA-4 pathway has a potent effect on naïve T cell activation and 
subsequent responses to parasite infection. Although PD-L1 treatment resulted in a 
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Figure 2.5. α-CTLA-4, but not α-PD-L1 treatment elicits sterile protection from challenge  
C57BL/6 mice were immunised with 10,000 γ-radiation attenuated Pb ANKA sporozoites i.v. 
with or without 200μg of blocking antibody (α-CTLA-4 or α-PD-L1) i.p. and all mice were 
challenged 2 weeks later with 1,000 Pb ANKA sporozoites. Sterile protection (A) and 
parasitaemia (B) were determined by microscopy with thin tail blood smears. Statistics 
performed using Kruskal-Wallis followed by Dunn’s multiple comparisons post-test for sterile 
protection and day 7 post-infection parasitaemia. Pooled data from 4 experiments with n=4 to 
7 mice per group. 
 
The experiments previously described show that CTLA-4 blockade with a single non-
protective immunisation of γ-radiation attenuated Pb ANKA sporozoites increases the 
numbers of sporozoite antigen-specific CD8+ T cells and additionally, it significantly 
increases sterile protection and reduces parasitaemia upon sporozoite challenge. In 
order to further investigate the mechanism of protection with CTLA-4 blockade 
concurrently with γ-radiation attenuated Pb ANKA sporozoites, I additionally depleted 
CD4, CD8 or IFNγ with antibodies at the same time as Pb ANKA sporozoite challenge 
(Figure 2.6). By depleting CD8, CD4 or IFNγ immediately prior to peptide re-
stimulation, it is possible to investigate the immune response in the absence of the 
influence of these molecules. Blockade of CTLA-4 followed by depletion of CD8 or 
CD4 resulted in patent parasitaemia in all mice. This shows that the protection elicited 
by CTLA-4 blockade during attenuated sporozoite immunisation is mediated by both 
CD8+ T cell and CD4+ T cell mechanisms and that neither of these T cell 
compartments can elicit sterile protection without the other. Blockade of IFNγ resulted 
in a single mouse in a single experiment (14.2%) maintaining sterile protection, 
highlighting the importance of IFNγ in the production of T cell-mediated immunity with 
CTLA-4 blockade. As Th1 CD4+ T cells and CD8+ T cells are jointly capable of 
producing IFNγ it is perhaps not surprising that both are involved in the protection 
elicited by CTLA-4 blockade. Interestingly, these experiments do not show the relative 
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contribution of CD4+ or CD8+ T cell mechanisms to protection. Although the majority 
of liver stage protection has previously been attributed to CD8+ T cells, we cannot 
confirm here whether this is also true in the absence of CTLA-4 signalling. It would 
perhaps be interesting to adoptively transfer CD8+ and CD4+ T cells from mice 
vaccinated with CTLA-4 blockade into naïve mice to investigate this. 
 
 
Figure 2.6. CD8+ T cells as well as CD4+ T cells are involved in α-CTLA-4-mediated 
sterile protection and this is at least in part due to IFNγ signalling. 
C57BL/6 mice were immunised with 10,000 γ-irradiation attenuated Pb ANKA sporozoites i.v. 
with or without 200μg of blocking antibody (α-CTLA-4 or α-PD-L1) i.p. On days 11 and 13 after 
immunisation, mice either received no treatment or were given 200μg of blocking antibody (α-
IFNγ, α-CD8 or α-CD4) i.v. On day 14 post immunisation, all C57BL/6 mice were challenged 
with 1,000 Pb ANKA sporozoites i.v. Sterile protection (A) and parasitaemia (B) were 
determined by microscopy from thin tail blood smears. Statistics performed using Kruskal-
Wallis with Dunn’s multiple comparisons post-test. Pooled data from 2 experiments with n=6 
mice per group. 
 
As the magnitude of CD8+ T cell responses to malaria pre-erythrocytic stage antigens 
after sporozoite immunisation is dependent on IL-4 secreting CD4+ T cells78, it is 
perhaps unsurprising that blockade of CD4 results in patent parasitaemia with 
challenge in mice given a non-protective sporozoite immunisation with CTLA-4 
blockade. Due to the loss of protection when CD8 is blocked with CTLA-4, it appears 
that CTLA-4 blockade alone increases antigen experienced, IFN+ CD8+ T cells which 
have a direct functional consequence on eliciting sterile protection in C57BL/6 mice. 
 
The experiments described so far solely investigate short term immune responses 
after a single sporozoite immunisation. In order to investigate the significance of long-
 
Page | 48  
 
term protection mediated by CTLA-4 blockade with immunisation, mice were left for 
45 days after γ-radiation attenuated Pb ANKA sporozoite immunisation with or without 
CTLA-4 or PD-L1 blockade before being challenged with wild type (WT) Pb ANKA 
sporozoites (Figure 2.7). In contrast to challenge 14 days after immunisation, if mice 
were given α-CTLA-4 with γ-radiation attenuated Pb ANKA sporozoite immunisation 
and challenged 45 days later, the majority of mice became positive for blood stage 
parasites (Figure 2.7A). A single mouse still showed no blood stage parasites in the 
group treated with α-PD-L1 with γ-radiation attenuated Pb ANKA sporozoite 
immunisation. As with the previous experiments, all mice in the immunisation only 
and naïve groups became positive for parasites. Another similarity was the 
differences in the development of parasitaemia between groups. Parasitaemias in 
mice given an immunisation alone or concurrently with α-PD-L1 treatment developed 
with very similar % parasitaemia values (Figure 2.7B). These groups had consistently 
higher parasitaemias than mice treated with α-CTLA-4 and immunisation. This led to 
parasitaemias at day 7 being significantly different between α-CTLA-4 treated mice 










Page | 49  
 
 
Figure 2.7. Memory responses to challenge after CTLA-4 or PDL-1 blockade does not 
elicit sterile protection  
C57BL/6 mice were immunised with 10,000 γ-irradiation attenuated Pb sporozoites i.v. with 
or without 200μg of blocking antibody i.p. 45 days later all mice were challenged with 1,000 
Pb ANKA sporozoites i.v. and parasitaemia was measured by microscopy of thin blood 
smears. A) Frequency of sterile protection measured by microscopic analysis of thick blood 
smears. B) Parasitaemia calculated as a % of RBCs infected with parasites in thin blood 
smears. Statistics performed using Kruskal-Wallis test with Dunn’s multiple comparisons post-
test for sterile protection and one-way ANOVA followed by Turkey’s multiple comparisons test 
for % parasitaemia. N=5 mice per group. 
 
All naïve mice were positive for parasites by day 5 and began showing early signs of 
ECM by day 7. Mice that were given a γ-radiation attenuated Pb ANKA sporozoite 
immunisation alone or with α-PD-L1 treatment were very similar in their daily 
progression to patency. All mice in these two groups became positive by day 7. 
Interestingly, unlike in the 2 week experiments, the majority of mice in the α-CTLA-4 
group succumbed to patency (Figure 2.8); however, the progression in this group was 
protracted compared to the other groups. The progression to patency with CTLA-4 
blockade was significantly reduced compared to the control group, but not the α-PD-
L1 group. There was no significant difference in progression to patency between 
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Figure 2.8. CTLA-4 blockade can delay the onset of patency through long-term memory 
responses.  
C57BL/6 mice were either naïve or given a single i.v. immunisation of 10,000 –irradiation 
attenuated Pb ANKA sporozoites with or without PD-L1 or CTLA-4 blocking antibodies. After 
45 days mice were challenged with 1,000 Pb ANKA sporozoites i.v. and monitored for the 
onset of parasitaemia through microscopy of thin blood smears. N=6 mice per group. Statistics 
performed using Mantel-Cox test. 
 
These results show that the addition of CTLA-4 blockade into a normally non-
protective single vaccination strategy with attenuated sporozoites is able to generate 
sterile immunity. This protection from challenge involves both CD4+ and CD8+ T cell 
mechanisms and is mediated at least in part by IFNγ production. CTLA-4 blockade 
with immunisation also significantly increases the number of parasite-specific CD8+ T 
cells. These T cells can functionally respond to antigen stimulation by producing IFNγ. 
Interestingly, this is not seen with PD-L1 blockade, highlighting the different 










T cell regulation has been shown to influence both immunopathologies and clearance 
during parasite infections. In malaria, signalling through the co-inhibitory receptors 
CTLA-4 and PD-1 has been shown to be non-redundant in blood stage infection94; 
however, there is a paucity of understanding regarding these pathways during pre-
erythrocytic stage malaria infection. Normal responses to TCR activation, in addition 
to conventional excitatory signalling, includes the upregulation of co-inhibitory 
receptors to the cell surface, which act to reduce T cell activation through 
mechanisms including the reduction of IL-2 signalling166, which helps to prevent 
atypical lymphoproliferation and pathologies including autoimmunity. In acute blood 
stage Pb infection, blockade of CTLA-4 is capable of inducing ECM in normally 
refractory mouse strains94. This is a result of increased T cell activation during blood 
stage infection, leading to localized inflammation in the brain and reduced integrity of 
the blood-brain barrier. With vaccination, blockade of CTLA-4 has been shown to 
increase the number of pathogen-specific effector T cells prior to infection, allowing 
effective protection from patent infection. To investigate the contribution of co-
inhibitory receptor pathways in liver stage malaria immunisation, a C57BL/6 mouse 
model was used. C57BL/6 mice are non-resistant to malaria and are susceptible to 
ECM167, making them a good model for severe malaria. 
 
I hypothesized that there is an upregulation of CTLA-4 and PD-L1 on T cells during 
pre-erythrocytic malaria and that they can also modulate responses to pre-
erythrocytic infection. To do this, upregulation of CTLA-4 and PD-1 after sporozoite 
immunisation was investigated. By re-stimulating with our TRAP peptide, I could 
measure the expression of CTLA-4 and PD-1 on CD8+ and CD4+ T cells that can 
protect against patent infection (Figure 2.1). A significant increase in CTLA-4 and PD-
1 expressing T cells in immunised mice compared to naïve controls suggested that 
both may be influenced by sporozoite immunisation.  This confirms a relationship 
between the liver stage immune response and CTLA-4 and PD-1 pathways but it does 
not confirm whether these increases in expression result in a significant functional 
response. In order to investigate this, I used antibody-mediated blockade of CTLA-4 
PD-L1 or PD-L2 concurrently with a non-protective γ-radiation attenuated Pb ANKA 
sporozoite immunisation. By measuring T cell responses to re-stimulation, I 
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investigated the contribution of CTLA-4, PD-L1 and PD-L2 to the pre-erythrocytic 
stage immune response (Figure 2.2).  Previous research has identified linear 
sporozoite epitopes that can be utilized as positive readouts in ex vivo experiments 
with C57BL/6 mouse models to show pre-erythrocytic stage parasite-specific CD8+ T 
cell activation66. Unfortunately this is not yet possible for dissecting the CD4+ T cell 
response so this study focused on CD8+ T cell functional responses and their 
contribution to protection. 
 
Antigen experienced effector and memory T cells upregulate expression of CD11a on 
their surface and has been shown to accurately distinguish these populations from 
naïve T cells168. By using the same strategy, I investigated the total antigen 
experienced T cell populations with or without CTLA-4, PD-L1 or PD-L2 blockade. In 
the spleen, PD-L1 or PD-L2 blockade did not significantly increase the number of 
antigen experienced CD8+ or CD4+ T cells compared to controls; however blockade 
of CTLA-4 did. Interestingly, this was not observed in the liver as there was no 
significant increase in CD11ahiCD4+ or CD11ahiCD8+ T cell populations between PD-
L1, PD-L2 and CTLA-4 blockade groups. CTLA-4 blockade did significantly increase 
the number of CD11ahiCD4+ and CD11ahiCD8+ T cells compared to immunised 
controls, whereas PD-L1 blockade only achieved significance for CD11ahiCD8+ T 
cells. This discrepancy between the spleen and liver could be due to the tolerogenic 
environment of the liver. An important mechanism in preventing undesired T cell 
activation is through PD-1 signalling via LSECs74. As the liver is capable of soliciting 
naïve T cell activation169,170, blockade of PD-L1 or PD-L2 would reduce this inhibition 
and increase naïve T cell activation. Therefore blockade of PD-L1 or PD-L2 in the 
liver would result in an increase in naïve T cell activation to a variety of antigens 
arriving from the large intestine, antigens that would be largely non-sporozoite-
specific. This would also explain how we see comparable CD11a positive CD8+ T 
cells; however there is a clear difference in functional IFNγ production after peptide 
re-stimulation. 
 
Parasite-specific CD11a positive CD8+ T cells produced IFNγ upon re-stimulation, 
indicating that these antigen experienced cells could specifically recognize 
immunogenic antigens on the sporozoite and respond by generating functional 
cytokines associated with resolving infection. In the spleen, CTLA-4 blockade 
resulted in a significant increase in IFNγ production compared to naïve and 
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immunised controls as well as the PD-L1 blockade group. Even with the additional 
blockade of PD-L1 at immunisation, there was no increase in the number of IFNγ 
positive CD8+ T cells, suggesting this pathway is not salient in inhibiting naïve T cell 
activation during sporozoite immunisation. In the liver there is also a clear trend 
towards an increase in IFNγ positive CD8+ T cells with CTLA-4 blockade; however 
this is not significantly different from PD-L1 or PD-L2 blockade. Indeed, only with 
TRAP re-stimulation does CTLA-4 blockade show a significant increase compared to 
immunised controls. Together, these data show that blockade of CTLA-4 increases 
the capacity for T cells to become antigen experienced and subsequently increases 
functional responses to pre-erythrocytic malaria antigens through IFNγ production. 
 
Although blockade of CTLA-4 and PD-L1 can lead to pathogenic T cell activation in 
the context of blood stage malaria infection, blockade with an immunisation can help 
to improve vaccine efficacy. After showing an increased T cell functional response, I 
wanted to investigate whether blockade of these pathways could improve the efficacy 
of a non-protective pre-erythrocytic vaccination. In my mouse model, a single 
vaccination with attenuated sporozoites was unable to produce sterilizing protection 
in any C57BL/6 mice when challenged with Pb WT parasites (Figure 2.4). By giving 
this immunisation concurrently with a blockade of CTLA-4 I observed a significant 
increase in mice that could control parasite challenge and prevent patent 
parasitaemia up to 7 days after challenge. This level of protection was not seen with 
blockade of PD-L1, suggesting it is not as influential in negatively regulating naïve T 
cell activation in response to sporozoite antigens. This is interesting because we saw 
a significant difference in CD8+ T cell production of IFNγ in response to sporozoite 
antigen with α-CTLA-4 compared to α-PD-L1 groups in the spleen, but not in the liver. 
It would appear that blockade of CTLA-4 increases CD8+ T cell responses above a 
protective threshold with attenuated sporozoite vaccination; however PD-L1 blockade 
does not. 
 
To confirm that protection elicited by CTLA-4 blockade with a single sporozoite 
immunisation is due to immune responses towards liver stage infection, we measured 
the liver load of parasites after challenge (Figure 2.4). 40 hours after challenge there 
was a significant reduction in parasite load with CTLA-4 blockade compared to control 
and α-PD-L1 groups. This confirms that the increased sterile protection seen in 
Figures 2.5 and 2.6 with CTLA-4 blockade is due to detection and clearance of the 
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parasite in the liver, preventing patent infection. Whether the CD8+ T cell populations 
responsible for this are circulating or liver resident T cells is unknown and warrants 
further investigation. 
 
To further understand the mechanism of protection, I investigated the contribution of 
CD8+ T cells, CD4+ T cells and IFNγ to CTLA-4-mediated protection (Figure 2.7). By 
blocking CTLA-4 with immunisation, followed by blocking CD8, CD4 or IFNγ 3 days 
and 1 day before challenge, I was able to identify the contribution of each to 
protection. Interestingly, both CD8 and CD4 blockade resulted in reversal of the sterile 
protection elicited by CTLA-4 blockade, showing that both T cell populations are 
required in CTLA-4 blockade-mediated sterile immunity. Patent parasitaemia was 
also seen with neutralisation of IFNγ, highlighting its importance in the generation of 
effector responses in T cells. Therefore, sterile immunity elicited by CTLA-4 blockade 
with a single γ-radiation attenuated Pb ANKA sporozoite immunisation requires both 
CD4+ and CD8+ T cells and is mediated at least in part by IFNγ. Interestingly, the 
sterile protection offered by CTLA-4 blockade with sporozoite immunisation is not as 
effective in the context of long term memory responses. Although I show a significant 
delay in the onset of parasitaemia compared to immunised controls, I saw blood stage 
infection in 66.7% of mice in the α-CTLA-4 group by day 7 post-challenge. 
 
Taken together, the results of this study are a proof of principle that blockade of co-
inhibitory T cell signalling pathways can significantly improve the efficacy of pre-
erythrocytic vaccine responses in mice. It is important to note however; that this 
protection can only be achieved through targeting specific pathways as not all are 




There is a clear global need to improve the efficacy of vaccines for both infectious 
and non-infectious diseases. Modulating regulation of T cell responses is increasingly 
becoming a focus of vaccinology as it has been shown to improve vaccine efficacy in 
both human and non-human trials. In malaria, T cell regulation in pre-erythrocytic 
infection is poorly understood; however, co-inhibitory receptors including CTLA-4 and 
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PD-1 have been shown to be non-redundant in blood stage infection. In this study, I 
show that it is possible to improve a normally non-protective single immunisation with 
attenuated whole sporozoites by concurrently blocking CTLA-4. This protection is 
mediated by CD8+ and CD4+ T cells and is dependent on production of IFNγ. These 
data provide strong evidence for a proof of principle that blockade of co-inhibitory 
receptors concurrently with a normally non-protective pre-erythrocytic vaccination can 
elicit sterile protection. Further research into other potential inhibitory or stimulatory 
receptors that could be targeted to improve pre-erythrocytic vaccine efficacy is critical 
to improve our understanding of T cell regulation and to identify pathways that could 
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2.6 Supplementary Data 
 
Figure 2.S1. Both CTLA-4 or PD-L1 blockade with immunisation do not increase TNFα 
production by parasite-specific CD8+ T cells in the spleen and liver. 
C57BL/6 mice were either naïve or immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. with or without 200μg of blocking antibody (α-CTLA-4 or α-PD-L1) i.p. After 2 
weeks spleens and livers were taken and lymphocytes were stimulated with 10μg/ml of TRAP 
(SALLNVDNL) or S20 (VNYSFLYLF) peptide for 6 hours with BFA. After stimulation, cells 
were stained for T cell markers CD3a, CD4, CD8a, CD11a and TNFα. Total numbers of 
antigen experienced (CD11a+) CD8+ and CD4+ T cells producing TNFα after peptide re-
stimulation (TNFα+ CD11ahi). Statistics performed using Kruskal-Wallis test with Dunn’s 
multiple comparisons post-test. Pooled data from three experiments with n=5 mice per group 
per experiment.
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Protection against malaria requires a complex collection of immune responses that 
must adapt as infection progresses from the pre-erythrocytic stages to the blood 
stage. During the clinically silent pre-erythrocytic stage of infection, Plasmodium 
sporozoites that enter the vertebrate host via a blood meal from an infected female 
Anopheles mosquito quickly localise to the liver and begin hepatic development, 
which ultimately results in patent, clinical blood stage infection. While infection is 
limited to the pre-erythrocytic stage, the principle mediators of protection are parasite 
antigen-specific CD8+ T cells41,56. Their mechanism of protection is so significant that 
depleting CD8+ T cells by antibody depletion before sporozoite challenge can 
completely abrogate any protection elicited by immunisation in both mice and rhesus 
monkeys42,171. This further supports evidence that successful immunisation of 
humans, either by whole sporozoite immunisation or subunit immunisation, results in 
increased functional, IFNγ producing CD8+ T cells that are associated with 
protection56,172. Unfortunately, although protective CD8+ T cell responses can be 
induced against pre-erythrocytic malaria, the current gold standard requires multiple 
immunisations with very high numbers of attenuated sporozoites as a single 
immunisation is not sufficient. Therefore the question is, what mechanisms are 
regulating CD8+ T cell responses to pre-erythrocytic malaria in order to necessitate 
multiple exposures to high concentrations of antigen.  
 
Due to the potential pathogenic consequences of T cell activation during blood stage 
malaria, regulatory pathways have been investigated to a much greater extent than 
for the pre-erythrocytic stage. Using a model of blood stage malaria infection, Kimura 
and colleagues identified FoxP3- CD4+ T cells that performed a regulatory role through 
IL-27 cytokine production leading to reduced proliferation of effector T cells173. Using 
RT-PCR they showed that infection of FoxP3hCD2 knock-in mice with blood stage Pb 
parasites resulted in a significant increase in the expression of the IL-27 subunits 
IL27p28 and Epstein Barr virus induced gene 3 (EBi3) by FoxP3-CD11a+CD4+ T cells 
when stimulated with Pb antigen and anti-TCR. The negative regulatory function of 
IL-27 in blood stage malaria has also been shown through its promotion of increased 
production of IL-10 by CD4+ T cells during infection174,175, reduction in the capacity of 
CD4+ T cells to migrate to the liver176 and the non-redundant role of IL-27 in inhibiting 
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pathogenic Th1 activation during blood stage malaria as shown in the work of Gwyer 
Findlay et al., using mice that do not express WSX-1, the alpha subunit of IL-27R102. 
As WSX1-/- mice cannot express the full IL-27R, signalling through this receptor is 
prevented and the effects of its absence can be investigated. Interestingly, Gwyer 
Findlay et al. showed that, although depletion of CD4+ T cells in WSX1-/- mice reduced 
liver pathology in blood stage infection, depletion of CD8+ T cells did not. Additionally, 
they showed that there was no difference in CD8+ T cell production of IFNγ in their 
model of infection between IL-27 signalling deficient or WT mice. This suggests that 
CD8+ T cell activation may not be regulated by IL-27 in blood stage Pb infection. 
Despite the expression of WSX-1 and gp130 on CD8+ T cells177 and the protective 
function of IFN production, the role of IL-27 signalling on CD8+ T cell regulation 
during liver stage malaria infection has not been fully investigated.  
 
In humans, it has been shown that individuals with circulating CD4+ T cells that 
produce higher levels of IL-10 are more likely to have had a greater number of malaria 
episodes99; however, these individuals also experience more asymptomatic 
infections. This trend was confirmed by de Mendonca et al. whilst investigating Pv 
infections178. These investigations highlight that the severity of malaria infections is at 
least partially dependent on the inflammatory phenotype of T cells and that IL-10 
expression by CD4+ T cells correlates with control of clinical disease. This has also 
been shown in mouse models during blood stage malaria infection. IL-10 signalling 
has been shown in a BALB/c model to be a regulatory factor that reduces immune 
pathology95 and a C57BL/6 infection model of lethal and non-lethal Py showed that 
the likely source for IL-10 is from regulatory type I T cells and that classical regulatory 
T cells do not influence the outcome of infection179. These studies show that IL-10 is 
non-redundant in regulating CD4+ T cell activation and immune pathology during 
blood stage infection; however it’s regulation of CD8+ T cells during infection is 
unknown. 
 
IL-27 is a member of the IL-12 family, a group of type I cytokines including IL-12, IL-
23, IL-27 and IL-35. These cytokines are heterodimeric and their subunits have been 
shown to be capable of promiscuity between different binding partners to form the 
different cytokines. IL-12 itself consists of the subunits IL-12p40 and IL-12p35; 
however the p40 subunit is also used in IL-23 (IL-12p40 binding to IL-12p19)180 and 
the p35 subunit is required for IL-35 (IL-12p35 binding to EBi3)181. IL-27 is the result 
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of a heterodimer between IL-27p28 and EBi3182 and has a complex role in the immune 
response. The majority of IL-27 production is via innate myeloid cells, particularly 
monocytes, macrophages and dendritic cells183 after activation of Toll-like receptors 
(TLR), CD40, CD137184,185 or stimulation with type I or type III interferons following 
infection186–190. 
 
IL-27 is recognized by its receptor IL-27R, which consists of IL-27R and the shared 
receptor subunit gp130182, which is also used in several other cytokine receptors 
including IL-6R and IL-11R. Recognition of IL-27 by its receptor has been shown to 
influence both innate and adaptive immunity. Signalling promotes activation of natural 
killer (NK) cells191, increases the survival of eosinophils192 and indirectly reduces the 
activity of neutrophils193. For adaptive immune responses, IL-27 appears to be 
particularly important in CD4+ T cell responses as it polarizes the population towards 
a type I CD4+ helper T cell (Th1) phenotype. This is achieved through activation of 
the transcription factor T-bet and increasing ICAM1 and IL12R2 expression while 
also actively inhibiting GATA-binding protein 3 expression194, which is responsible for 
Th2 differentiation. In addition to CD4+ T cells, CD8+ T cells are also activated via IL-
27 stimulation of T-bet leading to increased IFN secretion and the production of 
granzyme B and perforin to promote cytotoxic activity195. Interestingly, IL-27 is also 
associated with negative regulation of immune responses. Signalling increases 
production of the anti-inflammatory cytokine IL-10196, inhibits the production of IL-
2197,198 and promotes regulatory T cell differentiation199. In particular, type I regulatory 
CD4+ T cell differentiation is promoted, leading to suppression of effector T cell 
activation, increased tolerance through IL-10 secretion, removal of APC’s through 
perforin and granzyme B secretion and reduction of the capacity of APC’s to activate 
effector cells200. 
 
The apparent dichotomy of IL-27 signalling outcomes with infection is largely 
attributed to the inflammatory environment. Early studies suggested IL-27 signalling 
as pro-inflammatory due to its ability to promote Th1 responses with peptide 
stimulation201,202 or during infection with Listeria monocytogenes 182,202 and 
Leishmania major 203. More recently however, a mouse model showed that 
Toxoplasma gondii infection in the absence of IL-27 prevents downregulation of CD4+ 
T cell responses following the acute phase, leading to lethal inflammatory disease204. 
Similarly, with Mycobacterium tuberculosis the absence of IL-27 leads to a decrease 
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in the bacterial load and severe lung pathology205 and with Trypanosoma cruzi 
infection, IL-27 is responsible for regulating excessive production of the pro-
inflammatory cytokines IL-6, TNFα and IFN206. Together, these studies suggest that 
IL-27 can promote early pro-inflammatory immune responses and polarize T cell 
differentiation; however it also limits the duration and intensity of inflammatory 
responses. It would appear that these properties have greater or lesser effects on 
immunity depending on the infectious agent. Interestingly, it has been suggested that 
the particular cellular source of IL-27 could have some contribution to the apparent 
diversity of IL-27 signalling consequences183. 
 
IL-10, unlike IL-27 is associated with purely anti-inflammatory immune regulation and 
is the original member of the IL-10 family of class II cytokines (also including IL-19, 
IL-20, IL-22, IL-24 and IL-26). As a major mediator of anti-inflammatory signalling its 
expression is tightly regulated as over expression can lead to poorer responses to 
cancer207 and deficiency leads to uncontrolled inflammation208–214. IL-10 is produced 
as a homodimer by the majority of leukocytes215 and acts through Jak1/STAT3 
signalling. Upon recognition of IL-10 by the IL-10R Jak1 is recruited and 
phosphorylated, allowing the activation of STAT3 and its formation of homodimers. 
Translocation of STAT3 homodimers to the nucleus allows for transcriptional 
inhibition of factors involved in inflammation including TNF, IFN, IL-4, IL-5 and IL-
2216–218 and the activation of mechanisms that inhibit inflammatory responses such as 
apoptosis. Due to the importance of IL-10 in negatively regulating T cell activation 
and the protective nature of CD8+ T cell activation during pre-erythrocytic stage 
infection, an important area of investigation is whether this pathway can modulate 
CD8+ T cells and their capacity to protect against patent blood stage infection. 
 
As the field of T cell regulation becomes increasingly complex, it is crucial to 
understand how different pathways are employed in different pathogenic contexts. 
This is particularly important for infections that are known to require T cell activation 
for protection, such as liver stage infection in malaria. By understanding the influence 
of the multitude of regulatory mechanisms available, we can greater understand 
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3.2 Materials and Methods 
 
3.2.1 Mosquito and mouse conditions 
C57BL/6 and WSX-1-/- mice between 5-8 weeks were bred in-house at London School 
of Hygiene and Tropical Medicine (LSHTM) or by Charles River Laboratories (UK). 
They were housed in filter-topped cages up to 6 per cage with absorbent bedding, 
nesting material and enrichment. Their diet consisted of autoclaved water and food 
pellets. Procedures were performed under license from the United Kingdom Home 
Office under the Animals (Scientific Procedures) Act 1986 and approved by the 
Animal Care and Ethical Review Committee. 
 
Pb ANKA infected Anopheles stephensi mosquitoes grown at LSHTM were kept at 
22°C with 80% humidity and fed on 10% glucose solution (10% D-Glucose [Sigma] 
in distilled water). In order to generate infectious Pb ANKA sporozoites, blood stage 
parasites were first collected from infected C57BL/6 mice via cardiac puncture into 
1.5ml Eppendorf tubes (Sigma) with heparin (Sigma) and kept on ice. Blood was 
diluted 1:2 in freezing media made from 7.5% Glycerol (Sigma) in RPMI complete 
(RPMI 1640 [Gibco] with 10% FCS [Gibco], 2% L-Glutamine [Gibco] and 1% Penicillin 
and Streptomycin [Gibco]) and kept at -80C. When required, blood stage parasites 
were thawed and 200μl was injected i.v. into a naïve C57BL/6 mouse. After three 
days, blood was collected from the infected mouse via cardiac puncture and 100,000 
parasites were passaged into two naïve C57BL/6 mice. 4 days after passage, mice 
were given a terminal dose (100-150μl) of anaesthesia consisting of 50% PBS, 33% 
ketamine (Ketamidor, 100mg/ml [National Veterinary Services Limited]) and 17% 
xylazine (Rompun, 2% w/v [National Veterinary Services Limited]) i.p. and placed on 
a cage of mosquitoes (70 mosquitoes per mouse) for a 30 minute blood feed. 
Ketamidor and Rompun were purchased under prescription through LSHTM’s Named 
Veterinary Surgeon. 18-20 days after blood feed, mosquitoes were judged to be 




Page | 63  
 
 
3.2.2 Whole sporozoite immunisation and challenge 
Female Anopheles stephensi salivary glands were dissected from infected 
mosquitoes in RPMI complete and Pb ANKA sporozoites were isolated through 
homogenisation and centrifugation. Glands were homogenised using autoclaved 
plastic pestles in Eppendorf tubes and centrifuged at 10,000 rpm for 3 minutes. The 
pellet was re-suspended in 200μl of RPMI complete and Pb ANKA sporozoites were 
counted on a C-chip haemocytometer (Digital bio). For immunisations, Pb ANKA 
sporozoites were diluted to 50,000/ml in RPMI complete. To attenuate by irradiation 
for immunisation, the suspension was exposed to gamma radiation at 1.2x104 
centigray (cGY) for 20.5 minutes. C57BL/6 mice were immunised by an i.v. injection 
of 10,000 attenuated Pb ANKA sporozoites per mouse. For challenge, Pb ANKA 
sporozoites were diluted to 5,000 per ml and 1,000 were given i.v. per mouse. 
Parasitaemia (%) was measured by microscopy using thin blood smears from mouse 
tail blood that were fixed in methanol and stained for 15 minutes with Giemsa (VWR 
Chemical) diluted 1:5 in water.  
 
3.2.3 Antibody blockade 
Antibodies were diluted from stock solutions to 1mg/ml in PBS. 0.2ml of α-IL-10R 
[JES5-2A5] (BioXcell) was given i.p. per mouse concurrently with γ-radiation 
attenuated Pb ANKA sporozoite immunisation. WSX-1-/- controls were given 0.2ml of 
PBS i.p. per mouse and no antibodies. Previous work by our group has shown that 
rat IgG isotype controls do not provide any protection against malaria challenge 94. 
 
3.2.4 Flow cytometry 
Spleens were passed through a 70nm pore nylon cell strainer (BD) and centrifuged 
at 1,800 rpm for 4 minutes. To lyse RBC’s the pellet was re-suspended in 1ml of 1x 
lysis buffer (10x lysis buffer [BD] diluted 1:10 in autoclaved distilled water) and 
incubated for 10 minutes. Splenocytes were washed by diluting to 10ml in RPMI 
complete followed by centrifugation at 1,800 rpm for 4 minutes, discarding the 
supernatant and diluted to 2 million cells per well. Livers were perfused with PBS 
during dissection and also passed through a 70nm nylon cell strainer. The 
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homogenate was centrifuged at 1,800 rpm for 4 minutes and the pellet was re-
suspended in Percoll gradient (4% 10x PBS [Gibco], 36% Percoll[GE Healthcare] and 
60% RPMI) and centrifuged at 2,000rpm for 10 minutes. Supernatant was discarded 
and RBC’s were lysed using lysis buffer for 5 minutes and washed in RPMI as with 
splenocytes before being re-suspended to 180μl per condition. 
 
Sporozoite peptides from TRAP (SALLNVDNL) and S20 (VNYSFLYLF) were 
synthesised by Mimotopes (Melbourne, Australia) using Fmoc chemistry and 
pseudoprolines to prevent unwanted coupling164. Lymphocytes were re-stimulated 
with 10μg of peptide and BFA (ebioscience). Lymphocytes were incubated for 6 hours 
at 37°C with 5% CO2. Cells were stained with α-CD3 (V500), α-CD4 (APC), α-CD8a 
(PerCP Cy5.5), α-CD11a (e450) or α-IFNy (PE Cy7) as required (ebioscience). 
 
3.2.5 Real Time PCR (RT-PCR) 
Liver sections were added to 3ml of TRIzol (Fisher Scientific) in a 15ml Falcon tube 
(Fisher Scientific) and homogenised using a Power Gen 125 tissue homogenizer 
(Fisher Scientific). Between samples the homogeniser was washed in distilled water 
and between groups it was washed in a 1% SDS (Sigma) solution. 200μl of sample 
was mixed with 300μl of TRIzol and stored at -80C until RNA extraction. For RNA 
extraction 200μl of chloroform was added to the 500μl sample and centrifuged at 
13,000 rpm for 15 minutes at 4C. The upper layer was then transferred into 1.5ml 
RNAse free eppendorf tubes (ThermoFisher). 250μl of isopropanol, 60μl of 3M 
Sodium Acetate and 0.5μl glycoblue (5mg/ml) was added per sample and all samples 
were left at -20C overnight. Tubes were spun at 13,000 rpm for 15 minutes at 4C 
and the supernatant was removed. Pellets were washed with 400μl of ice-cold ethanol 
and re-suspended before spinning at 13,000 rpm for 10 minutes at 4C. 80μl of 
RNAse/DNAse-free water (Sigma) was added per sample and all tubes were heated 
to 65C until pellets had dissolved. To 5μl of RNA sample, 5μl of Oligo dT-Primers 
and 0.5μl random primers (Retroscript kit, Ambion) were added. Tubes were 
centrifuged, put at 75C for 3 minutes and centrifuged again before being put on ice. 
To each sample a mix of 10x RT buffer, dNTP, 4x RNAse inhibitor and MMLV-RT 
enzyme (Retroscript kit, Ambion) was added before centrifugation. Samples were 
heated to 42C for 60 minutes followed by 90C for 10 minutes. cDNA was diluted 
and primers for the mouse endogenous control glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH) (forward 5'-CGTCCCGTAGACAAAATGGT-3', reverse 5'-
TTGATGGCAACAATCTCCAC-3') and Pb ANKA 18S (forward 5’-
TGAGGCCGGTGCTGAGTATGTCG-3’, reverse 5’- 
CCACAGTCTTCTGGGTGGCAGTG-3’), Pb ANKA IL-10 (forward 5’-
ATGCTGCCTGCTCTTACTGACTG-3’, reverse 5’-
CCCAAGTAACCCTTAAAGTCCTGC-3’), Pb ANKA IL-27p28 (forward 5’- 
CTGGTACAAGCTGGTTCCTG-3’, reverse 5’- CTCCAGGGAGTGAAGGAGCT-3’), 
Pb ANKA EBi3 (forward 5’- CAGAGTGCAATGCCATGCTTCTC, reverse 5’- 
CTGTGAGGTCCTGAGCTGAC-3’), Pb ANKA WSX-1 (forward 5’-
CAAGAAGAGGTCCCGTGCTG-3’, reverse 5’-  
TTGAGCCCAGTCCACCACAT-3’) (Eurofins) were added with SYBR Green I Master 
Mix (ThermoFisher). Samples were run for 15 minutes at 95C as an initial denaturing 
stage. Amplification was 40 repetitions at 95C (denaturation) for 15 seconds, 55C 
(annealing temp) for 15 seconds and 65C (data collection) for 45 seconds. The final 
sequence collected melting curve data, beginning at 95C (denaturation) for 15 
seconds then increasing from 60C by 1C per minute to a final temperature of 95C. 
A 7500 Fast & 7500 Real-Time PCR System (Applied Biosystems) was used and 




Deletion of the wsx-1 gene in mice abrogates IL-27R signalling203 by preventing the 
expression of the WSX-1 subunit of the IL-27R. As these mice were generated on a 
C57BL/6 genetic background, the use of this KO strain with C57BL/6 WT controls has 
been extensively used in mouse models to investigate IL-27R signalling in relation to 
immune responses. The outcome of IL-27R signalling during Plasmodium infection 
has been investigated primarily in relation to CD4+ T cell responses in blood stage 
infection due to its involvement in regulatory T cell development and function. 
Regarding cytotoxic responses, Gwyer Findlay and colleagues showed that blockade 
of CD8+ T cells during infection of WSX-1-/- KO mice did not lead to reduced pathology 
as mentioned previously102. In addition to this, CD8+ T cells in WSX-1-/- KO mice did 
not produce different levels of IFNγ in relation to WT during infection (data not shown). 
These results suggest that IL-27R signalling is not required for CD8+ T cell responses 
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during blood stage infection; however, its effect during liver stages has not been 
investigated. Although IFNγ production is associated with both blood and liver stage 
malaria57,219–221 its action is largely through different mechanisms, raising the question 
whether other immune pathways such as IL-10 and IL-27 could have differing 
influences on blood and liver stage responses.  
 
 
Figure 3.1. Pb ANKA sporozoite immunisation does not influence IL-10 or IL-27 cytokine 
expression, but does increase WSX-1 expression.  
C57BL/6 mice were either naïve or immunised with y-radiation attenuated Pb ANKA 
sporozoites i.v.. 14 days after immunisation, all mice were challenged with 1,000 Pb ANKA 
sporozoites and livers were collected 40 hours later. Expression of IL-27p28 (A), EBi3 (B), 
WSX-1 (C), IL-10 (D) and control mouse GAPDH RNA was measured by RT-PCR. Results 
are shown as target expression relative to mouse GAPDH expression. Data taken from two 
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Using RT-PCR I first investigated the amount of IL-10 RNA as well as WSX-1, 
IL27p28 and EBi3 RNA in naïve and immunised C57BL/6 mouse livers. Challenge 
with Pb sporozoites after immunisation did not lead to a significant increase in IL-27 
cytokine subunits IL-27p28 and EBi3 were not increased significantly (Figure 3.1A 
and Figure 3.1B respectively); however, there was a small but significant increase in 
the expression of WSX-1 (Figure 3.1C), which suggests there may be some influence 
of sporozoite immunisation on IL-27R expression in the liver. Regarding IL-10 
expression, there was not a significant increase after challenge with Pb sporozoites 
(Figure 3.1D). 
 
In this study WSX-1-/- mice and C57BL/6 WT controls were given a single non-
protective immunisation of γ-radiation attenuated Pb ANKA sporozoites to generate 
pre-erythrocytic stage immune responses. In C57BL/6 mouse models of malaria 
vaccination using radiation attenuated sporozoites, challenge after one immunisation 
is insufficient to elicit sterile protection59; however, 2 or more immunisations can. In 
my experiments, lymphocytes isolated from spleens and livers of C57BL/6 mice that 
were given a single immunisation were cultured with TRAP or S20 peptides, which 
allowed for the re-stimulation of Pb ANKA sporozoite-specific CD8+ T cells. It has 
been shown that antigen experienced T cells can be gated using CD11a as a marker 
of previous antigen exposure168. In order to compare the total numbers of antigen 
experienced CD8+ and CD4+ T cells, they were gated on CD11a as shown in figure 
3.2.  
 
There were no significant differences in the total numbers of CD8+ and CD4+ T cells 
between WT controls and WSX-1-/- mice that were immunised in both the spleen and 
the liver (Figure 3.2). This shows that with immunisation and re-stimulation, there is 
no significant increase or decrease in T cell expansion when IL-27R signalling is 
absent. As an increased population of T cells is expected with improved sporozoite 
vaccine-induced responses222, this suggests that IL-27R signalling is not critical in 
regulating functional pre-erythrocytic stage T cell responses in the spleen or the liver. 
Although there were no apparent differences in the size of CD8+ or CD4+ T cell 
populations, I wanted to further investigate functional antigen experienced CD8+ T 
cell responses by measuring the production of IFNγ upon exposure to Pb ANKA 
sporozoite peptides from TRAP and S20.  
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Figure 3.2 shows the capacity for CD8+ T cells to produce IFNγ after re-stimulation, 
also measured by flow cytometry. With TRAP peptide stimulation there was a slight 
trend towards more CD8+ T cells producing IFNγ in both the spleen and the liver for 
the WSX-1-/- compared to WT controls; however this did not achieve statistical 
significance in any of my experiments. By contrast, there was a significant difference 
in splenic and liver IFN+ CD8+ T cells between WSX-1-/- and WT immunised groups 
after S20 peptide re-stimulation (p=0.0217 and p=0.0213 respectively). This is 
interesting as it highlights the differing magnitude of CD8+ T cell responses to antigen; 
however, it is important to understand whether there is an improvement in the total 
functional response to challenge after whole sporozoite immunisation in the absence 
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Figure 3.2. Immunisation in the absence of IL-27R does not significantly influence the 
number of parasite-specific CD8+ T cells in the spleen and liver. 
C57BL/6 and WSX-1-/- mice were either naïve or immunised (Imm.) with 10,000 γ-radiation 
attenuated Pb ANKA sporozoites i.v. After 2 weeks spleens and livers were taken and 
lymphocytes were stimulated with 10μg/ml of TRAP or S20 peptide for 6 hours with BFA. After 
stimulation, lymphocytes were stained for activated T cell markers CD3a, CD4, CD8a, CD11a 
and intracellular IFN. Total antigen experienced (CD11ahi) CD8+ and CD4+ T cells are shown 
as well as activated CD8+ T cells after re-stimulation (IFN+ CD11a+). Statistics were 
performed using Kruskal-Wallis test with Dunn’s multiple comparisons post-test. Pooled data 
from 2 experiments, n=5 per group. 
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As there was a trend towards higher CD8+ T cell responses in WSX-1-/- immunised 
mice, I investigated their potential to reduce Pb ANKA parasite load in the liver after 
sporozoite challenge. I challenged WT and WSX-1-/- mice with 1,000 infectious Pb 
ANKA sporozoites i.v. and measured parasite load in the liver after 40 hours. By 
performing RT-PCR I measured the presence of the Pb gene 18S and calculated liver 
load in comparison to the expression of mouse GAPDH endogenous control (Figure 
3.3). Even though innate immune responses can contribute, sterile protection 
requires a substantial increase in parasite-specific CD8+ T cells after 
immunisation59,122. The results of figure 3.2 suggest a general trend; however, in the 
absence of a strong significant difference, I hypothesized there would be no increased 
reduction in parasite liver load in WSX-1-/- immunised mice compared to WT 
immunised mice after Pb ANKA sporozoite challenge. As expected, between 
immunised groups there was no significant difference, confirming my hypothesis. A 
single immunisation did decrease the relative parasite load in the liver of immunised 
mice vs naïve mice, but this is not sufficient for protection. These data show that, 
even though there may be a slight increase in functional CD8+ T cell responses, 
blockade of IL-27R signalling does not improve the protective capacity of a single 
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Figure 3.3. IL-27R signalling does not significantly inhibit the reduction of parasites in 
the liver. 
C57BL/6 and WSX-1-/- mice were immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. followed by challenge 2 weeks later with 1,000 Pb ANKA sporozoites i.v. Livers 
were taken 40 hours after challenge and parasite load was measured by measuring Pb 18S 
DNA using RT-PCR. Relative parasite load is shown (A), calculated by comparing the amount 
of 18S DNA relative to a control endogenous mouse gene GAPDH DNA for each sample. Fold 
change in relative parasite load between naïve and immunised groups for each strain is also 
shown (B). Pooled data from 2 experiments with n=5 per group. Statistics were performed 
using the Mann-Whitney t test. 
 
The experiments described so far have shown that IL-27R signalling blockade with 
immunisation compared to WT controls results in a trend, but not a significant 
increase in the magnitude of the functional CD8+ T cell response to liver stage malaria 
antigen (Figure 3.2). Additionally, IL-27R blockade with a single γ-radiation 
attenuated Pb ANKA immunisation does not lead to a significant increase in 
protection from Pb ANKA sporozoite challenge (Figure 3.3). However, the data 
provided so far does not address IL-27R signalling blockade with regard to memory 
CD8+ T cell responses. To investigate this; mice were similarly given a single 
immunisation of radiation attenuated Pb ANKA sporozoites but spleens and livers 
were not harvested until 45 days after immunisation. In this way, the long term CD8+ 
T cell response could be investigated by ex vivo re-stimulation. As with the previous 
experiments, there was no difference in the total number of antigen experienced CD8+ 
and CD4+ T cells (Figure 3.4). It is interesting that the trend in functional CD8+ T cell 
responses were also similar. With TRAP peptide re-stimulation there was a non-
significant trend towards more IFN+ CD8+ T cells in the spleen and liver. A trend was 
also apparent with S20 re-stimulation but in contrast to the previous experiments, 
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there was no significant difference. These results suggest that the small but 
consistent increase in IFN+ CD8+ T cells after immunisation is still apparent in CD8+ 
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Figure 3.4. Immunisation in the absence of IL-27R does not significantly influence 
responses by parasite-specific memory CD8+ T cells in the spleen and liver. 
C57BL/6 and WSX-1-/- mice were either naïve or immunised with 10,000 γ-radiation 
attenuated Pb ANKA sporozoites i.v. After 45 days spleens and livers were taken and 
lymphocytes were stimulated with 10μg/ml of TRAP or S20 peptide for 6 hours with BFA. After 
stimulation, lymphocytes were stained for activated T cell markers CD3a, CD4, CD8a, CD11a 
and intracellular IFN. Total antigen experienced (CD11ahi) CD8+ and CD4+ T cells are shown 
as well as activated CD8+ T cells after re-stimulation (CD11ahi IFN+). N=6 per group. Statistics 
were performed using Kruskal-Wallis test with Dunn’s multiple comparisons post-test. 
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As with my previous experiments, I also investigated whether the absence of IL-27R 
signalling led to an increased protection against Pb ANKA sporozoite challenge by 
measuring liver load (Figure 3.5). Perhaps unsurprisingly, after 45 days there was still 
no significant difference in the relative parasite load between naïve and immunised 
C57BL/6 and WSX-1-/- mice (Figure 3.5B).  
 
Figure 3.5. IL-27R signalling does not significantly inhibit the reduction of parasites in 
the liver long-term after immunisation. 
C57BL/6 and WSX-1-/- mice were immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. followed by challenge 45 days later with 1,000 Pb ANKA sporozoites i.v. Livers 
were taken 40 hours after challenge and parasite load was measured by measuring Pb 18S 
DNA using RT-PCR. Relative parasite load is shown (A), calculated by comparing the amount 
of 18S DNA relative to a control endogenous mouse gene GAPDH DNA for each sample. Fold 
change between naïve and immunised groups for each strain is also shown (B). N=6 per 
group. Statistics were performed using the Mann-Whitney t test. 
 
Together with these investigations into IL-27R signalling and liver stage Plasmodium 
infection, I examined the importance of IL-10R signalling in regulating the CD8+ T cell 
response. Rather than using a knockout strain of mouse, I used blocking antibodies 
that selectively block the IL-10R alongside a single immunisation of γ-radiation 
attenuated Pb ANKA sporozoites to C57BL/6 mice. As with my IL-27R investigation, 
CD8+ T cells were re-stimulated with TRAP or S20 peptide and stained for flow 
cytometry (Figure 3.6). With regard to total numbers of antigen experienced 
CD11ahiCD8+ T cells, immunisation increased numbers significantly compared to 
naïve mice in the spleen and liver; however, there was no difference between 
immunised controls and IL-10R blockade with immunisation. The same relationship 
was seen when comparing IFN+ CD8+ T cells after both TRAP and S20 peptide re-
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stimulation, suggesting that blockade of IL-10R signalling does not influence CD8+ T 
cell responses to liver stage malaria.  This does not however inform us as to the 
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Figure 3.6. IL-10R blockade with immunisation does not significantly influence the 
number of parasite-specific CD8+ T cells in the spleen and liver. 
C57BL/6 mice were either naïve or immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. with or without 200μg of blocking antibody in PBS (α-IL-10R) i.p. After 14 days 
spleens and livers were taken and lymphocytes were stimulated with 10μg/ml of TRAP or S20 
peptide for 6 hours with BFA. After stimulation, lymphocytes were stained for activated T cell 
markers CD3a, CD4, CD8a, CD11a and intracellular IFN. Total antigen experienced 
(CD11a+) CD8+ and CD4+ T cells are shown as well as activated CD8+ T cells after re-
stimulation (IFN+ CD11a+). Statistics performed using Kruskal-Wallis test with Dunn’s multiple 
comparisons post-test. Pooled data from two experiments with 4 mice per group per 
experiment. 
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As with our investigation of IL-27R signalling, we challenged mice 14 days after 
immunisation concurrently with or without IL-10R blockade to discern any possible 
protection in the liver compared to immunised controls (Figure 3.7). It is clear that the 
parasite load for the immunised control and -IL-10R groups is comparable, with no 
significant increased protection with IL-10R blockade. This confirms that the absence 
of IL-10R signalling does not improve the protective immune response to pre-
erythrocytic malaria infection and, with the data from figure 3.6, does not increase the 




Figure 3.7. Blockade of IL-10R does not reduce the liver load of parasites. 
C57BL/6 mice were naïve or immunised with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. with or without 200μg of blocking antibody in PBS (α-IL-10R) i.p. After 14 days 
all mice were challenged with 10,000 Pb ANKA sporozoites i.v. Livers were taken 40 hours 
after challenge and parasite load was measured by measuring Pb 18S RNA using RT-PCR. 
Relative parasite load is shown, calculated by comparing the amount of 18S cDNA relative to 
a control endogenous mouse gene GAPDH cDNA for each sample. Statistics performed using 



























Immune responses to malaria infection are not sufficient to induce sterile protection 
in subsequent exposure. This is at least in part due to regulatory mechanisms that 
reduce the capacity for immune cell activation and memory. As regulation is a crucial 
aspect of immune activation and function, increasing our understanding of these 
pathways allows us to better appreciate what mechanisms are involved in infection 
resolution. In addition it also provides insight into pathways that could potentially be 
utilised to the benefit of the individual. Two pathways that have been extensively 
investigated with regard to T cell regulation are IL-27 and IL-10, both of which have 
been implicated in blood stage immune responses to malaria. Interestingly, their 
involvement in immune responses to sporozoite infection has not been previously 
investigated. IL-27 has a complex role in immune regulation, in a study performed by 
Matsui and colleagues, concomitant administration of recombinant IL-27 and IL-23 
was given during a prime-boost immunisation regimen for hepatitis C virus (HCV)223. 
This resulted in an increase in virus-specific, IFN producing CD8+ T cells.  In contrast 
to this, Pennock et al. investigated subunit vaccination of Listeria monocytogenes or 
vaccinia virus and discovered that there were no significant differences in CD8+ T cell 
activation upon challenge between control mice and IL-27Rα knockout mice224. The 
role of IL-10 in immune regulation on the other hand, is much more binary. It is a 
master negative regulator of immune function, inhibiting pathogen clearance and 
reducing inflammatory pathology225. In this study, I have investigated the influence of 
these pathways using two mouse models for severe malaria. Interestingly, I have 
shown that IL-27R and IL-10R signalling appear to not be involved in CD8+ T cell 
regulation during responses to liver stage infection. As both of these pathways 
influence T cell activation during blood stage infection it is important to note that here 
I show regulation during blood stage infection cannot lead to assumptions of 
regulation during the liver stage. 
 
As IL-27R signalling is capable of inducing both pro- and anti-inflammatory immune 
responses to infection, an important question for this study was whether it influenced 
liver stage infection and, if so, how. By running flow cytometry on spleens and livers 
from immunised C57BL/6 and WSX-1-/- mice, I aimed to answer this question. After a 
single non-protective immunisation, followed by peptide re-stimulation I investigated 
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the magnitude of CD11ahiCD4+ and CD11ahiCD8+ T cell populations and the 
functional responses of antigen experienced CD8+ T cells. The size of both T cell 
populations was not significantly different 14 days after the single sporozoite 
immunisation, suggesting that there was no additional positive or negative influence 
of IL-27R signalling on antigen experienced T cell expansion. To measure functional 
responses, CD8+ T cells were stimulated ex vivo with TRAP or S20 peptides. Re-
stimulation by the sporozoite TRAP peptide resulted in a trend towards higher IFNγ 
CD8+ T cell numbers in the absence of IL-27R but this was not significant in both 
experiments (Figure 3.2). In contrast, with S20 peptide re-stimulation of both spleen 
and liver CD8+ T cells, there was a significant increase in WSX-1-/- IFNγ CD8+ T cell 
numbers (p=0.0217  and p=0.0213 respectively). Previous work by this group has 
shown that Th2 CD4+ T cells are required to control the magnitude of the CD8+ T cell 
responses in liver stage malaria78. The trend seen in my experiments could suggest 
a small, indirect influence of IL-27R signalling via a decrease in the proportion of Th2 
cells as the absence of IL-27 leads to an increase in the magnitude of the CD8+ T cell 
population. It is interesting that the S20 peptide would induce a stronger CD8+ T cell 
response than TRAP but the salient question from these experiments was whether 
the total CD8+ T cell response was sufficiently increased in WSX-1-/- mice to elicit 
increased protection from sporozoite challenge. 
 
The possibility that IL-27R signalling does influence the immune response to liver 
stage malaria was investigated by measuring parasite liver load after sporozoite 
challenge. A single immunisation with irradiated Pb ANKA sporozoites was again 
given to C57BL/6 and WSX-1-/- mice and 14 days later all were challenged i.v. with 
Pb sporozoites. EEF development in the liver occurs within 50 hours after infection226–
229 so livers were dissected between 40 and 42 hours after sporozoite challenge for 
RT-PCR quantification of parasitaemia. The rationale for 40-42 hours after challenge 
was that it is sufficient for successful hepatocyte invasion but not long enough for full 
schizont maturation, which has been similarly used in previous publications230. 
Immunisation elicited a significant reduction in parasite liver loads in both mouse 
conditions. Importantly however, even a two log reduction in parasite liver load is 
insufficient to elicit sterile protective responses. As a reliable CD4+ T cell epitope for 
liver stage infection isn’t available at the current time it is difficult to accurately 
measure CD4+ T cell activation in response to peptide re-stimulation; however, once 
a candidate is discovered, it would be interesting to investigate how IL-27R signalling 
 
Page | 80  
 
influences CD4+ T cell activation as well as CD8+ T cells using the methods described 
here. 
 
IL-27 has also been shown to be a regulator of long term T cell responses224,231. In 
order to fully understand whether IL-27 influences T cell memory, I repeated the single 
immunisation with C57BL/6 and WSX-1-/- that was performed in the experiments for 
figure 3.2, followed by a period of 45 days before dissecting livers and spleens for 
lymphocyte re-stimulation. Following initial exposure to an infectious agent, antigen-
specific T cell populations expand and differentiate to control infection. After 
resolution of infection, these T cell populations contract to prevent atypical activation. 
This leaves long-lived T cells that can respond to subsequent infection more rapidly 
and with greater avidity than the primary response232. Therefore, it is perhaps not 
surprising that there is almost a log reduction in the size of CD8+ and CD4+ T cell 
populations between 14 and 45 days. Similarly, there is a reduction in IFNγ producing 
CD8+ T cells following peptide re-stimulation, which is proportional across all 
experimental groups. Importantly, there is an additional contrast with experiments 
from figure 3.2 as there is no significant difference between WT and WSX-1-/- 
immunised groups after S20 peptide re-stimulation. It is interesting that a trend 
towards higher IFNγ production by parasite-specific CD8+ T cells persists with 
memory populations. As there is not a similar trend between naïve groups it would 
appear unlikely that this is the result of innate differences in the size of T cell 
populations between strains. It would seem that IL-27R signalling may have a small 
influence on functional CD8+ T cell responses to liver stage malaria; however, alone 
is not sufficient to significantly regulate them. 
 
Extensive research into IL-10 in the context of infectious disease has shown that it is 
capable of strong negative regulation of immune responses. During infection with 
malaria, IL-10 has been associated with protection against blood stage pathologies, 
which are at least in part a result of CD8+ T cell-mediated inflammation, leading to 
liver pathology, cerebral malaria, and other organ failures attributed to severe 
disease. As with IL-27R signalling, IL-10 is capable of influencing multiple cell types 
of both immune and non-immune lineages. Interestingly, again there is a paucity of 
information available regarding the influence of IL-10 signalling during the liver stage 
of malaria and specifically how it influences different T cell populations. 
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In this study I attempted to increase our understanding of IL-10-mediated regulation 
during liver stage infection. Using similar methods as for my investigation of IL-27R 
signalling, I immunised C57BL/6 mice with a single non-protective γ-radiation 
attenuated Pb ANKA sporozoite immunisation; however, rather than using a KO 
mouse strain, I blocked the IL-10R at immunisation using α-IL10R antibodies. Using 
flow cytometry to investigate T cell populations and functional responses, I observed 
no difference between control groups and mice that were given IL-10R blocking 
antibodies. This is interesting as IL-10 signalling has been implicated in T cell 
responses to blood stage malaria infection however, in the context of liver stage 
infection this does not appear to be the case. From these results, I also investigated 
whether blockade of IL-10R with immunisation offers any protection against Pb ANKA 
sporozoite challenge. As expected, there was no reduction in parasite liver load with 




Regulatory signalling through IL-27 and IL-10 have been widely studied; however, 
until now they have not been investigated in the context of CD8+ T cell responses to 
pre-erythrocytic stage malaria infection in a mouse model of ECM. With regard to IL-
27R signalling, there was a non-significant and non-protective increase in functional 
CD8+ T cells in WSX-1-/- mice compared to C57BL/6. This is interesting and could be 
further investigated in combination with other regulatory or excitatory pathways. IL-10 
signalling is also not involved in regulation of CD8+ T cells during liver stage infection 
but, by showing this I have increased our understanding of the complex subject of 
regulation in pre-erythrocytic stage malaria. Although both pathways have been 
implicated in T cell responses during blood stage infection, it is interesting that I have 
not found any significant contribution of either pathway to regulating protective CD8+ 
T cell responses. This shows that our understanding of regulation for blood stage 
malaria cannot lead to assumptions of regulation during the pre-erythrocytic stages 









4  |  Host Resistance to 
Plasmodium-Induced Acute 
Immune Pathology Is Regulated 
by Interleukin-10 Receptor 
Signalling 
  
The work presented in this chapter is adapted and extended from the following 
publication233 with permission: 
Carla Claser, J. Brian De Souza, Samuel G. Thorburn, Georges Emile Grau, 
Eleanor M. Riley, Laurent Rénia and Julius C. R. Hafalla. Host Resistance to 
Plasmodium-Induced Acute Immune Pathology Is Regulated by Interleukin-10 
Receptor Signaling. Infect. Immun. 85, e00941-16 (2017) 
 
My contribution to this investigation includes flow cytometric analysis of T cell 
responses to blood stage Pb malaria infection of BALB/c mice with IL-10R blockade 











The regulation of pathological mechanisms leading to cerebral malaria (CM), a severe 
complication of infection with the malaria parasite Plasmodium falciparum, remains 
obscure. ECM due to Pb ANKA infection in susceptible C57BL/6 mice mimics the 
neurological signs observed during human CM, including ataxia and/or paralysis, 
which rapidly deteriorate to convulsions, coma, and death 7 to 10 days 
postinfection234,235. Histological examination of both CM and ECM brain sections 
reveals the presence of petechial hemorrhages236–238. Furthermore, both CM and 
ECM are characterized by the accumulation of parasitized red blood cells (pRBCs) 
and leukocytes in the cerebral microvasculature.  
 
In C57BL/6 mice, the development of ECM is associated with CD8 Clec9A DCs, 
which prime naive CD4 and CD8+ T cells to become effector cells and secrete pro-
inflammatory cytokines such as IFNy239,240. The production of IFNy by CD4+ T cells is 
thought to enhance the recruitment of effector CD8+ T cells to brain microvessels, 
where pRBCs also accumulate89,241. These effector CD8+ T cells, upon recognition of 
the parasite-derived epitopes presented by the brain endothelial cells242,243, secrete 
perforin and granzymes, leading to breaching of the blood-brain barrier90–92 and 
causing hemorrhages. Besides neurological impairment, Pb ANKA-infected C57BL/6 
mice develop a multiorgan disease, and in the absence of cerebral pathology, animals 
die at a later time point because of anaemia and hyperparasitemia241.  
 
In contrast, Pb ANKA infection of BALB/c mice does not generally lead to ECM and 
therefore this strain is considered ECM resistant, although the infected animals 
succumb to anaemia and hyperparasitemia 2 to 3 weeks postinfection94,234. However, 
the immune mechanisms that confer resistance to ECM remain poorly understood. 
We previously showed that T cell inhibitory pathways, CTLA-4, and PD-1/PD-L1 
independently regulate host resistance to ECM94. Blockade of the CTLA-4 or PD-1/ 
PD-L1 pathway in Pb ANKA-infected BALB/c mice led to the development of ECM 
with characteristics similar to those observed in C57BL/6 mice.  
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IL-10, an anti-inflammatory cytokine, is a principal regulator of immunity to infection. 
IL-10 signalling through its receptor (IL-10R, CD210) is known to attenuate the 
production of IFNy and other pro-inflammatory responses244,245, which may otherwise 
induce immune pathology during acute infections. In the nonlethal models of P. 
chabaudi and Py blood stage malaria infection, deficiency in IL-10 signalling is 
associated with increased IFNy secretion and good parasite control at the expense 
of exacerbated immune pathology246–248. Likewise, IL-10 deficiency is fatal in the 
avirulent murine models of both Toxoplasma gondii and Trypanosoma cruzi210,249. 
Together, these studies clearly indicate a critical role for the IL-10R signalling pathway 
in preventing pathology. IL-10R signalling attenuates the production of IFNγ and other 
pro-inflammatory responses responsible for inducing immune-mediated pathology 
during acute parasitic infections.  
 
In the present study, we hypothesized that IL-10R signalling also regulates T-cell- 
mediated inflammatory responses in ECM-resistant BALB/c mice, thereby preventing 
the onset of ECM. Blockade of the IL-10R during Pb ANKA infection of BALB/c mice 
results in acute immune-mediated pathology with features resembling those of ECM 
in susceptible mice. Therefore, the IL-10R signalling pathway appears to effectively 
maintain the equilibrium between pathogen clearance and tissue damage during the 
early stages of a lethal malaria infection in BALB/c mice.  
 
4.2 Materials and Methods  
 
4.2.1 Animals 
In the United Kingdom, 6- to 12-week-old female BALB/cAnNCrl mice were 
purchased from Charles Rivers UK Ltd. and maintained under barrier conditions. 
Animal experiments were approved by the London School of Hygiene and Tropical 
Medicine Animal Welfare and Ethical Review Board and performed under Animals 
(Scientific Procedures) Act 1986. In Singapore, 6- to 7-week-old female BALB/cJ 
mice were bred and kept under specific-pathogen-free conditions in the Biomedical 
Resource Center of A*STAR. Animal experiments were approved by the A*STAR 
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Institutional Animal Care and Use Committee in accordance with the rules and 
regulations of the Singaporean Agri-Food and Veterinary Authority and the National 
Advisory Committee for Laboratory Animal Research.  
 
4.2.2 Parasites and experimental infections 
Experimental infections were initiated by i.v. inoculation of 104 pRBCs. In the United 
Kingdom, Pb ANKA parasites (Pb ANKA clone 15cy1250, referred to here simply as 
Pb ANKA) expressing green fluorescent protein were used. In Singapore, 
transgenic parasite Pb ANKA line 231cl1 expressing luciferase and green 
fluorescent protein (referred to here as Pb ANKA luc) was provided by Christian 
Engwerda (QIMR Berghofer Medical Research Institute, Brisbane, Australia). 
Infected mice were monitored for neurological signs (uncoordinated and reduced 
locomotion, paralysis, deviation of the head, ataxia, convulsions, and coma). 
Parasitemia levels were monitored by the examination of Giemsa-stained thin blood 
smears or by flow cytometry251. In some experiments, day 7 infected mice were 
sacrificed and perfused and their brains and livers were removed for histology or 
imaging (see below). Serum was stored at 70°C for cytokine quantification (see 
below).  
 
4.2.3 In vivo administration of antibodies 
All antibodies were administered by intraperitoneal injection. Blocking antibody to IL-
10R [1B1.3A] was administered at 0.3 mg/mouse on day 1 postinfection and at 0.2 
mg/mouse on days 1, 4, and 6 postinfection. Neutralizing antibody to IFNγ [XMG1.2] 
was administered at 0.4 mg/mouse on days 4 and 6 postinfection, and depleting 
antibodies to CD4 [GK1.5] and CD8 [53.6.72] were administered at 1 mg/mouse on 
day 6 postinfection. All antibodies were rat anti-mouse IgG, obtained from BioXCell 
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4.2.4 Flow cytometry 
The antibodies (clones) used for cell surface staining were (obtained from eBiosci- 
ence) anti-mouse CD4 (GK1.5), CD8 (53.6-7), CD11a (M17/4), and CD62L (MEL-
14) or (obtained from BD Biosciences) anti-mouse CD3 (145-2C11), CD4 (RM4-5), 
and CD8 (53-6.7). Isolated brain and splenic leukocytes were directly stained in 
accordance with standard protocols94. Antibodies used for intracellular staining were 
obtained from eBioscience (IFNγ [XMG1.2]). Intracellular staining was per- formed 
by permeabilizing cells with 0.1% saponin–PBS. Cells were analyzed with a 
FACSCalibur or LSR II (BD Immunocytometry Systems) and FlowJo software 
(TreeStar). Gating strategies were performed as previously described, where T cells 
are gated from singlets/live and lymphocyte populations94. Absolute numbers of 
lymphocytes were calculated from cell counts.  
 
4.2.5 Cytokine quantification 
Serum cytokine levels were assayed with the IFNγ Quantikine kit and the 
Quantikine ELISA mouse IL-10 kit (both from R&D Systems) in accordance with the 
manufacturer’s protocol. Intracellular IFNγ levels were measured by flow cytometry 
(as described above) following 5 h of spleen cell culturing in the presence of phorbol 
myristate acetate (PMA; 50 ng/ml), ionomycin (1 g/ml), and brefeldin A (1 g/ml).  
 
4.2.6 Bioluminescent imaging 
Daily in vivo imaging was done to monitor the Pb ANKA luc parasite distribution 
(IVIS; Xenogen, Alameda, CA). Infected mice were shaved, anesthetized, and 
injected subcutaneously with 100 l of D-luciferin potassium salt (5 mg/ml in PBS; 
Caliper Life Sciences). Two minutes later, bioluminescence images were acquired 
with a medium binning factor and a field of view (FOV) of 21.7 cm for the whole 
body (ventral) or 4 cm for the head (dorsal). The exposure imaging time was 5 to 60 
s. For ex vivo imaging, mice were given a second injection of luciferin and 
anesthetized and 3 min later perfused and sacrificed. Brains were removed and 
imaged with a 10-cm FOV. To allow comparisons of images from different days, 
uninfected mice injected with luciferin were imaged for background subtraction. 
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Bioluminescence quantification was done by using Living Imaging 4.2 software and 




Infected mice were sacrificed on day 7 postinfection. Mice were perfused with PBS, 
and their isolated brains and livers were immersed in 4% formaldehyde and 
embedded in paraffin. Sagittal sectioning was performed to obtain 5- m-thick brain 
and liver sections, which were stained with hematoxylin and eosin (H&E). Slides 
were acquired on a Metafer4 (MetaSystems), and numbers of hemorrhages, 
leukocytes, and necroses (of the liver) were manually determined.  
 
4.2.8 Statistical analysis 
Differences in survival were assessed with the log rank (Mantel-Cox) test, and 
Bonferroni correction was used to adjust for multiple comparisons within the log 
rank (Mantel-Cox) test. The cumulative ECM incidence between two groups was 
analyzed with Fisher’s exact test. Comparisons of two groups were made with the 
Mann-Whitney test, and for multiple comparisons (more than two groups), statistical 
significance was determined with the Kruskal-Wallis test with Dunn’s multiple 
comparisons post-test. For log-transformed values to allow normal distribution of the 
data, analysis of variance with Bonferroni’s posttest for multiple groups was used. 
The data were analyzed with GraphPad Prism software (version 6.0) with P 0.05 as 
the level of significance.  
 
4.3 Results  
 
To establish whether IL-10R signalling regulates ECM pathogenesis in an otherwise 
ECM- resistant mouse strain, the outcomes of Pb ANKA infection in control mice and 
mice treated with blocking antibodies to IL-10R were compared. While control BALB/c 
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mice (treated with rat IgG or phosphate-buffered saline [PBS]) survived for up to 2 
weeks postinfection, mice treated with anti-IL-10R antibody developed classical 
neurological signs of ECM and were euthanized on day 7 or 8 postinfection (Figure 
4.1A and B). Both the survival curve and the cumulative ECM incidence of anti-IL-
10R antibody- treated mice differ significantly from those of control mice. Strikingly, 
anti-IL-10R antibody-treated mice presented significantly lower parasitemia levels on 
days 5 and 7 postinfection than control mice (Figure 4.1C). Consistent with the 
development of ECM, the number of accumulated intravascular CD8+ T cells was 
higher in the brains of anti-IL- 10R antibody-treated mice than in those of control mice 
(Figure 4.1D).  A key feature of human CM and ECM in mice is the accumulation of 
pRBCs in the brain microvasculature. To determine the effects of IL-10R signalling 
on parasite accumulation, control and anti-IL-10R antibody-treated mice were 
infected with Pb ANKA luc parasites that express luciferase. The survival curve and 
cumulative ECM incidence (Figure 4.2A and B) of Pb ANKA luc-infected control and 
anti-IL-10R antibody-treated mice were similar to those of Pb ANKA-infected mice, 
although the onset of ECM was somewhat delayed. Anti-IL-10R antibody-treated P. 
berghei ANKA luc-infected mice developed ECM between days 7 and 12 
postinfection, and control mice survived until day 25. Pb ANKA luc-infected anti-IL-
10R antibody-treated mice presented with significantly lower parasitemia values on 
days 5 and 7 postinfection than control mice (Figure 4.2C). However, when parasite 
accumulation was measured by luminescence in the whole body (Figure 4.2D), head 
(Figure 4.2E), and isolated brain (Figure 4.2F and G), the values were significantly 
higher in anti-IL-10R antibody-treated mice than in control mice. These results 
indicate that despite a lighter peripheral parasite burden in anti-IL-10R antibody-
treated mice than in control mice, the generalized parasite biomass is significantly 
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Figure 4.1: IL-10R blockade in Pb ANKA-infected BALB/c mice results in ECM.  
 
BALB/c mice were infected i.v. with 104 Pb ANKA pRBCs and treated with anti-IL-10R 
antibodies. Control mice received either no antibody or rat IgG. (A) Cumulative survival curve. 
Closed circles, control (n 12); open circles, anti-IL-10R antibody (n 12). ***, P 0.0001 (log rank 
[Mantel-Cox] test). (B) Cumulative incidence of mice developing ECM (based on neurological 
signs, i.e., ataxia and paralysis). ***, P 0.0001 (Fisher’s exact test). Mice that survived were 
euthanized on day 14 because of high parasitemia and anaemia. (C) Parasitemia levels, 
shown as the mean the standard deviation, of Pb ANKA-infected mice. Closed circles, control; 
open circles, anti-IL-10R antibody. The data shown are representative of three independent 
experiments with four to six mice per group. *, P 0.05 (Mann-Whitney U test). (D) Absolute 
numbers of CD8 T lymphocytes that have accumulated in the brain. The data shown (mean 
standard deviation) are representative of two independent experiments with four mice per 
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Figure 4.2: ECM after IL-10R blockade in Pb ANKA-infected BALB/c mice is associated 
with parasite accumulation in the brain.  
BALB/c mice were infected i.v. with 104 Pb ANKA luc pRBCs and either left untreated (control) 
or treated with anti-IL-10R antibodies. (A) Cumulative survival curve. Closed diamonds, 
control (n 16); open diamonds, anti-IL-10R antibody (n 15); ***, P 0.0001 (log rank [Mantel-
Cox] test). (B) Cumulative incidence of mice developing ECM. ***, P 0.0001 (Fisher’s exact 
test). Similar to Figure 4.1, mice that survived were euthanized because of high levels of 
parasitemia and anaemia. (C) Parasitemia levels, shown as the mean the standard deviation, 
of Pb ANKA-infected mice. The data shown are representative of two independent 
experiments performed with five mice per group. *, P 0.05 (Mann-Whitney U test). (D to G) 
Parasite accumulation in the whole body (D), head (E), and isolated brain (F, G) as measured 
by luciferase activity on day 7 postinfection. The data shown are representative of two 
independent experiments performed with five mice per group. In panels D, E, and G, the data 
shown are the mean the standard deviation. *, P 0.05; **, P 0.001 (Mann-Whitney U test).  
 
Histological examination of the brains and livers of Pb ANKA luc-infected control and 
anti-IL-10R antibody-treated mice was also performed. The numbers of brain 
petechial hemorrhages were significantly higher in anti-IL-10R antibody-treated mice 
than in control mice (Figure 4.3A, B), while the numbers of microvessels with 
leukocytes did not differ between the two groups (Figure 4.3C). Moreover, there was 
also no difference between the numbers of perivascular infiltrates in the liver in the 
two groups (Figure 4.3E), although there was a trend of finding necrosis in anti-IL-
10R antibody-treated mice but not in control mice (Figure 4.3D and F). Taken 
together, these findings signify that blocking IL-10R signalling in otherwise ECM-
resistant mice results in the development of immune pathology with all of the features 
of ECM.  
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Figure 4.3: ECM after IL-10R blockade in Pb ANKA-infected BALB/c mice is associated 
with brain pathology.  
(A) Histological examination of H&E-stained brain sections from uninfected and day 7 Pb 
ANKA luc pRBC-infected mice (n 7 per group). Asterisks indicate areas of vessels with 
leukocytes, while circumflexes signify hemorrhages. Magnification, 20. Graphs show the 
quantification of the number of petechial hemorrhages (B) and vessels with leukocytes (C). 
(D) Similar to panel A but with liver sections. Graphs show the scoring of pigmented 
macrophages (E) and necrosis (F). In panels B, C, E, and F, the data shown are the mean the 
standard deviation. *, P 0.05; ***, P 0.0001 (Mann-Whitney U test). 
 
ECM is a result of T-cell-mediated inflammation in C57BL/6 mice. The development 
of ECM in Pb ANKA-infected anti-IL-10R antibody-treated BALB/c mice was 
indicative of an amplified inflammatory response. As an indicator of systemic 
inflammation, serum IFNγ concentrations (Figure 4.4A) were significantly higher in 
anti-IL-10R antibody-treated mice than in control and uninfected mice on day 7 
postinfection. Consistent with the blockade of IL-10R signalling, serum IL-10 
concentrations (Figure 4.4B) were also significantly higher in anti-IL-10R antibody-
treated mice than in control and uninfected mice. The levels of splenic activation were 
also evaluated on day 6 postinfection. The flow cytometry gating strategies used are 
shown in Figure 4.5 A, B, and F in the supplemental material. There was a trend 
toward larger proportions of splenic CD4+ and CD8+ T cells expressing CD62L and 
CD11a and producing IFNγ in the anti-IL-10R antibody- treated mice than in the 
control and uninfected mice (see Figure 4.5 B-I). Considering splenic leukocyte 
counts, a statistically significant difference between the control and anti-IL-10R 
antibody-treated groups was reached for the total numbers of CD4+ T cells expressing 
CD11a , and CD4+ and CD8+ T cells producing IFNγ (Figure 4.4C to H). Taken 
together, the results show that the development of ECM in Pb ANKA-infected anti-IL-
10R antibody-treated BALB/c mice correlates with higher levels of systemic 
inflammation and T cell activation.  
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Figure 4.4: Enhanced effector responses after IL-10R blockade in Pb ANKA-infected 
BALB/c mice.  
BALB/c mice were infected i.v. with 104 Pb ANKA luc pRBCs (A and B) or 104 Pb ANKA 
pRBCs (C to E) and either left untreated (control) or treated with anti-IL-10R antibodies. Serum 
IFNγ (A) and IL-10 (B) levels were determined with Quantikine kits from R&D Systems. For 
cellular analyses, splenocytes were prepared from uninfected or day 6 infected mice and 
stained for surface CD3, CD4, CD8, CD62L, and CD11a. The data shown are gated on CD3 
T cells (see Figure 4.5). The absolute numbers (mean standard deviation) of CD4 CD62L cells 
(C), CD4 CD11a cells (D), CD8 CD62L cells (F), and CD8 CD11a cells (G) are shown. 
Splenocytes were also stimulated with PMA/ionomycin for 5 h in the presence of brefeldin A; 
this was followed by intracellular IFNγ staining. The absolute numbers (mean standard 
deviation) of CD4 IFNγ cells (E) and CD8 IFNγ cells (H) are shown. The results shown are 
pooled data from two similar experiments (three to five mice per group). The data shown are 
the mean the standard deviation. *, P 0.05; **, P 0.001; ***, P 0.0001 (Kruskal-Wallis 
test/Dunn’s multiple comparisons test).  
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Figure 4.5: Flow cytometric analysis of splenocytes after IL-10R blockade in PbA-
infected BALB/c mice. 
BALB/c mice were infected i.v. with 104 Pb ANKA pRBCs and either left untreated (control) 
or treated with anti-IL-10R antibodies. For cellular analyses, splenocytes were prepared from 
uninfected or day 6 infected mice and stained for surface CD3, CD4, CD8, CD62L, and 
CD11a. Gating strategies are shown (A, B and F) for CD8+ and CD4+ T cells. The absolute 
numbers (mean standard deviation) of CD4 CD62L cells (C), CD4 CD11a cells (D), CD8 
CD62L cells (G), and CD8 CD11a cells (H) are shown. Splenocytes were also stimulated with 
PMA/ionomycin for 5 h in the presence of brefeldin A; this was followed by intracellular IFNγ 
staining (E and I). The results shown are pooled data from two similar experiments (three to 
five mice per group). The data shown are the mean and the standard deviation. *, P 0.05; **, 
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The data presented so far indicate that blockade of IL-10R signalling leads to full ECM 
susceptibility in otherwise resistant BALB/c mice, and this is associated with amplified 
T cell activation and higher serum IFNγ concentrations. These findings are consistent 
with the hypothesis that signalling through the IL-10R switches off T cell reactivity and 
thus inhibits the development of ECM. To ascertain whether T cell populations are 
the targets of IL-10R-mediated regulation, anti-IL-10R antibodies were combined with 
depletion of antibodies specific for CD4+ or CD8+ T cells in vivo. Depletion of either 
CD4+ or CD8+ T cells during Pb ANKA luc infection prevented the development of 
ECM in anti-IL-10R antibody-treated mice (Figure 4.5A and B). CD4 or CD8 T-cell-
depleted mice developed severe anaemia and eventually died 2 to 3 weeks 
postinfection. The role of IFNγ in the development of ECM in anti-IL-10R antibody-
treated Pb ANKA luc-infected BALB/c mice was also determined by combination with 
anti-IFNγ neutralizing antibodies throughout infection. Neutralization of IFNγ during 
Pb ANKA luc infection prevented the development of ECM in anti-IL-10R antibody-
treated mice (Figure 4.5A and B). Pb ANKA luc-infected anti-IL-10R antibody-treated 
mice presented peripheral parasitemia levels similar to those of mice given anti-CD8 
, -CD4 , or -IFNγ antibodies (Figure 4.5C). Interestingly, treatment with anti-CD8 , -
CD4 , or -IFNγ antibodies led to significantly less parasite accumulation in the whole 
bodies (Figure 4.5D) and heads of infected animals (Figure 4.5E). These data 
demonstrated that while the parasite biomass is increased by IL-10R blockade, the 
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Figure 4.6: ECM after IL-10R blockade in Pb ANKA-infected BALB/c mice is dependent 
on T cells and IFNγ.  
BALB/c mice were infected i.v. with 104 Pb ANKA luc pRBCs and treated with anti-IL-10R 
antibody. (A) Cumulative survival curves of IL-10R blockade alone ( n 10), with anti-CD8+ T 
cell depletion (n 8), with anti-CD4+ T cell depletion ( n 7), and with anti-IFNγ neutralization (n 
7). P values (log rank [Mantel-Cox] test) are shown. (B) Cumulative incidence of mice 
developing ECM. *, P 0.05; **, P 0.001; ***, P 0.0001 (Fisher’s exact test). Similar to Figure 
4.1 and 4.2, mice that survived were euthanized because of high levels of parasitemia and 
anaemia. (C) Parasitemia levels, shown as the mean the standard deviation, of Pb ANKA luc-
infected mice represented by the same symbols as in panel A. (D, E) Parasite accumulation 
in the whole body (D) and head (E) as measured by luciferase activity on day 7 postinfection. 
The data shown are the mean the standard deviation. **, P 0.001; ***, P 0.0001 (Kruskal-
Wallis test/Dunn’s multiple-comparison test). The data shown are representative of two 
independent experiments of at least seven animals per group. 
 
Previous work by our group has investigated the role of CTLA-4 and PD-1 signalling 
during acute blood stage infection and shows that blockade of either of these 
pathways results in severe immune pathology94. As we have already shown that IL-
10R signalling is critical for protection against immune pathology, I also investigated 
whether blockade of the IL-10R influenced CTLA-4 and PD-1 expression on activated 
CD8+ and CD4+ T cells (Figure 4.7 A and B respectively). Interestingly, I observed 
that blockade of IL-10R signalling during blood stage infection increased the 
frequency of CTLA-4+PD-1+ double positive CD8+ and CD4+ T cells. A significant 
increase was also seen in total CTLA-4+ compared to controls; however, this was not 
seen with total PD-1 expressing T cells. 
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Figure 4.7. Blockade of IL-10R leads to increased CTLA-4, but not increased PD-1 
expression during blood stage Pb infection 
BALB/c mice were infected i.v. with 104 Pb ANKA pRBCs and either left untreated (control) 
or treated with anti-IL-10R antibodies. For cellular analyses, splenocytes were prepared from 
uninfected or day 6 infected mice and stained for surface CD3, CD4, CD8, CD62L, CD11a 
and PD-1 and intracellular CTLA-4. Proportions of CTLA-4+PD-1+, CTLA-4+ and PD-1+ 
populations are shown for CD8+ (A) and CD4+ (B) T cells. The results shown are pooled data 
from two similar experiments (three to five mice per group). The data shown are the mean and 
the standard deviation. *, P 0.05; **, P 0.001; ***, P 0.0001 (Kruskal-Wallis test followed by 












Our findings provide an increased understanding of the regulatory pathways that 
impact the outcome of infection with an ECM-inducing rodent malaria strain that 
mimics the pathological processes associated with CM due to P. falciparum in 
humans. We have shown that blocking IL-10R facilitates the development of acute 
immune pathology in normally ECM-resistant BALB/c mice with pathological features 
compatible with ECM in susceptible C57BL/6 mice. Neuropathological signs were 
associated with heavy parasite loads, the development of IFNγ secreting CD4 and 
CD8+ T cells in the spleen, and an influx of CD8+ T cells into the brains of IL-10R-
treated mice. Thus, IL-10R signalling plays a vital role in the prevention of immune-
mediated neuropathology during Pb ANKA infection of ECM-resistant BALB/c mice.  
 
The outcomes reported in this study expand those reported in our previous work, 
where blockade of CTLA-4 or PD-1/PD-L1 inhibitory pathways in Pb ANKA- infected 
BALB/c mice also rendered the animals susceptible to ECM94. Both studies show that 
depletion of T cells and neutralization of IFNγ abrogated the effects of regulatory 
pathway blockade, validating the notion that ECM has similar aetiologies in both 
BALB/c mice and susceptible C57BL/6 mice. Both studies further corroborate that 
CD8+ T cells and IFNγ are the critical effectors of ECM. While damage to brain vessels 
has implicated perforin and granzyme B secretion in Pb ANKA-infected C57BL/6 
mice90–92, the roles of these molecules in BALB/c mice warrant further investigation. 
While it appears that the CTLA-4, PD-1/PD-L1, and IL-10-R pathways independently 
regulate host resistance to Pb ANKA infection of BALB/c mice, we have shown that 
the CTLA-4 and/or PD-1/PD-L1 axes are influenced by the blockade of IL-10R.  
 
Signalling through CTLA-4 and IL-10 provides two distinct mechanisms for T cell 
inhibition however, there is evidence that in the absence of one, the other works to 
compensate to provide correct T cell responses. With Pb blood stage infection, 
blockade of CTLA-4 leads to fatal cerebral malaria in normally refractory mice as well 
as a significant increase in IL-10 production by T cells after re-stimulation94. Similarly, 
the Jacobs group investigated whether blockade of CTLA-4 during non-lethal or lethal 
Py infection influenced the outcome of disease 163. Using a non-lethal strain, they 
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found a reduced peak parasitaemia with CTLA-4 blockade. A protective increase in 
serum IFN production was accompanied by a significant increase in IL-4 and IL-10. 
In comparison, infection with a lethal Py strain concurrently with CTLA-4 blockade led 
to decreased survival with pathology due to increased IFN and TNF. Interestingly, 
there was also a significant increase in IL-4 and a noticeable, but non-significant 
increase in IL-10. This suggests that CTLA-4 blockade induces overproduction of IL-
10 during infection which may contribute to preventing pathology in non-lethal Py 
infection, but is not sufficient to protect against pathology with lethal infection. Tang 
and colleagues used constitutive expression of CTLA-4Ig to specifically investigate 
Treg cells and their functional relationship with CTLA-4 252. They found that even in 
the absence of CTLA-4, Treg cells could still suppress proliferation of WT T cells, 
indicating no loss in suppressive capacity. CTLA-4-/- Treg cells produced 5-fold more 
IL-10 than WT controls however, further blockade of IL-10 in addition to CTLA-4 did 
not abrogate normal suppressive function of WT T cells in vitro. This observation 
differs from findings by Read et al. who investigated CTLA-4 blockade of Treg cells 
in vivo using CTLA-4 blocking antibodies 253. Using a model of colitis, they found that 
blockade of CTLA-4 did not alter Treg ability to prevent colitis when transferred with 
WT CD4+CD45RBhigh cells into BALB/c.RAG2 KO mice. When they blocked the IL-
10R receptor as well as CTLA-4 this protective suppression was completely 
abrogated. This suggests that blockade of CTLA-4 induces alternative suppressive 
pathways as WT Treg cells protect from colitis through pathways independent of IL-
10 254. Although CTLA-4 is constitutively expressed on Treg cells, it is a crucial co-
receptor in conventional T cell activation. Paterson et al. used a conditional knock out 
mouse model of CTLA-4 to investigate adult T cell function in the absence of CTLA-
4 255. After knocking out CTLA-4 with tamoxifen administration they implanted a 
tumour using MC38 tumour cells and investigated T cell responses. As well as an 
increase in IL-10, LAG3 and PD-1 in Treg cells, there was a significant increase in IL-
10 production by conventional CD4 T cells and CD8 T cells. Interestingly, the absence 
of CTLA-4 did not lead to reduced tumour size, possibly due to the increase in Treg 
numbers and compensatory inhibitory mechanisms. 
 
Although there appears to be an agreement that blockade of CTLA-4 leads to an 
increase in IL-10 in mouse models of infection and inflammation, studies differ in the 
method and duration of CTLA-4 abrogation. It would appear however, that short-term, 
targeted CTLA-4 blockade increases compensatory mechanisms but not to a level 
that suppresses increased T cell activation. With long-term blockade there may be 
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time for these mechanisms, including IL-10 signalling, to reach levels that restore 
more of a balance between T cell activation and inhibition. 
 
While our depletion experiments suggest that the pathological effects of IL-10R 
blockade result from the regulation of T cell responses, additional studies are required 
to ascertain the roles of IL-10R expression and IL-10R blockade in other immune 
cells. DCs and monocytes have been shown to produce IL-10 during malaria 
infections256–258. Similarly, B cells have also been reported to produce IL-10 in Pb 
ANKA-infected C57BL/6 mice259. Recently, tissue-resident CD169 macrophages 
were shown to produce high levels of IL-10 during Pb ANKA infection in BALB/c mice 
and to restrict inflammatory responses260. Concerning T cells, protection against ECM 
may also be due to balanced IFNγ /IL-10 secretion in activated T cells versus 
regulatory T cells Tregs. The failure of IL-10 to counterbalance IFNγ release during 
IL-10R blockade may be attributed to a failure in the IL-10 signalling pathway in both 
activated T cells and Tregs with consequent release of IFNγ. This assumption on 
Tregs is backed up by recent findings of a loss of FoxP3 expression in Treg cells with 
increased pro-inflammatory cytokine release during P. chabaudi AS infection in IL-
10R-treated DBA/2 mice261. Failure of the IL-10R signalling pathway in Tregs has also 
been associated with loss of FoxP3 expression and inflammatory cytokine release in 
a murine model of inflammatory bowel disease262,263. Furthermore, in the murine 
model of hepatitis C virus infection, IL-10R blockade steers the inflammatory 
response toward a type 1 IFNγ-mediated T cell response264.  
 
IL-10 production is also increased during Pb ANKA infection of ECM- susceptible 
C57BL/6 mice265,266. It is likely that IL-10 performs a similar regulatory role in C57BL/6 
mice, although its failure to provide protection against ECM remains unclear. It is 
possible that an over exuberant inflammatory response supersedes the physiological 
levels of regulation facilitated by IL-10R signalling. Alternatively, down- stream IL-10R 
signalling is impaired on target cells.  
 
Although the kinetics and precise interactions between the effector and regulatory 
pathways remain undefined in this model of ECM, our studies reveal the importance 
of maintaining a balance between effector and regulatory immune responses for 
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preventing ECM. Disproportionate pro-inflammatory responses consistently lead to 
immuno- pathology, although there is reasonable control of parasitemia. Equally, poor 
antiparasite immune responses generated concurrently with strong regulatory 
responses permit parasitemia with harmful consequences, as demonstrated in this 
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There is strong evidence that during liver stage infection, high titres of parasite-
specific antibodies are capable of neutralising sporozoites and subsequently 
preventing patent disease79,267,268. Passive transfer of antibodies from immunised 
animals to naïve animals has been shown to be protective in mouse models of malaria 
against Pb and Py sporozoites and in monkey models against Pv and Pk 
sporozoites171,269. Monoclonal antibodies specific to Pb sporozoites are capable of 
neutralising sporozoites in vitro 85 as well as in vivo 84. This can also be seen with 
monoclonal antibodies towards Pf CSP that can neutralise Pf sporozoites and prevent 
hepatocyte invasion of splenectomised chimpanzees270. In experiments done by 
Oliveira and colleagues, BALB/c and C57BL/6 mice that were deficient in β2-
microglobulin and therefore had no activation of cytotoxic T cells through Class I MHC 
were used. They found that immunisation of these mice with irradiated Pb or Py 
sporozoites still elicited sterile protection and this was mediated through CD4+ T cell 
activation and antibodies that neutralised extracellular sporozoites79. Further support 
for antibody protection in pre-erythrocytic malaria can be seen in endemic settings 
where the presence of memory B cells specific to Pf CSP have been identified271 and 
in a study by John et al. the presence of antibodies against CSP and liver stage 
antigen type-1 (LSA-1) in Kenyan children was associated with a decreased risk of 
clinical malaria272. These studies show that CSP is a highly immunodominant surface 
protein and other studies have shown that the target of antibodies is the region of 
tandem repeats268,273,274. Currently, RTS, S is the most advanced malaria vaccine that 
utilises this property of CSP, including both antibody and T cell epitopes. Surprisingly, 
although preliminary research was very promising for the RTS, S vaccine and 
immunisation produces high antibody titres, phase III trials have shown it to have 
lower long-term efficacy than hoped275–279. Despite the understanding that antibody 
responses are known to be protective, there is a paucity in known immunogenic 
antibody antigens other than CSP.  
 
The ability to identify immunologically relevant epitopes requires either the 
identification of monoclonal functional antibodies, accurate prediction of antibody 
binding to putative epitope sequences, the parallel synthesis of many potential 
epitopes for simultaneous analysis or a combination of these strategies. The 
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immunodominant protein CSP was identified through hybridoma generation of 
protective monoclonal antibodies84, which is now considered a long and costly 
strategy for identifying novel antigens. It is limited by the breadth of the immune 
response that can be investigated in one set of experiments. The popular 
development of reverse vaccinology techniques since the beginning of the ‘genome 
era’ has allowed for the analysis of epitopes on a whole genome, transcriptome or 
proteome scale. Taking advantage of this, work done by the Fernan Aguero group 
used a high-density peptide microarray to design the largest investigation of fine 
antibody specificities for a human infection117. Using the annotated T. cruzi CL-Brener 
genome, they identified 457 proteins which were synthesised as peptides 15 amino 
acids in length with an overlap of 14 amino acids with the previous peptide in the 
sequence, resulting in over 175,000 peptides. Sera from T. cruzi infected patients 
was incubated with the microarray and after analysis, more than 120 novel antibody 
antigenic determinants were identified. This study highlights how the use of novel 
technology now allows for the simultaneous investigation of hundreds of thousands 
of potential epitopes towards improved diagnostics, therapeutics and vaccines. 
Although experiments of this kind are still expensive and microarray slides cannot be 
used many times for multiple experiments, it is significantly cheaper than 
experimentally investigating the same number of potential epitopes using any other 
technique and ultimately requires significantly less serum. Unfortunately, probing a 
peptide microarray with serum only assists in the identification of linear epitopes. This 
means that discontinuous epitopes cannot be discovered, leaving potentially up to 
90% of antigenic determinants not investigated. Although whole protein microarrays 
can be done, the synthesis of physiologically correct proteins raises further problems 
that peptide microarrays do not have.  
 
Significant development has occurred in the technological ability to map epitopes 
experimentally. Currently, peptide microarrays offer the most high throughput 
approach to linear epitope identification, allowing tens or hundreds of thousands of 
peptides to be probed simultaneously. For this study, I designed a microarray that 
allows for the investigation of the entire sporozoite and liver stage Pb ANKA 
proteome. As CSP is a highly immunodominant protein, I also used a novel 
immunisation schedule that specifically boosts all non-CSP antigens through the use 
of a transgenic Pb strain that expresses Pf CSP rather than Pb CSP (Pb[PfCSP])280. 
Pb CSP and Pf CSP are homologous proteins that are both expressed on the surface 
of the sporozoite but they only share a similarity in protein sequence of 47.6% (Figure 
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5.1). Therefore, a boosting immunisation with Pb(PfCSP) does not expose the host 
immune system to the majority of the PbCSP sequence. This means that all other Pb 
proteins are available for boosting immune responses; however, PbCSP is not. In this 
way, non-CSP proteins can be preferentially targeted with an immunisation schedule 
using two separate immunisations. 
 
Figure 5.1. Alignment of Pb and Pf CSP protein sequences. 
Protein alignment of the protein sequences for Pf CSP and Pb CSP was performed using the 









5.2.1 Mosquito and mouse conditions 
C57BL/6 mice between 5-8 weeks were bred in-house at London School of Hygiene 
and Tropical Medicine (LSHTM) or by Charles River Laboratories (UK). They were 
housed in filter-topped cages up to 6 per cage with absorbent bedding, nesting 
material and enrichment. Their diet consisted of autoclaved water and food pellets. 
Procedures were performed under license from the United Kingdom Home Office 
under the Animals (Scientific Procedures) Act 1986 and approved by the Animal Care 
and Ethical Review Committee. 
 
Pb ANKA infected Anopheles stephensi mosquitoes grown at LSHTM and the Max 
Planck Institute for Infection Biology, Berlin were kept at 22°C with 80% humidity and 
fed on 10% glucose solution (10% D-Glucose [Sigma-Aldrich] in distilled water). 
Pb(PfCSP) infected Anopheles stephensi mosquitoes were grown at the Max Planck 
Institute for Infection Biology, Berlin and were also kept at 22°C with 80% humidity 
and fed on 10% glucose solution (10% D-Glucose in distilled water). In order to 
generate infectious Pb sporozoites, blood stage parasites were first collected from 
infected C57BL/6 mice via cardiac puncture into 1.5ml Eppendorf tubes (Sigma) with 
heparin (Sigma) and kept on ice. Blood was diluted 1:2 in freezing media made from 
7.5% Glycerol (Sigma) in RPMI complete (RPMI 1640 [Gibco] with 10% FCS [Gibco], 
2% L-Glutamine [Gibco] and 1% Penicillin and Streptomycin [Gibco]) and kept at -
80C. When required, blood stage parasites were thawed and 200μl was injected i.v. 
into a naïve C57BL/6 mouse. After three days, blood was collected from the infected 
mouse via cardiac puncture and 100,000 infected RBCs were passaged into two 
naïve C57BL/6 mice. 4 days after passage, mice were given a terminal dose (100-
150μl) of anaesthesia consisting of 50% PBS, 33% ketamine (Ketamidor, 100mg/ml 
[National Veterinary Services Limited]) and 17% xylazine (Rompun, 2% w/v [National 
Veterinary Services Limited]) i.p. and placed on a cage of mosquitoes (70 mosquitoes 
per mouse) for a 30 minute blood feed. 18-20 days after blood feed, mosquitoes were 
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5.2.2 Whole sporozoite immunisation 
Female Anopheles stephensi salivary glands were dissected from infected 
mosquitoes in RPMI complete and Pb ANKA sporozoites were isolated through 
homogenisation and centrifugation. Glands were homogenised using autoclaved 
plastic pestles in Eppendorf tubes and centrifuged at 10,000 rpm for 3 minutes. The 
pellet was re-suspended in 200μl of RPMI complete and Pb ANKA sporozoites were 
counted on a C-chip haemocytometer (Digital bio). For immunisations, Pb ANKA 
sporozoites were diluted to 50,000/ml in RPMI complete. To attenuate by irradiation 
for immunisation, the suspension was exposed to gamma radiation at 1.2x104 
centigray (cGY) for 20.5 minutes. C57BL/6 mice were immunised by an i.v. injection 
of 0.2ml attenuated Pb ANKA sporozoites per mouse. 14 days after the final 
immunisation, blood was collected via tail vein puncture in heparin. 28 days after the 
final immunisation blood was also collected via cardiac puncture. After blood 
collection at both time points, blood was centrifuged at 1,000 x g for 10 minutes and 
serum was taken by pipette. Serum was stored at -80°C until needed. 
 
5.2.3 Immunofluorescence Assay (IFA) 
Pb ANKA sporozoites were air dried on microscope slides in spots of 20μl with 5,000 
sporozoites per spot and kept at -20 until required. When needed, slides were fixed 
by dipping in cold acetone for 1 minute and rehydrated in 20μl of PBS at room 
temperature for 20 minutes. Spots were blocked by removing the PBS and adding 
20μl of RPMI complete followed by a 1 hour incubation in a humid chamber at 37°C. 
After incubation 20ul of serum was added to each spot in a serial dilution in RPMI 
complete followed by a further 1 hour incubation at 37C in a humid chamber. Spots 
were washed three times with RPMI complete before adding 20ul of AlexaFluor 
546/488 goat anti-mouse IgG (Sigma) diluted 1:2,000 in RPMI complete. Slides were 
incubated at 37C for 1 hour in the dark before a final three washes with PBS and 
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5.2.4 Hepatocyte Invasion Assay 
Huh7 cells were cultured in RPMI complete (RPMI [Gibco] with 10% FCS [Gibco], 2% 
L-Glutamine [Gibco] and 1% Penicillin and Streptomycin [Gibco]) at 37C with 5% 
CO2. 24 hours before sporozoite invasion, cells were seeded into Labtek wells 
(ThermoFisher Scientific) at 30,000 cells per well. On the day of infection salivary 
glands were dissected from Pb infected female Anopheles stephensi mosquitoes. 
Glands were homogenised and sporozoites were isolated by centrifugation. After 
counting, 5,000 to 10,000 sporozoites were added per experimental Labtek well. 
Slides were centrifuged and incubated for 2 hours at 37C with 5% CO2 to allow for 
invasion before being washed 3 times with RPMI complete. Slides were incubated for 
a further 48 hours to allow for EEF development. To stain, cells were first fixed with 
4% paraformaldehyde (PFA) and permeabalised with 0.3% Triton X-100 (Sigma). As 
our Pb ANKA strain constitutively expresses GFP, EEFs were stained with chicken 
antibodies specific to green fluorescent protein (GFP) at 1:300 dilution, followed by 
goat anti-chicken IgG Alexa Fluor 488 fluorescent antibodies (ThermoFisher 
Scientific) at 1:1,000 dilution. Nuclei were stained with DAPI (ThermoFisher 
Scientific). Cells were coated in Vectashield under a sealed coverslip. Imaging was 
performed on a Zeiss LSM510 confocal microscope. 
 
5.2.5 Cell Traversal Assay 
HepG2 cells were cultured in RPMI complete at 37C with 5% CO2. 24 hours before 
sporozoite invasion, cells were seeded into 96 well plates (ThermoFisher Scientific) 
at 10,000 cells per well. Sporozoites were diluted to 5,000 per sample and serum was 
added at a dilution of 1:5. Sporozoites were kept on ice with serum for 40 minutes. 
Fluorescent rhodamine B isothiocyanate high molecular weight dextran (Sigma) was 
added and 50μl was added per well to HepG2 cells. Sporozoites were sedimented by 
centrifugation for 10 mins at 2,200 rpm with no brake and cells were incubated at 
37°C for 3 hours. After incubation wells were washed three times with PBS. 50μl of 
Trypsin was added per well and incubated for 10 minutes at 37°C. Trypsin was diluted 
with 150μl of medium and centrifuged at 1500rpm for 2 minutes followed by removing 
the medium and replacing it with 200μl FACS buffer (PBS with 1% BSA). Cells were 
run on a Guava Easycyte flow cytometer (Millipore) 
 
 




A list of the proteins of sporozoite and liver stages of Pb ANKA were determined using 
previously published experimental data available from PlasmoDB, resulting in 2977 
proteins in total. Sequences for all proteins were divided into 15 amino acid oligomers 
with an 11 amino acid overlap with the previous sequence. This produced a total of 
519,319 peptides that were randomly organised over the microarray slide. Microarray 
slides were synthesised by the company Schafer-N. This was done using maskless 
photolithography, whereby a digital micro-mirror device focuses 365nm light onto a 
derivatised glass slide with high resolution. An amino acid spacer was bound to the 
slide surface, followed by the synthesis of Pb ANKA peptides using 3′-
nitrophenylpropyloxycarbonyl (NPPOC) photoprotected amino acids. In this way, light 
directed by the DMD removed the NPPOC block from specific peptides and allowed 
for the addition of the next amino acid in the sequence, each with a 9-
fluorenylmethoxycarbonyl (Fmoc) group block. Once all amino acids for the layer 
were added, the Fmoc groups were removed and replaced with NPPOC blocks. This 
was repeated until all peptides were synthesised. Slides were probed with immunised 
mouse serum (25μl/ml), followed by secondary fluorescent antibody Cy3 sheep anti-
mouse IgG (Fab)2 (Sigma) (1 µg/ml). Fluorescence was measured using an 
InnoScan900 microarray scanner (Innopsys) with an excitation wavelength of 
532nm.  
 
5.2.7 Enzyme Linked Immunosorbent Assay (ELISA) 
Antigens were diluted to 20μg/ml in coating buffer (for 1 litre, 1.59g Na2CO3 and 
2.93g NaHCO3 dissolved in 1 litre of distilled water) and added to a 96 well Maxisorp 
ELISA plate (NUNC) at 50μl per well. Plates were left at 4°C overnight for antigen 
adsorption. The following day, plates were washed three times in a PBS/Tween wash 
solution (PBS with 0.05% Tween 20) and 150μl of blocking solution (3% BSA [Gibco] 
in PBS) was added per well. Plates were incubated at 37°C for 1 hour and washed a 
further three times with PBS with 0.5% BSA. Serum samples were diluted 1:200 in 
PBS and 50μl was added per well and incubated at 37°C for 1 hour followed by a 
further three washes with PBS with 0.5% BSA. Horseradish peroxidase conjugated 
sheep anti-mouse IgG (Sigma) was diluted 1:6,000 in PBS/0.5%BSA and 50μl was 
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added per well with a further 1 hour incubation at 37°C. After a final five washes with 
PBS with 0.5% BSA, OPD (Sigma) was made up according to instructions and 100ul 
was added per well. After 15 minutes the reaction was stopped by the addition of 25ul 





CSP is a highly immunodominant protein on the surface of the malaria parasite, but 
antibodies against CSP do not contribute to 100% of the pre-erythrocytic stage-
specific antibody response. In order to fully understand non-CSP antibody responses, 
I adopted a novel vaccination schedule to preferentially boost antibody responses to 
non-CSP Pb antigens (Figure 5.2). To do this, C57BL/6 and BALB/c mice were 
vaccinated with two different Pb strains. A primary vaccination consisted of Pb γ-
radiation attenuated sporozoites, which was followed two weeks later by a secondary 
vaccination using Pb(PfCSP) γ-radiation attenuated sporozoites. The rationale for 
such a schedule is that mice are exposed to all non-CSP antigens twice, providing a 
prime-boost strategy; however, Pb CSP is only encountered once as the second 
vaccination only exposes the immune system to Pf CSP. Serum was collected 14 
days and 28 days after the final vaccination so that I could investigate short term and 
persisting antibody responses. As this is a novel vaccination regimen, I performed 
some preliminary experiments to confirm, firstly, that vaccinated mouse sera 
recognised Pb sporozoites and both Pb and Pf CSP and, secondly, that such a 
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Figure 5.2. Vaccination and serum collection. 
C57BL/6 and BALB/c mice were given a primary vaccination of 10,000 γ-radiation attenuated 
Pb ANKA sporozoites i.v. followed by a second vaccination 14 days later with 10,000 γ-
radiation attenuated Pb(PfCSP) sporozoites i.v. Blood was collected by tail bleed at 14 days 
and cardiac puncture at 28 days after the final vaccination. Serum was isolated by 
centrifugation and stored for further analyses. This vaccination was performed twice with 5-7 
mice per strain. 
 
In order to investigate whether antibodies generated using my novel immunisation 
schedule could recognise WT Pb ANKA sporozoites, I performed an IFA to determine 
Pb ANKA sporozoite recognition (Figure 5.3A) and to compare antibody titers 
between experimental groups (Figure 5.3B). Air dried Pb sporozoites were incubated 
with serum collected from immunised mice to allow for antibody binding. This was 
followed by washing with a fluorescent anti-mouse secondary antibody to visualise 
antibody-specific binding to Pb sporozoites. As serum was collected by tail bleed at 
14 days and cardiac puncture at 28 days, there was much more material available to 
investigate serum responses at 28 days. As the microarray would be performed using 
serum collected at 28 days and material from collections on 14 and 28 days were to 
be used for ELISA experiments, I decided to perform IFA’s for 28 days only to save 
material. Interestingly, BALB/c serum was consistent in its higher antibody titer 
compared to C57BL/6 serum. As expected, antibody titers of Pb(PfCSP)+WT were 
similar to 1x WT for both BALB/c and C57BL/6. The majority of surface protein on the 
sporozoite surface is CSP and therefore, as Pb(PfCSP)+WT immunisation only 
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Figure 5.3. IFA of vaccinated C57BL/6 and BALB/c serum to confirm antibody recognition of Pb ANKA sporozoites. 
Serum from C57BL/6 and BALB/c mice was collected 28 days after vaccination. Vaccination schedules consisted of 10,000 γ-radiation attenuated sporozoites 
i.v. using WT Pb ANKA or transgenic Pb(PfCSP) sporozoites. 1 vaccination with WT was compared with 2 WT vaccinations and a novel strategy of 
Pb(PfCSP)+WT. Boost vaccinations were given 14 days after the primary vaccination. Pb ANKA sporozoites were isolated from infected female Anopheles 
stephensi mosquito salivary glands, diluted to 100,000 per ml and air dried on glass slides. Slides were incubated with serial dilutions of serum and probed with 
anti-mouse FITC antibodies (A and B) to identify the endpoint titer of sporozoite-specific antibody (C). Representative results from IFA shown in A and B and 
pooled results from two experiments shown in C. Statistics were performed using Kruskal-Wallis non-parametric t test followed by Dunn’s multiple comparisons 
test.
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To confirm successful antibody recognition of Pb CSP I performed ELISA 
experiments using known immunogenic peptides from the repeat region of Pb ANKA 
CSP (Figure 5.4). As all mice were exposed to Pb CSP only once, I compared antigen 
recognition of the novel schedule with a single and prime-boost vaccination schedules 
using only Pb ANKA WT sporozoites. For BALB/c responses, Pb(PfCSP)+WT was 
very similar to 1x WT vaccination as expected, with greater antigen binding at 28 days 
(Figure 5.4B) compared to 14 days (Figure 5.4A). Interestingly, C57BL/6 appeared to 
have higher responses with Pb(PfCSP)+WT compared to 1x WT vaccination. Both 
mouse strains showed greater antigen recognition if serum was collected 28 days 
after vaccination in Pb(PfCSP)+WT and 1x WT groups, but not for 2x WT. This is to 
be expected due to the nature of antibody responses to primary and secondary 
antigen exposure. In other models of immunisation, a primary vaccination initiates 
specific IgM antibodies as well as some IgG antibody responses that peak at around 
3-4 weeks. This high titre rapidly wanes to baseline; however, upon secondary 
stimulation high titres of high affinity IgG antibodies are rapidly produced, peaking 
after only a few days. Also unlike primary responses, these higher antibody titres are 
much more long-lasting. Therefore, after a single exposure I would expect antibody 
titers to be increasing between 1 and 28 days post vaccination. In contrast, after a 
boosting secondary response I would expect antibody titres to already be peaking 
before 14 days and for titres to still be high at 28 days. Overall, these results show 
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Figure 5.4. Use of a novel vaccination strategy successfully induces antibody 
responses to Pb CSP peptide antigen. 
Serum from C57BL/6 and BALB/c mice was collected 14 and 28 days after vaccination. 
Vaccination schedules consisted of 10,000 γ-radiation attenuated Pb ANKA sporozoites i.v. 
using WT Pb ANKA or transgenic Pb(PfCSP) sporozoites. 1 vaccination with WT was 
compared with 2 WT vaccinations and a novel strategy of Pb(PfCSP)+WT. Boost vaccinations 
were given 14 days after the primary vaccination. Antibody responses at 14 days (A) and 28 
days (B) after the final vaccination were measured against the Pb CSP94-108 peptide 
PPPPNPNDPPPPNPN by ELISA. Pooled data from two experiments with 5-10 mice per 
group. Statistics were performed using Kruskal-Wallis non-parametric t test followed by 
Dunn’s multiple comparisons test.  
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To confirm that vaccinating with our transgenic Pb(PfCSP) sporozoites was also 
successful, I performed similar ELISA experiments to measure antibody recognition 
of Pf recombinant CSP (Figure 5.5). As WT vaccinations did not expose mice to Pf 
antigens, I hypothesised that antibody recognition of Pf CSP would only occur in mice 
vaccinated with Pb(PfCSP). As expected, antibody responses for Pf CSP were 
present in the Pb(PfCSP)+WT group, but not in mice vaccinated only with WT Pb. 
This persisted between 14 days (Figure 5.5A) and 28 days (Figure 5.5B) after the 
boost vaccination. The kinetics of antibody responses resembled the Pb(PfCSP)+WT 
and 1x WT groups in experiments performed for figure 5.3 as they increased in both 
mouse strains if serum was collected on day 28. This would suggest that the 
responses are characteristic of a single exposure, which is as expected. Another 
similarity between experiments performed for figures 5.3 and 5.5 is that there was a 
trend towards BALB/c having higher antibody responses to antigen. This could be 
due to the fact that BALB/c mice are more resistant to Pb infection than C57BL/6 
mice165. As ELISA experiments for figure 5.4 were performed with recombinant 
protein generated using E. coli, there is a possibility that antibody responses were for 
bacterial antigens rather than recombinant protein. To confirm antibody responses 
were towards CSP alone, I performed an ELISA comparing antibody recognition of 
the well characterised Pf Merozoite Surface Protein 1 19kDa region of the C-terminal 
(MSP1-19)282–285 and Pf CSP recombinant protein (Supplementary Figure 5.S1). As 
MSP1 is a blood stage protein it is not expressed by liver stage malaria parasites, 
therefore any responses would be towards E.Coli bacterial antigen. As expected, 
there was no antibody recognition of antigen in the MSP1-19 condition, confirming 
successful purification of Pf CSP product.  Together, figure 5.3 and figure 5.4 show 
that vaccination with Pb(PfCSP)+WT Pb elicits antibody responses to both Pb and Pf 
CSP antigen with the kinetics of a single exposure. As antibody responses were 
consistently higher in serum collected 28 days after the final vaccination, I chose to 
continue with these sera for future experiments. In addition, as serum collected at 14 
days was taken by tail bleed and serum collected at 28 days was by cardiac puncture, 
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Figure 5.5. Use of a novel vaccination strategy successfully induces antibody 
responses to Pf recombinant CSP. 
Serum from C57BL/6 and BALB/c mice was collected 14 and 28 days after vaccination. 
Vaccination schedules consisted of 10,000 γ-radiation attenuated sporozoites i.v. using WT 
Pb ANKA or transgenic Pb(PfCSP) sporozoites. 1 vaccination with WT was compared with 2 
WT vaccinations and a novel strategy of Pb(PfCSP) followed by WT. Boost vaccinations were 
given 14 days after the primary vaccination. Antibody responses at 14 days (A) and 28 days 
(B) after the final vaccination were measured against recombinant Pf CSP by ELISA. Pooled 
data from two experiments with 5-10 mice per group. Statistics were performed using Kruskal-
Wallis non-parametric t test followed by Dunn’s multiple comparisons test.  
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The previous experiments show that my novel immunisation schedule generates 
immune responses to both vaccinations with kinetics that were expected and that 
serum from these immunisations correctly recognises Pb ANKA sporozoites. My next 
question was whether the binding of these antibodies resulted in functional 
neutralisation of sporozoites to the extent that cell traversal across the liver and EEF 
development within hepatocytes was reduced. In vitro techniques have been used 
extensively to investigate this286 and I employed some of these strategies to answer 
my question. In order to investigate the neutralising effects of my pooled serum, Pb 
ANKA sporozoites were incubated with serum from each group diluted 1:5 for 40 
minutes on ice before adding them to a culture of immortalised Huh7 cells for 2 hours. 
Although Huh7 cells are originally of human origin, Pb ANKA sporozoites have been 
shown to be relatively promiscuous in their ability to invade several hepatocyte cell 
lines287. After exposure, cells were washed and incubated for 48 hours before 
immunofluorescent staining to allow for counting of EEFs (Figure 5.6A). As can be 
seen in figure 5.6B, all immunisation schedules decreased the invasion rate 
compared to naïve controls but this was only statistically significant for 2x WT Pb 
ANKA immunisations and Pb(PfCSP)+WT Pb ANKA. Interestingly, the reduction in 
invasion rate between both imunisation schedules is very similar, suggesting that the 
functional responses of antibodies generated is the same. As the only difference is 
the absence of exposure to Pb ANKA CSP boosting in one immunisation schedule, 
this suggests that the repertoire of non-CSP-specific antibodies may contribute to a 
similar neutralising effect. 
 
An as yet not fully explained phenomenon of sporozoite invasion of the liver is that 
sporozoites traverse multiple hepatocytes before finally beginning development into 
an EEF in a final hepatocyte288. This is a non-phagocytic movement of sporozoites 
through hepatocytes, which results in damage of the cell membrane of the traversed 
cell289. As this is a typical feature of sporozoite invasion of the liver and antibody 
neutralisation inhibits the development of EEFs, I also investigated by flow cytometry 
the amount of hepatocytes that are traversed by sporozoites after exposure to pooled 
serum from each of my immunisation groups (Figure 5.7). This was done by exposing 
HepG2 hepatocyte cells to sporozoites in the presence of high molecular weight 
fluorescent dextran. As cell membranes are disrupted by cell traversal, dextran enters 
the hepatocyte and allows it to be detected by flow cytometry. Similar to my results 
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showing EEF development, immunisation led to a reduction in cell traversal in all 
groups apart from C57BL/6 serum from a single Pb ANKA immunisation. It is also 
interesting that the reduction of cell traversal is also comparative between two Pb 
ANKA immunisations and Pb(PfCSP) followed by Pb ANKA, perhaps for reasons 
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Figure 5.6. Immunisation with all schedules results in a reduction of EEFs in 
hepatocytes in vitro. 
Serum from C57BL/6 and BALB/c mice was collected 28 days after vaccination. Vaccination 
schedules consisted of 10,000 γ-radiation attenuated sporozoites i.v. using WT Pb ANKA or 
transgenic Pb(PfCSP) sporozoites. 1 vaccination with WT was compared with 2 WT 
vaccinations and a novel strategy of Pb(PfCSP) followed by WT. Boost vaccinations were 
given 14 days after the primary vaccination. Pb ANKA sporozoites were isolated from infected 
female Anopheles stephensi mosquito salivary glands and incubated with pooled serum from 
each schedule or naïve for 40 minutes on ice. Sporozoites were cultured on Huh7 hepatocytes 
for 2 hours before being washed. After 48 hours of incubation, cells were permeabalised and 
stained FITC green for EEFs (*) and blue for nuclei (A). EEFs in an area of 0.8 cm2 per well 
were counted for each condition and calculated as an invasion rate (%) as the number of EEFs 
as a percentage of the control with no serum (B). Results shown from two experiments with 
pooled serum in triplicate. Statistics performed using Kruskal-Wallis non-parametric t test 
followed by Dunn’s multiple comparisons post-test. 
 




Figure 5.7. Cell traversal of Pb ANKA sporozoites through hepatocytes is reduced after 
exposure to serum from immunised mice. 
Serum from C57BL/6 and BALB/c mice was collected 28 days after vaccination. Vaccination 
schedules consisted of 10,000 γ-radiation attenuated sporozoites i.v. using WT Pb ANKA or 
transgenic Pb(PfCSP) sporozoites. 1 vaccination with WT was compared with 2 WT 
vaccinations and a novel strategy of Pb(PfCSP) followed by WT. Boost vaccinations were 
given 14 days after the primary vaccination. Pb ANKA sporozoites were isolated from infected 
female Anopheles stephensi mosquito salivary glands and incubated with serum from each 
schedule or naïve for 40 minutes on ice. Sporozoites were cultured on Huh7 hepatocytes for 
3 hours in the presence of fluorescent high molecular weight dextran. Hepatocytes that had 
been damaged by cell traversal were identified using flow cytometry. Results shown for two 
experiments with n=7 per group per experiment. Statistics performed using Kruskal-Wallis 
non-parametric t test followed by Dunn’s multiple comparisons post-test. 
 
The promising results shown so far confirm that my novel immunisation schedule 
successfully generates immune responses for immunisation with γ-radiation 
attenuated Pb(PfCSP) and Pb ANKA. Additionally, these immunisations generate 
antibodies that recognise Pb ANKA sporozoites and are capable of functionally 
inhibiting cell traversal and EEF development. From these results I was confident that 
serum from these immunisations would be suitable for further investigation into non-
CSP antibody antigens using microarray technology. I first generated a list of proteins 
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that are expressed in the sporozoite and liver stages of Pb ANKA development using 
the PlasmoDB online database. This resulted in 2977 genes needed to be 
synthesised as peptides 15 amino acids in length on the microarray chip. As antibody 
epitopes do not consist of more than 15 linear amino acids, the sequences that were 
synthesised allowed for an overlap of 11 amino acids from the previous oligomer. This 
allows for a ‘sliding window’ and if there is a true antibody epitope, antibodies would 
be expected to have affinities to more than one peptide, suggesting a region of 
antigenicity. This resulted in a total of 519,139 peptides being synthesized on a single 
chip for each immunisation condition. This was done as outlined in figure 5.8. First, 
alanine amino acids that have a photosensitive block are covalently bound to the 
microarray slide. Using photolithography, light directed at certain points on the slide 
removes the block and allows for the second amino acid to be added to some of the 
chains. This is repeated with each of the 21 amino acids until all peptides are a 2 
amino acid chain. This process is repeated until all peptides are synthesized. The 
microarray slide is probed with the serum of interest and bound antibodies are 
determined using species specific secondary fluorescent antibodies. A fluorescent 
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Figure 5.8. Schematic of the process of microarray chip synthesis and analysis. 
First Alanine (A) amino acids are covalently bound to the microarray slide. Each A amino acid 
has a block that prevents the condensation reaction between amino acids, therefore 
preventing any unwanted polymerisation. Light is directed at the microarray chip, which 
degrades the block at certain points on the slide. This allows for a second amino acid to be 
added, leading to polymerisation at only specific points on the slide. This is repeated for each 
amino acid as required until all peptides are synthesised. The slide is probed with serum of 
interest, allowing for antibody binding to specific peptides. The slide is washed and any 
antibody binding is recognised by a secondary fluorescent antibody-specific for the species of 
origin for the serum of interest. Once fluorescence is measured, signals for each peptide can 
be put together to show potential regions of antigenicity for each protein included in the 
microarray. 
 
In order to reduce any non-specific binding in the microarray experiment the 
microarray slides were first incubated with pooled naïve serum and for both 
experiments there was no positive detection of antibody binding to peptides (data not 
shown). After probing with serum from mice immunised with γ-radiation attenuated 
Pb(PfCSP)+WT Pb ANKA  or from mice immunised twice with Pb ANKA, most 
peptides elicited negligible antibody responses (Figure 5.9). It is probably not 
surprising that the majority of positive responses to epitopes are very low (Figure 5.9) 
due to the efficiency with which sporozoites can evade the immune response. With 
peptides that did elicit an antibody signal, there is a clear difference in the magnitude 
of responses between the two strains of mice. Pooled serum from immunised BALB/c 
mice show higher signals for more peptides compared to C57BL/6. This supports 
previous results shown here that BALB/c responses were consistently higher for 
ELISA and functional experiments. 
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Figure 5.9. Representative output of microarray for C57BL/6 and BALB/c mice after 
Pb(PfCSP) followed by Pb ANKA immunisation. 
Serum from C57BL/6 and BALB/c mice was collected 28 days after final vaccination. 
Vaccination schedules consisted of 10,000 γ-radiation attenuated sporozoites i.v. using 
Pb(PfCSP) followed by Pb ANKA. Boost vaccinations were given 14 days after the primary 
vaccination. Pooled serum was used to probe a microarray consisting of 519,139 peptides, all 
15 amino acids in length, which covered the Pb ANKA sporozoite and liver stage proteome. 
Each sequential peptide had an 11 amino acid overlap with the previous peptide sequence. 
The microarray output was measured by a fluorescent signal produced from secondary 
mouse-specific antibodies. Graphs show the total output for each peptide for each strain with 
peptides ordered from the lowest signal to the highest. Data is representative for two 
experiments using pooled serum from 5-10 mice per group. 
 
The use of pooled serum from mice immunised twice with γ-radiation attenuated Pb 
ANKA sporozoites was to validate the microarray technique. Using this immunisation 
schedule I hypothesised that there would be clear antibody responses to previously 
validated sporozoite and liver stage antigens. Microarray results for two such antigens 
are shown in figure 5.10. As expected, antibody responses were observed for the 
repeat region of Pb CSP; however, in addition to this antibody responses are also 
seen for the previously validated antigen CelTOS290.  
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Figure 5.10. Validated antigens are recognised by antigens from mice immunised twice 
with Pb ANKA sporozoites using microarray technique. 
Serum from C57BL/6 and BALB/c mice was collected 28 days after vaccination. Vaccination 
schedules consisted of two immunisations with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. Boost vaccinations were given 14 days after the primary vaccination. Pooled 
serum was used to probe a microarray consisting of 519,139 peptides, all 15 amino acids in 
length, which covered the Pb ANKA sporozoite and liver stage proteome. Each sequential 
peptide had an 11 amino acid overlap with the previous peptide sequence. The microarray 
output was measured by a fluorescent signal produced from secondary mouse-specific 
antibodies. Graphs show the output for both mouse strains for two proteins that have 
previously been validated as antigens that generate functional antibody responses against 
Plasmodium sporozoites. Experiments were performed using pooled serum from 5-10 mice 
per group. 
 
With these results it was possible to continue analysis of the microarray data to 
investigate any novel non-CSP antigens. Firstly though, the data was smoothed for 
each protein. This process uses one or more rules that are applied to the data in order 
to remove antibody signals that are less likely to be towards true epitopes. Some 
peptides elicited strong antibody responses; however, their flanking peptides did not. 
Although a true epitope could be in a single peptide, antibody responses to flanking 
peptides provides greater evidence that there is a region of antigenicity. As not all 
peptides could be further investigated, rules were applied to the data to preferentially 
rank peptides that were more likely to be epitopes. This approach has previously been 
used by the Nielsen group, who used similar rules to smooth data from a peptide 
microarray for T. cruzi117. 
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In order to perform the smoothing, 4 rules were implemented. Firstly, a running 
median score was calculated for each peptide and its flanking peptides. If the middle 




Signal Peptide Outcome 
0 A   
21 B 0 
0 C   
 
If; however, the flanking peptides have a signal but the central peptide does not, it 
can be assumed that these signals are not from the same antigenic region. If this is 
the case, the value returned is for the lowest signal score: 
Signal Peptide Outcome 
150 A   
0 B 0 
89 C   
 
An important consideration in analysing the microarray data is that all peptides were 
analysed only once on the microarray. Therefore signals returned for repeat 
sequences are not for multiple peptides but from a single peptide on the microarray. 
If this is the case, the peptide before the repeat region and the peptide after the repeat 
region are considered and the median value is returned for the whole repeat region: 
Signal Peptide Outcome 
0 A   
212 B 30 
212 B 30 
212 B 30 
212 B 30 












Another possibility is that a peptide is flanked by two peptides of the same sequence 
(i.e. the same peptide that was analysed only once). In this instance, a median score 
is calculated using other peptides that differ in sequence by the central peptide by 1 
amino acid: 
 
Signal Peptide Outcome 
0 A   
204 B 0 
0 A   
   
Signal Peptide New Outcome 
204 B   
87 B1 87 
21 B2   
48 B3   
 
After applying these rules an additional filter was added to further increase the chance 
of identifying true regions of antigenicity. Amino acids have individual characteristics 
due to their varying structure and molecular formula, one important characteristic 
being their electrostatic charge. It is known that peptide sequences that have a high 
proportion of charged amino acids, even if they have a very low complexity, can show 
high antibody binding purely due to their charged nature291. As a result of this, it is 
possible that certain peptides would be given a high signal due to this single feature 
rather than due to an induced immune response from the immunisation schedule. In 
order to account for this, any sequence that had more that 50% aspartic acid (D) or 
glutamic acid (E) was not considered for further ranking. In addition, any sequence 
that had more than 3 consecutive D or E amino acids would also not be considered. 
Filtering for these two amino acids in particular was because these are both charged, 
hydrophilic amino acids that consistently appeared in high percentages of the top 
ranking peptides by their original signal. Although there is a possibility that antibody 
responses to these peptides are functional only a small number of peptides could be 
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further analysed and therefore filtering was used to increase the chances of finding 
novel, functional peptides. An example of the results after smoothing is shown in 




Figure 5.11. Example of smoothing raw microarray output 
Serum from C57BL/6 and BALB/c mice was collected 28 days after vaccination. Vaccination 
schedules consisted of two immunisations with 10,000 γ-radiation attenuated Pb ANKA 
sporozoites i.v. Boost vaccinations were given 14 days after the primary vaccination. Pooled 
serum was used to probe a microarray consisting of 519,139 peptides, all 15 amino acids in 
length, which covered the Pb ANKA sporozoite and liver stage proteome. Each sequential 
peptide had an 11 amino acid overlap with the previous peptide sequence. The microarray 
output was measured by a fluorescent signal produced from secondary mouse-specific 
antibodies. Graphs show the original output for both mouse strains for Pb ANKA CSP before 
and after smoothing. Experiments were performed with pooled serum from 5-10 mice per 
group. 
 
The microarray experiment was performed twice with pooled serum from two 
independent immunisation experiments. Previous research has been performed 
using the same microarray technique to show the experimental reproducibility when 
using the same serum samples117. I analysed the results from both experiments to 
determine the biological reproducibility and the strain specificity of antibody 
responses to Plasmodium sporozoite immunisation (Figure 5.12). By plotting the 
signal for C57BL/6 antibody results against BALB/c, I investigated the agreement 
between both strains for each experiment (Figure 5.12A-B). Using Pearson’s 
correlation coefficient (PCC), there was a positive but weak correlation for experiment 
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1 (PCC=0.4949) and a moderate positive correlation for experiment 2 (PCC=0.5410). 
In addition, I measured the correlation for each strain between both experiments 
(Figure 5.12C-D). A moderate positive correlation was observed for both C57BL/6 
(PCC=0.5120) and BALB/c (PCC=0.5208). It is promising that there is consistent 
positive correlation for these analyses; however, correlation is relatively low. This 
could be due to biological differences during immunisation e.g. viability of sporozoites 
at immunisation, or it could be a result of noise due to the large amount of peptides 
that were analysed, the majority of which will not induce functional antibody 
responses and therefore may have a more stochastic antibody-mediated response. 
 
 
Figure 5.12. Correlation between C57BL/6 and BALB/c antibody responses to 
immunisation 
Serum from C57BL/6 and BALB/c mice was collected 28 days after final vaccination. 
Vaccination schedules consisted of 10,000 γ-radiation attenuated sporozoites i.v. using 
Pb(PfCSP) followed by Pb ANKA. Boost vaccinations were given 14 days after the primary 
vaccination. Pooled serum was used to probe a microarray consisting of 519,139 peptides, all 
15 amino acids in length, which covered the Pb ANKA sporozoite and liver stage proteome. 
Each sequential peptide had an 11 amino acid overlap with the previous peptide sequence. 
The microarray output was measured by a fluorescent signal produced from secondary 
mouse-specific antibodies. Graphs show correlation between both mouse strains for 
experiment 1 and experiment 2 using pooled serum from 5-10 mice per group as well as 
correlation for each strain between experiments. Statistics performed using Pearson’s 
Correlation Coefficient (PCC). 
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A small percentage of the total number of peptides generated strong signals in each 
microarray experiment. Using the protein rank after smoothing was applied to the 
data, the 15 top proteins were chosen for further analysis in order to maximise 
chances of identifying a true immunogenic region in a manageable number of 
candidate proteins. These proteins were considered to be the best candidates for 
novel antibody epitopes against Pb ANKA sporozoite and liver stages. As these 
antigens are under current investigation, they are presented here as numbered 
antigens 1-15. The decision was made based on the proteins that ranked highest in 
both experiments for both C57BL/6 and BALB/c. All proteins had published evidence 
of expression during the sporozoite and/or liver stages that was available from the 
PlasmoDB database. 65% of the top proteins showed evidence of a signal sequence 
when sequences were put through SignalP software (Center for Biological Sequence 
analysis [CBS]) and all proteins showed no homology with mouse (mus musculus) or 
human (homo sapien) proteomes. The top peptide for each protein was synthesized 
for ELISA investigation, with 2 peptides synthesized for antigen 3 due to the presence 
of two distinct regions of putative antigenicity. ELISA results are shown in figure 5.13; 
however, the majority of measured responses were not significantly different from 
naïve serum responses. Interestingly, antibody responses from immunised C57BL/6 
mice against all peptides was not different from the naïve control but in contrast, 
BALB/c immunised responses were much more likely to be increased compared to 
naïve controls. Unfortunately, only two peptides showed a statistical increase in 
antibody responses by ELISA in immunised sera compared to naïve sera (one 
peptide for Antigen 3 and the peptide for Antigen 11).  
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Figure 5.13. ELISA investigation of Pb ANKA putative antibody epitopes identified by 
microarray. 
Serum from C57BL/6 and BALB/c mice was collected 28 days after final vaccination. 
Vaccination schedules consisted of 10,000 γ-radiation attenuated sporozoites i.v. using a 
novel strategy of Pb(PfCSP)+WT Pb ANKA. Boost vaccinations were given 14 days after the 
primary vaccination. Antibody responses were measured against 15 putative epitopes of 15 
amino acids in length by ELISA. Putative epitopes were identified by microarray. Pooled 
data from two experiments with pooled serum from 7 mice per group. Statistics were 
performed using Kruskal-Wallis non-parametric t test followed by Dunn’s multiple 
comparisons test.  
 
 




The generation of long-lived, specific antibody responses against infection is an 
attractive avenue of investigation for vaccinology. This is due to the efficacy with 
which antibodies can recognise and respond to free antigen and the ease with which 
B cells can be stimulated relative to the induction of T cell responses. With regard to 
malaria, the parasite spends most of its life in the vertebrate host inside host cells. 
Therefore, there are only two opportunities for antibodies to neutralise the parasite. 
These are early during infection when sporozoites are locating to the liver and 
infecting hepatocytes and during blood stage infection when merozoites rupture their 
host RBC and move freely through the blood system before infecting a new RBC. 
Antibody responses towards the blood stage merozoites have been researched to a 
greater extent than liver stages, particularly due to the amount of antigen available 
during blood stage infection to induce antibody responses. A difficulty with inducing 
antibody responses to the sporozoite is that there is a relatively short window of 
minutes before the parasite has sequestered in the liver; however, it has been shown 
that antibodies are capable of functionally neutralising sporozoite invasion79. Another 
difficulty is that the sporozoite surface is coated with a high density of CSP. This would 
not necessarily be a problem if antibody responses to CSP alone were sufficient to 
protect from malaria infection in humans. Early investigations of antibody responses 
to CSP were very promising in mice, offering complete protection when 
administered268 and later shown to be protective with CSP immunisation292. This has 
led to the first malaria vaccine RTS, S, which uses epitopes from CSP to stimulate B 
and T cell responses. Unfortunately, Phase 3 trials show that the efficacy of this 
vaccine is lower than what was expected after non-human animal investigations. It is 
promising that antibodies from RTS, S vaccinations do have a protective impact on 
malaria infection293; however, responses to CSP alone appear to not be sufficient in 
a non-laboratory setting. Therefore, knowing that antibodies against liver stage 
infection can be protective but responses against CSP alone does not confer 
particularly good efficacy as a vaccine, there appears to be a clear question of 
whether there are more immunogenic antigens that could be used and whether they 
would facilitate a CSP vaccine. As part of this investigation, I attempted to answer the 
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In order to investigate novel non-CSP antibody antigens I first designed a novel 
immunisation schedule to promote antibody responses to non-CSP proteins. CSP is 
a highly immunodominant protein on the sporozoite and as such, it can dampen 
antibody responses to other immunogenic antigens. To avoid this, immunisations 
were performed using a transgenic Pb ANKA strain that expressed Pf CSP rather 
than Pb ANKA CSP. An initial immunisation with WT, followed by a booster 
immunisation with the transgenic Pb ANKA strain would preferentially boost non-CSP 
antibody responses. As this is a new schedule it was crucial that I validated it by 
investigating antibody recognition of known antigens and functional responses. As 
expected, I observed antibody recognition of Pb ANKA CSP and Pf CSP after both 
immunisations (Figures 5.3 and 5.4 respectively) and further showed that serum from 
immunised mice recognised Pb ANKA sporozoites (Figure 5.5). In these experiments 
BALB/c serum consistently gave higher antibody responses compared to C57BL/6 
serum. As BALB/c mice are more resistant to Pb ANKA infection, being refractory to 
ECM, these results are probably due to an immunological variance between the two 
mouse strains. 
 
Further to purely recognising Pb ANKA CSP and Pf CSP, it was crucial that my 
immunisations elicited functional antibody responses. It is particularly interesting that 
antibody neutralisation of sporozoites, preventing EEF development in vitro, was 
similar between my immunisation schedule and 2x WT Pb ANKA immunisations for 
both BALB/c and C57BL/6 serum (Figure 5.6). Also, this appeared to be the case for 
my investigation into the inhibition of cell traversal (Figure 5.7). This might suggest 
that the comparable neutralisation was due to additional non-CSP-specific antibodies.  
 
The use of microarray technology has previously been used to investigate novel 
antibody antigenic determinants for infectious disease117,294,295. This offers a versatile, 
high-density technology for the simultaneous investigation of hundreds of thousands 
of antigenic candidates for vaccine, diagnostic and therapeutic discovery. By using 
this technology I was able to investigate 519,139 peptides that covered the entire 
sporozoite and liver stage proteome. As expected, there was clear antibody 
recognition of CSP and another previously validated liver stage antigen CelTOS 
(Figure 5.10), but this quantity of data raises problems with analysis in order to 
accurately identify true antibody epitopes. In order to address this problem I 
incorporated a smoothing strategy, similar to the one used by Carmona et al.117 and 
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described in detail earlier in this chapter. This increased the probability that the 
highest ranked peptides were part of a region of antigenicity and had sequences of 
higher complexity. Unfortunately, due to the nature of the results obtained for all 
peptides, it was not possible to determine a threshold using finite mixture model 
statistics. Because of this, 15 proteins that consistently ranked highly in both 
experiments between both mouse strains were chosen for further investigation and 
validation. It is interesting that several of the chosen peptides from these proteins did 
not show a significant antibody response with the same pooled mouse sera when 
ELISA was performed. This could be due to several factors including the limit of 
detection for ELISA and microarray techniques, differences in peptide presentation to 
antibody as peptide adsorption on the ELISA plate is stochastic, or perhaps as a result 
of differences in peptide synthesis. From all the ELISA results, two antigens appear 
to be the most promising candidates for further investigation as they showed 
increased antibody responses with immunisation in both the novel and 2x Pb ANKA 
immunisation schedules. For these two proteins further investigation would be 
particularly interesting. Synthesis of these proteins would allow for further study via 
protein immunisation of mice. Showing that protein immunisation using these 
candidates leads to functional inhibition of sporozoite invasion in vitro and protection 





Research towards novel vaccines against liver stage malaria requires the 
investigation of novel antigenic determinants. Antibodies have been shown to be 
protective against liver stage malaria; however, there is a paucity of information 
regarding non-CSP antibody targets that could be used for future vaccines. In this 
study, I have used a novel immunisation schedule to promote non-CSP antibody 
responses and investigated them using high throughput microarray technology. 
Results show promising candidates that should be investigated further towards 
confirmation of their eligibility for vaccine research. 
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5.6 Supplementary Data 
 
Figure 5.S1. Antibody recognition of recombinant Pf CSP is not due to the generation 
of E. coli-specific antibody 
Serum from C57BL/6 and BALB/c mice was collected 28 days after vaccination. Vaccination 
schedules consisted of 10,000 γ-radiation attenuated sporozoites i.v. using transgenic 
Pb(PfCSP) followed by WT Pb ANKA. Boost vaccinations were given 14 days after the 
primary vaccination. Antibody responses were measured against recombinant Pf CSP (A) 
and MSP1-19 (B) by ELISA. Data from two experiments with 5-10 mice per group. Statistics 
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6.1 Summary and significance of findings 
 
The majority of the work presented in this thesis investigates how CD8+ T cell 
responses are regulated during malaria infection. In chapter 2 I used antibody-
mediated blockade to investigate co-inhibitory regulatory molecules CTLA-4 and PD-
1 and their respective signalling pathways during exposure to pre-erythrocytic 
infection in a mouse model of malaria. By immunising C57BL/6 mice with a non-
protective single dose of γ-radiation attenuated Pb ANKA sporozoites, I attempted to 
discern the possibility that CTLA-4, PD-1/PD-L1 and PD-1/PD-L2 signalling 
negatively regulate CD8+ T cell activation upon attenuated sporozoite exposure, 
therefore preventing sterile immunity. Antibody-mediated blockade of CTLA-4 
resulted in a significant increase in antigen experienced CD8+ T cells that produced 
IFNγ upon stimulation with Pb sporozoite antigens as measured by flow cytometry, 
whereas blockade of PD-L1 or PD-L2 did not. On a functional level, blockade of 
CTLA-4 with a single γ-radiation attenuated Pb ANKA sporozoite immunisation 
elicited sterile protection against Pb ANKA sporozoite challenge; however, this was 
not the case with blockade of PD-L1 as challenge resulted in patent parasitaemia in 
all mice. Protection via CTLA-4 blockade with Pb ANKA sporozoite immunisation was 
due to CD4+ and CD8+ T cells and the cytokine IFNγ as depletion of any of these 
abrogated protection from challenge. The level of protection with CTLA-4 blockade 
concurrently with a non-protective Pb ANKA immunisation appears to wane over time. 
When challenged 45 days after immunisation and blockade, the majority of mice 
succumb to patent infection; however, there is a reduction in parasitaemia and a delay 
in patency compared to controls. Taken together, this is a novel investigation into the 
mechanisms of CD8+ T cell regulation during pre-erythrocytic malaria, an area of 
research that is currently lacking. Further to this, it is a proof of principle that a non-
protective pre-erythrocytic sporozoite vaccine can be significantly increased in 
efficacy through concurrent immune modulation. 
 
In chapter 3 I continued my investigation of CD8+ T cell regulation during pre-
erythrocytic malaria infection, this time by focusing on two cytokines that are known 
to have immunoregulatory functions. The roles of IL-27 and IL-10 have not been 
investigated with regard to their regulation of CD8+ T cell responses to whole 
sporozoite exposure in a mouse model. Using knock-out mice that do not express the 
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wsx-1 gene and therefore are deficient in the IL-27R, I gave a non-protective 
immunisation with γ-radiation attenuated Pb ANKA sporozoites. Compared to 
C57BL/6 controls, WSX-1-/- mice did indeed show a trend towards more antigen 
experienced sporozoite-specific CD8 T+ cells upon exposure to antigen; however, this 
only achieved significance with S20 peptide re-stimulation and significance was lost 
if re-stimulation was delayed until 45 days after immunisation. Despite the trend, 
challenge of WSX-1-/- mice with Pb ANKA 14 or 45 days after immunisation resulted 
in very similar fold reductions in parasite liver load to C57BL/6 controls that are not 
protected from ECM. In the previous chapter, a reduction of over 3 log was required 
before protection could be seen with CTLA-4 blockade concurrently with a single Pb 
ANKA sporozoite immunisation. In order to investigate IL-10 signalling, I used 
antibody blockade similarly to chapter 2. Using this method my results showed that 
blockade of IL-10R with a non-protective Pb ANKA sporozoite immunisation did not 
lead to an increase in sporozoite antigen-specific CD8+ T cells. Additionally, it does 
not lead to any decrease in parasite liver load upon challenge with Pb ANKA 
sporozoites. Although IL-27R and IL-10R signalling do not appear to negatively 
regulate CD8+ T cell activation with Pb sporozoite exposure in my mouse model, it 
does highlight that CD8+ T cell regulatory mechanisms are different between pre-
erythrocytic and blood stage infection and should be thought of as such. 
 
Continuing with regulation but moving into blood stage malaria infection, chapter 4 
investigates the role of IL-10R regulatory signalling in resistance to acute immune 
pathology. Antibody blockade of IL-10R in normally ECM resistant BALB/c mice 
resulted in an increase in leukocyte and CD8+ T cell infiltration into the brain, 
increased brain haemorrhage and increased IFNγ and CD8+ T cell activation. From 
these results, it appears that IL-10R signalling can indeed regulate pathogenic CD8+ 
T cell responses in an ECM resistant mouse model of blood stage malaria infection. 
It is understood that there are subtle variations in how the adaptive immune system 
responds to blood stage malaria infection through previous work on various mouse 
models93. As human malaria blood stage infection can also lead to a multitude of 
varying pathogenic or non-pathogenic outcomes, it is important for us to better 
understand the specificities of these varying responses. Chapter 4 contributes to our 
understanding of how inhibitory pathways can significantly influence CD8+ T cell 
activation to the extent that, in certain conditions a single pathway can completely 
protect from immune-mediated pathology. 
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My final data chapter is not concerned with T cell regulation, rather it focuses on the 
antibody response to pre-erythrocytic malaria in a mouse model. There is a paucity 
in information concerning what antigens (other than CSP) in the pre-erythrocytic stage 
generate functional antibody responses that may contribute to protection. In chapter 
5 I used a novel immunisation schedule in a mouse model to maximise the potential 
for identifying non-CSP epitopes. Immunising once with γ-radiation attenuated 
transgenic Pb ANKA that expresses Pf CSP rather than Pb ANKA CSP and boosting 
with WT Pb ANKA meant that all non-CSP antigens were boosted, whereas CSP was 
not. As microarray technology now allows for incredibly high-density peptide 
microarrays, this was used to simultaneously investigate all potential antibody 
antigenic determinants in Pb ANKA pre-erythrocytic infection of BALB/c and C57BL/6 
mice. Due to the incredible amount of data generated and the low to absent antibody 
binding to the majority of peptides, a threshold for positive and negative antibody 
responses was not identified. Instead, by ranking peptides and adopting a smoothing 
strategy to remove peptides not from an antigenic region, a selection of top 
candidates could be investigated. As expected, previously validated antibody 
antigens were ranked very highly. Additionally, there were several antigens that 
warranted further investigation due to their rank as well as other properties such as 
the presence of a signal region. Performing ELISA with a selection of putative 
epitopes resulted in only two candidates having a significant antibody response in 
immunised sera compared to control sera. Due to the moderate agreement in 
antibody responses between both microarray experiments, these peptides were 
expected to generate an increased antibody response in ELISA. The discrepancy 
between these two techniques could be due to differences between them such as 
synthesis of peptides, the way in which peptides were presented to antibody or the 
sensitivity of each technique. Regardless, these results provide evidence for two 
novel putative antibody epitopes that warrants further investigation into their 
functionality and potential as vaccine candidates. 
 
6.2 Opportunities for further research 
My investigations into the regulation of CD8+ T cells during pre-erythrocytic malaria 
infection in chapters 2 and 3 have aimed to increase our understanding of an as yet 
poorly researched facet of malaria infection. Antibody-mediated blockade of CTLA-4 
with a non-protective γ-radiation attenuated Pb ANKA sporozoite immunisation 
elicited sterile immunity in C57BL/6 mice. This is a proof of concept that immune 
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regulation of T cell activation can influence protective T cell responses to whole 
sporozoite immunisation. Therefore, broadening our understanding of this could 
contribute to better malaria vaccine design. It is interesting that blockade of PD-L1 
with immunisation did not lead to an increase in CD8+ T cell activation or protection 
from sporozoite challenge. A potential avenue of research in this regard could be 
blockade of PD-L1 with blockade of another regulatory molecule. Previous research 
in blood stage malaria has shown that concurrent blockade of PD-L1 and LAG3 leads 
to an improvement in parasitaemia control with non-lethal infection of outbred Swiss 
Webster or C576L/6 with Py or P. chabaudi respectively105. The synergistic nature of 
PD-1 and LAG3 blockade has already been described in an investigation into immune 
responses to tumours in a mouse model by Woo et al.296. More evidence from cancer 
studies has shown that PD-1 blockade and OX40 activation can also lead to a 
synergistic protection against a mouse model of ovarian cancer, which is dependent 
on T cell activation297. Therefore, there are also opportunities for investigating 
concurrent blockade of co-inhibitory molecules and excitation of co-stimulatory 
molecules with regard to CD8+ T cell regulation during whole sporozoite 
immunisation. 
 
In chapter 3 I did not observe any decrease in parasite liver load if a challenge of Pb 
ANKA sporozoites was given following a non-protective γ-radiation attenuated Pb 
ANKA sporozoite immunisation in the absence of IL-27R or IL-10R signalling. This is 
in itself quite interesting as both pathways have been implicated in T cell regulation 
in blood stage infection and pathology. To continue this line of research it may be 
interesting to investigate other regulatory cytokines such as TGFβ, which has also 
been investigated with regard to regulation during blood stage malaria298,299. TGFβ 
negatively regulates CD8+ as well as CD4+ T cell responses300; however, its role in 
regulation of CD8+ T cells during pre-erythrocytic infection is as yet unknown.  
 
A particularly interesting avenue of future research regarding my work in chapter 4 
would be towards a greater understanding of the protective capacity of antigens 
identified using high-density peptide microarrays. My work has resulted in at least two 
proteins that are expressed during the pre-erythrocytic stage of Pb that are 
recognised by antibodies in both a microarray and ELISA using C57BL/6 and BALB/c 
sera from mice immunised with γ-radiation attenuated Pb(PfCSP) followed by Pb 
ANKA sporozoites. In order to better understand the functional capacity of antibodies 
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that recognise these antigens, it would be interesting to synthesise these proteins for 
use in a protein immunisation experiment. In this way, there is the exciting possibility 
that immunisation with these novel antigens could elicit a level of functional protective 
immunity. This would give further evidence to support the investigation of these 
antigens with regard to their potential as malaria vaccine candidates. Additionally, it 
would allow for the investigation of any elicited protection in two mouse models of 
malaria infection, BALB/c and C57BL/6. If indeed there does appear to be a functional 
protection from antibodies generated towards these antigens, another important 
investigation would be to identify epitopes. As regions of antigenicity have been 
identified using high-density peptide microarrays as discussed in chapter 4, the 
salient epitope sequences could be identified using Alanine scans. In this way, 
replacing amino acids within the regions of antigenicity with the unreactive Alanine in 
a sequential manner could result in the true epitopes that generate functional 
antibodies. 
 
The work presented in this thesis offers some insight into how CD8+ T cells are 
regulated during exposure to a non-protective attenuated Pb ANKA sporozoite 
immunisation in a mouse model of ECM. Further to this, the regulation of CD8+ T 
cells during blood stage infection and its relation to immune-mediated pathology has 
also been investigated. These studies attempt to increase our understanding of 
CD8+ T cell regulation in mouse models of malaria; however, this understanding is 
far from complete. Further investigation is particularly important to allow for, among 
other things, better vaccine design. My final data chapter also contributes to 
research towards better malaria vaccines through its investigation of non-CSP 
antibody antigenic determinants in mouse models. Although this offers some 
promising results, further work is required in order to fully understand whether the 
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